Venetoclax Clinical Trials (2026): 686 Studies for Acute Myeloid Leukemia & Chronic Lymphocytic Leukemia

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

686 Venetoclax clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 232 indications (including Acute Myeloid Leukemia & Chronic Lymphocytic Leukemia) and 79,548 total planned enrollment. 59 Phase 3 Venetoclax trials and 269 Phase 2, 5 Phase 4 are listed. 303 Venetoclax clinical trials are actively recruiting at 2,387 U.S. sites across 50 states. Most recent activity: NCT05725200 (Dec 2040).

Where to Participate: All Venetoclax Trial Sites in the U.S. (2,387 sites across 50 states)

Every actively recruiting Venetoclaxtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ALChildren's Hospital of AlabamaBirmingham35233NCT06317662Map
ALO'Neal Comprehensive Cancer Center, University of AlabamaBirmingham35233NCT04588922Map
ALThe Kirklin Clinic of UAB HospitalBirmingham35233NCT03850574Map
ALUniversity of Alabama at BirminghamBirmingham35294NCT03331198Map
ALUniversity of Alabama at BirminghamBirmingham35294NCT06852222Map
ALUniversity of Alabama at BirminghamBirmingham35294NCT07044544Map
ALUniversity of Alabama at Birmingham Cancer CenterBirmingham35233NCT05554393Map
ALUniversity of Alabama at Birmingham Cancer CenterBirmingham35233NCT05554406Map
ALUniversity of Alabama at Birmingham Cancer CenterBirmingham35233NCT05564390Map
ALUniversity of Alabama at Birmingham Cancer CenterBirmingham35233NCT06317649Map
ALUniversity of Alabama BirminghamBirmingham35294NCT03331198Map
AKProvidence Alaska Medical CenterAnchorage99508NCT06317662Map
AZBanner MD Anderson Cancer CenterGilbert85234NCT03331198Map
AZBanner MD Anderson Cancer CenterGilbert85234NCT03331198Map
AZBanner MD Anderson Cancer CenterGilbert85234NCT07007312Map
AZCancer Treatment Center of America PhoenixGoodyear85338NCT06852222Map
AZCity of Hope - PhoenixGoodyear85338NCT04588922Map
AZBanner Children's at DesertMesa85202NCT06317662Map
AZMayo Clinic - PhoenixPhoenix85054NCT05735184Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT05554406Map
AZMayo Clinic Hospital in ArizonaPhoenix85054NCT05564390Map
AZPhoenix Children's HospitalPhoenix85016NCT05183035Map
AZArizona Oncology - Tucson - Rudasill /ID# 267552Tucson85704NCT06428019Map
AZBanner University Medical Center - TucsonTucson85719NCT05554393Map
AZBanner University Medical Center - TucsonTucson85719NCT05554406Map
AZBanner University Medical Center - TucsonTucson85719NCT05564390Map
AZBanner University Medical Center - TucsonTucson85719NCT04840602Map
AZBanner University Medical Center - TucsonTucson85719NCT04269902Map
AZBanner University Medical Center - TucsonTucson85719NCT06317649Map
AZBanner University Medical Center - TucsonTucson85719NCT06672146Map
AZSouthern VA Health Care System /ID# 266254Tucson85723NCT06428019Map
AZThe University of Arizona Cancer CenterTucson85724NCT06852222Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT05554393Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT05554406Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT05564390Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT04840602Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT04269902Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT06317649Map
AZUniversity of Arizona Cancer Center-North CampusTucson85719NCT06672146Map
ARNEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro72401NCT04269902Map
ARSt Bernards Medical CenterJonesboro72401NCT06846671Map
ARArkansas Children's HospitalLittle Rock72202NCT05183035Map
ARArkansas Children's HospitalLittle Rock72202-3591NCT06317662Map
ARUniversity of Arkansas at Little RockLittle Rock72204NCT06852222Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT05554393Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT05554406Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT05564390Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT06317649Map
ARUniversity of Arkansas for Medical SciencesLittle Rock72205NCT06672146Map
ARHighlands Oncology Group ( Site 5405)Springdale72762NCT05947851Map
CAKaiser Permanente-AnaheimAnaheim92806NCT04269902Map
CAKaiser Permanente-Baldwin ParkBaldwin Park91706NCT04269902Map
CAKaiser Permanente-BellflowerBellflower90706NCT04269902Map
CAAlta Bates Summit Medical Center-Herrick CampusBerkeley94704NCT05554406Map
CAAlta Bates Summit Medical Center-Herrick CampusBerkeley94704NCT06317649Map
CAAlta Bates Summit Medical Center-Herrick CampusBerkeley94704NCT06672146Map
CAMarshall Cancer CenterCameron Park95682NCT04269902Map
CAThe Oncology Institute Clinical ResearchCerritos90703NCT05963074Map
CAUCSF FRESNO/Community Cancer Institute /ID# 270874Clovis93611NCT06428019Map
CAUCSF-FresnoClovis93611NCT04905810Map
CAUniversity of California, FresnoClovis93611NCT07007312Map
CAUC Irvine Health Cancer Center-NewportCosta Mesa92627NCT04269902Map
CACity of HopeDuarte91010NCT03331198Map
CACity of HopeDuarte91010NCT03113643Map
CACity of HopeDuarte91010NCT06852222Map
CACity Of HopeDuarte91010NCT03331198Map
CACity of Hope (City of Hope National Medical Center, City of Hope Medical Center)Duarte91010NCT04227847Map
CACity of Hope Comprehensive Cancer CenterDuarte91010NCT04269902Map
CACity of Hope Comprehensive Cancer CenterDuarte91010NCT06311227Map
CACity of Hope Medical centerDuarte91010NCT03523975Map
CACity of Hope Medical CenterDuarte91010NCT05861050Map
CACity of Hope Medical CenterDuarte91010NCT03969446Map
CACity of Hope Medical CenterDuarte91010NCT06501196Map
CACity of Hope Medical CenterDuarte91010NCT06763341Map
CACity of Hope Medical CenterDuarte91010NCT07133997Map
CACity of Hope Medical CenterDuarte91010NCT07218510Map
CACity of Hope National Medical CenterDuarte91010NCT04588922Map
CAIP Address: City of Hope Investigational Drug Services(IDS)Duarte91010NCT04227847Map
CAKaiser Permanente DublinDublin94568NCT05564390Map
CAKaiser Permanente DublinDublin94568NCT06317649Map
CAKaiser Permanente-FontanaFontana92335NCT04269902Map
CAKaiser Permanente-FremontFremont94538NCT05564390Map
CAKaiser Permanente-FremontFremont94538NCT06317649Map
CAKaiser Permanente Fresno Orchard PlazaFresno93720NCT05564390Map
CAKaiser Permanente Fresno Orchard PlazaFresno93720NCT06317649Map
CAKaiser Permanente-FresnoFresno93720NCT05564390Map
CAKaiser Permanente-FresnoFresno93720NCT06317649Map
CAKaiser Permanente South BayHarbor City90710NCT04269902Map
CACity of Hope SeacliffHuntington Beach92648NCT04269902Map
CACity of Hope at Irvine LennarIrvine92618NCT04269902Map
CACity of Hope at Irvine LennarIrvine92618NCT06311227Map
CACity of Hope at Irvine LennarIrvine92618NCT07218510Map
CAKaiser Permanente-IrvineIrvine92618NCT04269902Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT05564390Map
CAUCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine92612NCT04269902Map
CAUniversity of California IrvineIrvine92697NCT03850574Map
CAMoores Cancer Center at UC San Diego /ID# 230157La Jolla92093NCT04895436Map
CAMoores UC San Diego Cancer CenterLa Jolla92093NCT05735184Map
CAUC San Diego Moores Cancer CenterLa Jolla92093NCT03331198Map
CAUniversity Of California San Diego Moores Cancer CenterLa Jolla92093NCT03331198Map
CAUniversity of California, San DiegoLa Jolla92093NCT07007312Map
CAUci Health Laguna HillsLaguna Hills92653NCT06943872Map
CAUCI Health Laguna HillsLaguna Hills92653NCT04269902Map
CACity of Hope Antelope ValleyLancaster93534NCT04269902Map
CALoma Linda University Medical CenterLoma Linda92354NCT06317662Map
CACity of Hope at Long Beach ElmLong Beach90813NCT04269902Map
CACity of Hope at Long Beach ElmLong Beach90813NCT07218510Map
CAMemorialCare Health System - Long Beach Medical Center ( Site 5421)Long Beach90806NCT05947851Map
CAMemorialCare Miller Children's and Women's Hospital Long BeachLong Beach90806NCT05183035Map
CAMiller Children's and Women's Hospital Long BeachLong Beach90806NCT06317662Map
CACancer and Blood Specialty ClinicLos Alamitos90720NCT05963074Map
CACedars-Sinai Medical CenterLos Angeles90048NCT05554393Map
CACedars-Sinai Medical CenterLos Angeles90048NCT05554406Map
CACedars-Sinai Medical CenterLos Angeles90048NCT05564390Map
CACedars-Sinai Medical CenterLos Angeles90048NCT06317649Map
CACedars-Sinai Medical CenterLos Angeles90048NCT06649812Map
CACedars-Sinai Medical CenterLos Angeles90048NCT07007312Map
CADavid Geffen School of Medicine at the University of California at Los AngelesLos Angeles90095-1406NCT06810778Map
CAKaiser Permanente Los Angeles Medical CenterLos Angeles90027NCT04269902Map
CAKaiser Permanente West Los AngelesLos Angeles90034NCT04269902Map
CAKeck School of Medicine of USCLos Angeles90089NCT04256317Map
CARonald Reagan UCLA Medical CenterLos Angeles90095NCT04227847Map
CAUCLA - Bowyer Oncology CenterLos Angeles90095NCT05735184Map
CAUCLA Department of Medicine HematologyoncologyLos Angeles90095-3075NCT06846671Map
CAUCLA Hematology-Oncology ClinicLos Angeles90095NCT04227847Map
CAUCLA Ronald Reagan Medical CenterLos Angeles90095NCT03013998Map
CAUniversity of California Los AngelesLos Angeles90095NCT06501196Map
CAUniversity of California, Los AngelesLos Angeles90095NCT03331198Map
CAUniversity of California, Los AngelesLos Angeles90095NCT06456463Map
CAUniversity of California, Los AngelesLos Angeles90095NCT07007312Map
CAUSC / Norris Comprehensive Cancer CenterLos Angeles90033NCT05735184Map
CAUSC/Norris Comprehensive Cancer CenterLos Angeles90033NCT03850574Map
CAValkyrie Clinical Trials /ID# 268151Los Angeles90067NCT06428019Map
CAFremont - Rideout Cancer CenterMarysville95901NCT04269902Map
CAKaiser Permanente- Modesto MOB IIModesto95356NCT05564390Map
CAKaiser Permanente- Modesto MOB IIModesto95356NCT06317649Map
CAKaiser Permanente-ModestoModesto95356NCT05564390Map
CAKaiser Permanente-ModestoModesto95356NCT06317649Map
CACity of Hope Newport BeachNewport Beach92660NCT04269902Map
CAHoag Family Cancer CenterNewport Beach92663NCT04988555Map
CAKaiser Permanente-OaklandOakland94611NCT05564390Map
CAKaiser Permanente-OaklandOakland94611NCT06317649Map
CAKaiser Permanente-OaklandOakland94611NCT06317662Map
CAUCSF Benioff Children's Hospital OaklandOakland94609NCT06317662Map
CAKaiser Permanente-OntarioOntario91761NCT04269902Map
CAChao Family Comprehensive Cancer CenterOrange92868-3201NCT06943872Map
CAChildren's Hospital of Orange CountyOrange92868NCT06317662Map
CAChildren's Hospital of Orange County Main Campus - OrangeOrange92868NCT05183035Map
CAUC Irvine Health - Chao Family Comprehensive Cancer CenterOrange92868NCT04256317Map
CAUC Irvine Health Chao Family Comprehensive Cancer CenterOrange92868NCT05735184Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT05564390Map
CAUC Irvine Health/Chao Family Comprehensive Cancer CenterOrange92868NCT04269902Map
CAUCI Chao Family Comprehensive Cancer CenterOrange92868NCT06382168Map
CAUniversity of California, IrvineOrange92868NCT07007312Map
CAStanford Cancer CenterPalo Alto94304NCT03850574Map
CAStanford Cancer CenterPalo Alto94304NCT06501196Map
CAStanford Cancer InstitutePalo Alto94304-2205NCT06943872Map
CAKaiser Permanente - Panorama CityPanorama City91402NCT04269902Map
CAKaiser Permanente-RiversideRiverside92505NCT04269902Map
CAKaiser Permanente-RosevilleRoseville95661NCT05564390Map
CAKaiser Permanente-RosevilleRoseville95661NCT06317649Map
CAKaiser Permanente Downtown CommonsSacramento95814NCT05564390Map
CAKaiser Permanente Downtown CommonsSacramento95814NCT06317649Map
CAKaiser Permanente-South SacramentoSacramento95823NCT05564390Map
CAKaiser Permanente-South SacramentoSacramento95823NCT06317649Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT05554406Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT05564390Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT04905810Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT04269902Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT06317649Map
CAUniversity of California Davis Comprehensive Cancer CenterSacramento95817NCT06317662Map
CAUniversity of California Davis Health (UC Davis Health)Sacramento95817NCT05184842Map
CAUniversity of California, DavisSacramento95817NCT03850574Map
CAKaiser Permanente-San Diego ZionSan Diego92120NCT04269902Map
CARady Children's HospitalSan Diego92132NCT06177067Map
CARady Children's HospitalSan Diego92123NCT06390319Map
CAScripps Prebys Cancer CenterSan Diego92103-2106NCT06943872Map
CABenioff Children's Hospital - Mission BaySan Francisco94158NCT05183035Map
CAKaiser Permanente-San FranciscoSan Francisco94115NCT05564390Map
CAKaiser Permanente-San FranciscoSan Francisco94115NCT06317649Map
CASan Francisco VA Medical Center, San Francisco, CASan Francisco94121-1563NCT06520098Map
CAUCSF Medical Center-Mission BaySan Francisco94158NCT06317662Map
CAUCSF Medical Center-ParnassusSan Francisco94143NCT05554393Map
CAUCSF Medical Center-ParnassusSan Francisco94143NCT05554406Map
CAUCSF Medical Center-ParnassusSan Francisco94143NCT05564390Map
CAUCSF Medical Center-ParnassusSan Francisco94143NCT06317649Map
CAUCSF Medical Center-ParnassusSan Francisco94143NCT06672146Map
CAUniversity of California San Francisco-Benioff Children's HospitalSan Francisco94158NCT05292664Map
CAUniversity of California, San FranciscoSan Francisco94143NCT03331198Map
CAUniversity of California, San FranciscoSan Francisco94143NCT03013998Map
CAKaiser Permanente-Santa Teresa-San JoseSan Jose95119NCT05564390Map
CAKaiser Permanente-Santa Teresa-San JoseSan Jose95119NCT06317649Map
CAKaiser Permanente San LeandroSan Leandro94577NCT05564390Map
CAKaiser Permanente San LeandroSan Leandro94577NCT06317649Map
CASLO Oncology and Hematology Health CenterSan Luis Obispo93401NCT05963074Map
CAKaiser Permanente-San MarcosSan Marcos92078NCT04269902Map
CAMills Health CenterSan Mateo94401NCT05554406Map
CAMills Health CenterSan Mateo94401NCT06317649Map
CAMills Health CenterSan Mateo94401NCT06672146Map
CAKaiser San Rafael-GallinasSan Rafael94903NCT05564390Map
CAKaiser San Rafael-GallinasSan Rafael94903NCT06317649Map
CAKaiser Permanente Medical Center - Santa ClaraSanta Clara95051NCT05564390Map
CAKaiser Permanente Medical Center - Santa ClaraSanta Clara95051NCT06317649Map
CAKaiser Permanente-Santa RosaSanta Rosa95403NCT05564390Map
CAKaiser Permanente-Santa RosaSanta Rosa95403NCT06317649Map
CAProvidence Medical FoundationSanta Rosa95403NCT05963074Map
CACity of Hope South PasadenaSouth Pasadena91030NCT04269902Map
CAKaiser Permanente-South San FranciscoSouth San Francisco94080NCT05564390Map
CAKaiser Permanente-South San FranciscoSouth San Francisco94080NCT06317649Map
CAStanford Health CareStanford94305NCT06456463Map
CACity of Hope South BayTorrance90503NCT04269902Map
CACity of Hope UplandUpland91786NCT04269902Map
CAKaiser Permanente-VallejoVallejo94589NCT05564390Map
CAKaiser Permanente-VallejoVallejo94589NCT06317649Map
CAKaiser Permanente-Walnut CreekWalnut Creek94596NCT05564390Map
CAKaiser Permanente-Walnut CreekWalnut Creek94596NCT06317649Map
CABerenson Cancer CenterWest Hollywood90069NCT06115135Map
CAPIH Health HospitalWhittier90602NCT05963074Map
CAPih Health Whittier HospitalWhittier90602NCT06846671Map
CAKaiser Permanente-Woodland HillsWoodland Hills91367NCT04269902Map
COChildren's Hospital ColoradoAurora80045NCT05292664Map
COChildren's Hospital ColoradoAurora80045NCT05183035Map
COChildren's Hospital ColoradoAurora80045NCT06177067Map
COChildren's Hospital ColoradoAurora80045NCT06317662Map
COCU Anschutz Medical CampusAurora80045NCT05287568Map
CORocky Mountain Cancer CentersAurora80012NCT06852222Map
CORocky Mountain Cancer Centers - Aurora /ID# 267549Aurora80012NCT06428019Map
CORocky Mountain Cancer Centers (Williams) UsorAurora80012-5405NCT06846671Map
CORocky Mountain Cancer Centers (Williams) UsorAurora80012-5405NCT06943872Map
COUniversity of ColoradoAurora80045NCT05735184Map
COUniversity of ColoradoAurora80045NCT07007312Map
COUniversity of Colorado HospitalAurora80045NCT05287568Map
COUniversity of Colorado HospitalAurora80045NCT06429449Map
COUniverstiy of Colorado HospitalAurora80045NCT06232655Map
COColorado Blood Cancer InstituteDenver80218NCT04988555Map
COColorado Blood Cancer InstituteDenver80218NCT05735184Map
COColorado Blood Cancer InstituteDenver80218NCT03331198Map
COColorado Blood Cancer InstituteDenver80218NCT06634394Map
COColorado Blood Cancer InstituteDenver80218NCT07007312Map
COGrand Valley OncologyGrand Junction81505NCT04269902Map
COGrand Valley OncologyGrand Junction81505NCT05963074Map
CTSmilow Cancer Hospital-Derby Care CenterDerby06418NCT06649812Map
CTSmilow Cancer Hospital Care Center - GuilfordGuilford06437NCT06649812Map
CTConnecticut Children's Medical CenterHartford06106NCT06317662Map
CTHartford HealthCare Cancer InstituteHartford06106NCT07007312Map
CTYale Cancer Center and Smilow Cancer HospitalNew Haven06510NCT05735184Map
CTYale UniversityNew Haven06520NCT05554406Map
CTYale UniversityNew Haven06520NCT05564390Map
CTYale UniversityNew Haven06510NCT04256317Map
CTYale UniversityNew Haven06520NCT03850574Map
CTYale UniversityNew Haven06511NCT05183035Map
CTYale UniversityNew Haven06520NCT06317649Map
CTYale UniversityNew Haven06520NCT06317662Map
CTYale UniversityNew Haven06520NCT06649812Map
CTYale University School of MedicineNew Haven06510NCT07007312Map
CTYale University School of Medicine /ID# 266224New Haven06510NCT06428019Map
CTYale University Yale Cancer CenterNew Haven06520-8028NCT06943872Map
CTYale-New Haven HospitalNew Haven06510NCT06419634Map
CTEastern Connecticut Hematology and OncologyNorwich06360-2700NCT06943872Map
CTVeterans Affairs Connecticut Healthcare System-West Haven CampusWest Haven06516NCT05564390Map
CTVeterans Affairs Connecticut Healthcare System-West Haven CampusWest Haven06516NCT06317649Map
DEBeebe South Coastal Health CampusMillville19967NCT04269902Map
DEHelen F Graham Cancer CenterNewark19713NCT04269902Map
DEMedical Oncology Hematology Consultants PANewark19713NCT04269902Map
DEMedical Oncology Hematology Consultants, PANewark19713NCT06852222Map
DEBeebe Health CampusRehoboth Beach19971NCT04269902Map
DEAlfred I duPont Hospital for ChildrenWilmington19803NCT06317662Map
DENemours Alfred I. Dupont Hospital for ChildrenWilmington19803NCT05183035Map
DCChildren's National - Main HospitalWashington D.C.20010NCT05183035Map
DCChildren's National Medical CenterWashington D.C.20010NCT06317662Map
DCGeorgetown University Medical CenterWashington D.C.20007NCT03331198Map
DCSibley Memorial HospitalWashington D.C.20016NCT04269902Map
FLUM Sylvester Comprehensive Cancer Center at AventuraAventura33180NCT06311227Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables33146NCT06311227Map
FLUniversity of Miami, Lennar Foundation Medical CenterCoral Gables33146NCT05530421Map
FLUM Sylvester Comprehensive Cancer Center at Coral SpringsCoral Springs33065NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at Coral SpringsCoral Springs33065NCT06311227Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT06311227Map
FLUniversity of Miami, Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach33442NCT05530421Map
FLUM Sylvester Comprehensive Cancer Center at DoralDoral33166NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at DoralDoral33166NCT06311227Map
FLHoly Cross HospitalFort Lauderdale33308NCT04269902Map
FLFlorida Cancer Specialists & Research InstituteFort Myers33901NCT06852222Map
FLFlorida Oncology and HematologyFort Myers33912NCT06846671Map
FLGolisano Children's Hospital of Southwest FloridaFort Myers33908NCT05183035Map
FLMalcolm Randall V.A. Medical Center /ID# 267825Gainesville32608NCT06428019Map
FLUF Health Cancer Institute - GainesvilleGainesville32610NCT05564390Map
FLUF Health Cancer Institute - GainesvilleGainesville32610NCT06317649Map
FLUF Health Cancer Institute - GainesvilleGainesville32610NCT06317662Map
FLUniversity of Florida Health Shands Children's HospitalGainesville32610NCT05183035Map
FLMemorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood33021NCT06317662Map
FLMemorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood33021NCT06672146Map
FLUM Sylvester Comprehensive Cancer Center at HollywoodHollywood33021NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at HollywoodHollywood33021NCT06311227Map
FLBaptist Md Anderson Cancer CenterJacksonville32207-8432NCT06846671Map
FLCancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713Jacksonville32256NCT06428019Map
FLMayo ClinicJacksonville32224NCT03331198Map
FLMayo Clinic - JacksonvilleJacksonville32224NCT03331198Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT05554406Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT05564390Map
FLMayo Clinic in FloridaJacksonville32224-9980NCT04840602Map
FLMayo Clinic JacksonvilleJacksonville32224NCT05735184Map
FLNemours Children's Clinic-JacksonvilleJacksonville32207NCT06317662Map
FLNemours Children's Specialty Care JacksonvilleJacksonville32207NCT05183035Map
FLJupiter ResearchJupiter33458NCT06852222Map
FLMiami Cancer InstituteMiami33176NCT05554393Map
FLMiami Cancer InstituteMiami33176NCT05554406Map
FLMiami Cancer InstituteMiami33176NCT05564390Map
FLMiami Cancer InstituteMiami33176NCT06317649Map
FLMiami Cancer InstituteMiami33176NCT06672146Map
FLSylvester Comprehensive Cancer CenterMiami33136NCT06501196Map
FLUM Sylvester Comprehensive Cancer Center at KendallMiami33176NCT04840602Map
FLUM Sylvester Comprehensive Cancer Center at KendallMiami33176NCT06311227Map
FLUniversity of MiamiMiami33136NCT05442216Map
FLUniversity of MiamiMiami33136NCT05597306Map
FLUniversity of MiamiMiami33136NCT04988555Map
FLUniversity of MiamiMiami33136NCT06456463Map
FLUniversity of MiamiMiami33124NCT06634394Map
FLUniversity of MiamiMiami33136NCT06782542Map
FLUniversity of MiamiMiami33136NCT07007312Map
FLUniversity of Miami - Miller School of MedicineMiami33136NCT03850574Map
FLUniversity of Miami - Sylvester Comprehensive Cancer CenterMiami33136NCT04256317Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT04840602Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT06311227Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT06317662Map
FLUniversity of Miami Miller School of Medicine-Sylvester Cancer CenterMiami33136NCT06504459Map
FLUniversity of Miami, Sylvester Comprehensive Cancer CenterMiami33136NCT05530421Map
FLMount Sinai Medical Center CampusMiami Beach33140-2948NCT05963074Map
FLUniversity of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami33181NCT04840602Map
FLThe Oncology InstituteNorth Miami Beach33169NCT05963074Map
FLMid Florida Hematology OncologyOrange32763NCT05963074Map
FLMid Florida Hematology And Oncology Center /ID# 269159Orange City32763NCT06428019Map
FLAdventHealth Cancer InstituteOrlando32804NCT06456463Map
FLAdventHealth OrlandoOrlando32803NCT05442216Map
FLAdventHealth OrlandoOrlando32803NCT06317662Map
FLArnold Palmer Hospital for ChildrenOrlando32806NCT06317662Map
FLNemours Children's HospitalOrlando32827NCT06317662Map
FLNemours Children's Hospital - OrlandoOrlando32827NCT05183035Map
FLOrlando Health Cancer InstituteOrlando32806NCT06852222Map
FLMemorial Hospital WestPembroke Pines33028NCT05554393Map
FLMemorial Hospital WestPembroke Pines33028NCT05554406Map
FLMemorial Hospital WestPembroke Pines33028NCT05564390Map
FLMemorial Hospital WestPembroke Pines33028NCT06672146Map
FLMemorial Hospital West ( Site 5410)Pembroke Pines33028NCT05947851Map
FLNemours Children's Clinic - PensacolaPensacola32504NCT06317662Map
FLUM Sylvester Comprehensive Cancer Center at PlantationPlantation33324NCT04840602Map
FLComprehensive Hematology Oncology /ID# 267644St. Petersburg33709NCT06428019Map
FLJohns Hopkins All Children's HospitalSt. Petersburg33701NCT06317662Map
FLMoffit Cancer centerTampa33612NCT06852222Map
FLMoffitt Cancer CenterTampa33612NCT06501196Map
FLMoffitt Cancer CenterTampa33612NCT06511882Map
FLMoffitt Cancer CenterTampa33612NCT06660368Map
FLMoffitt Cancer Center & Research InstituteTampa33612NCT07007312Map
FLSaint Joseph's Hospital - TampaTampa33607NCT05183035Map
FLSaint Joseph's Hospital/Children's Hospital-TampaTampa33607NCT06317662Map
FLSaint Mary's Medical CenterWest Palm Beach33407NCT06317662Map
FLCleveland Clinic FloridaWeston33331-3609NCT06846671Map
FLCleveland Clinic FloridaWeston33331NCT06852222Map
FLCleveland Clinic FloridaWeston33331-3609NCT06943872Map
GAPhoebe Putney Memorial HospitalAlbany31701NCT05554393Map
GAPhoebe Putney Memorial HospitalAlbany31701NCT05554406Map
GAPhoebe Putney Memorial HospitalAlbany31701NCT05564390Map
GAPhoebe Putney Memorial HospitalAlbany31701NCT06317649Map
GAChildren's Healthcare of AtlantaAtlanta30322NCT05183035Map
GAChildren's Healthcare of AtlantaAtlanta30329NCT06177067Map
GAChildren's Healthcare of Atlanta - Arthur M Blank HospitalAtlanta30329NCT06317662Map
GAChildren's Healthcare of Atlanta at Arthur M. Blank HospitalAtlanta30329NCT05292664Map
GAEmory Healthcare - The Emory ClinicAtlanta30308NCT05735184Map
GAEmory UniversityAtlanta30308NCT03013998Map
GAEmory University Winship Cancer InstituteAtlanta30322-1013NCT06846671Map
GAEmory Winship Cancer InstituteAtlanta30322NCT04068597Map
GANorthside Cancer CenterAtlanta30342NCT06846671Map
GAThe Blood and Marrow Transplant Group of Georgia (BMTGA)Atlanta30342NCT03331198Map
GAUniversity of Emory - Winship Cancer InstituteAtlanta30322NCT04256317Map
GAWinship Cancer Institute of Emory University /ID# 230643Atlanta30322NCT04895436Map
GAAugusta University Medical CenterAugusta30912NCT05554406Map
GAAugusta University Medical CenterAugusta30912NCT05564390Map
GAAugusta University Medical CenterAugusta30912NCT06317649Map
GAAugusta University Medical CenterAugusta30912NCT06672146Map
GAGeorgia Cancer Center at Augusta UniversityAugusta30912NCT05735184Map
GACity of Hope - AtlantaNewnan30265NCT04588922Map
GACity of Hope Atlanta Cancer CenterNewnan30265NCT07218510Map
HIHawaii Cancer Care - Westridge‘Aiea96701NCT05554406Map
HIHawaii Cancer Care - Westridge‘Aiea96701NCT05564390Map
HIHawaii Cancer Care - Westridge‘Aiea96701NCT06317649Map
HIPali Momi Medical Center‘Aiea96701NCT05554406Map
HIPali Momi Medical Center‘Aiea96701NCT05564390Map
HIPali Momi Medical Center‘Aiea96701NCT06317649Map
HIHawaii Cancer Care Inc - Waterfront PlazaHonolulu96813NCT05554406Map
HIHawaii Cancer Care Inc - Waterfront PlazaHonolulu96813NCT05564390Map
HIHawaii Cancer Care Inc - Waterfront PlazaHonolulu96813NCT06317649Map
HIKaiser Permanente Moanalua Medical CenterHonolulu96819NCT05564390Map
HIKaiser Permanente Moanalua Medical CenterHonolulu96819NCT06317649Map
HIKapi'olani Medical Center for Women and ChildrenHonolulu96826NCT05183035Map
HIKapiolani Medical Center for Women and ChildrenHonolulu96826NCT05554406Map
HIKapiolani Medical Center for Women and ChildrenHonolulu96826NCT05564390Map
HIKapiolani Medical Center for Women and ChildrenHonolulu96826NCT06317662Map
HIStraub Clinic and HospitalHonolulu96813NCT05554406Map
HIStraub Clinic and HospitalHonolulu96813NCT05564390Map
HIStraub Clinic and HospitalHonolulu96813NCT06317649Map
IDBoise VA Medical CenterBoise83702NCT05963074Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT05554393Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT05554406Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT05564390Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT04269902Map
IDSaint Alphonsus Cancer Care Center-BoiseBoise83706NCT06317649Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05554393Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05554406Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT05564390Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT06317649Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT06317662Map
IDSaint Luke's Cancer Institute - BoiseBoise83712NCT06672146Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT05554393Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT05554406Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT05564390Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT04269902Map
IDSaint Alphonsus Cancer Care Center-CaldwellCaldwell83605NCT06317649Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT05554393Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT05554406Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT05564390Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT04269902Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT06317649Map
IDKootenai Health - Coeur d'AleneCoeur d'Alene83814NCT06672146Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05554393Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05554406Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT05564390Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT06317649Map
IDSaint Luke's Cancer Institute - FruitlandFruitland83619NCT06672146Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05554393Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05554406Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT05564390Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT06317649Map
IDSaint Luke's Cancer Institute - MeridianMeridian83642NCT06672146Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05554393Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05554406Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT05564390Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT04840602Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT04269902Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT06317649Map
IDSaint Alphonsus Cancer Care Center-NampaNampa83687NCT06672146Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05554393Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05554406Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT05564390Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT06317649Map
IDSaint Luke's Cancer Institute - NampaNampa83687NCT06672146Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT05554393Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT05554406Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT05564390Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT04269902Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT06317649Map
IDKootenai Clinic Cancer Services - Post FallsPost Falls83854NCT06672146Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT05554393Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT05554406Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT05564390Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT04269902Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT06317649Map
IDKootenai Clinic Cancer Services - SandpointSandpoint83864NCT06672146Map
ILAdvocate Outpatient Center - AuroraAurora60506NCT05564390Map
ILRush-Copley Medical CenterAurora60504NCT04269902Map
ILAdvocate Good Shepherd HospitalBarrington60010NCT05564390Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT05554406Map
ILIllinois CancerCare-BloomingtonBloomington61704NCT05564390Map
ILOSF Saint Joseph Medical CenterBloomington61701NCT05554406Map
ILOSF Saint Joseph Medical CenterBloomington61701NCT05564390Map
ILIllinois CancerCare-CantonCanton61520NCT05554406Map
ILIllinois CancerCare-CantonCanton61520NCT05564390Map
ILIllinois CancerCare-CarthageCarthage62321NCT05554406Map
ILIllinois CancerCare-CarthageCarthage62321NCT05564390Map
ILCentralia Oncology ClinicCentralia62801NCT05554393Map
ILCentralia Oncology ClinicCentralia62801NCT04840602Map
ILAdvocate Illinois Masonic Medical CenterChicago60657NCT05564390Map
ILAnn & Robert H Lurie Children's Hospital of ChicagoChicago60611NCT05292664Map
ILAnn & Robert H. Lurie Children's Hospital of ChicagoChicago60611NCT05183035Map
ILComer Children's HospitalChicago60637NCT05183035Map
ILLurie Children's Hospital-ChicagoChicago60611NCT06317662Map
ILNorthwesternChicago60611NCT04988555Map
ILNorthwestern Medicine - Northwestern Memorial Hospital Galter PavilionChicago60611NCT06501196Map
ILNorthwestern Memorial HospitalChicago60611NCT03331198Map
ILNorthwestern Memorial HospitalChicago60611NCT06419634Map
ILNorthwestern UniversityChicago60611NCT05554393Map
ILNorthwestern UniversityChicago60611NCT05554406Map
ILNorthwestern UniversityChicago60611NCT05564390Map
ILNorthwestern UniversityChicago60611NCT04269902Map
ILNorthwestern UniversityChicago60611NCT03331198Map
ILNorthwestern UniversityChicago60611NCT06317649Map
ILNorthwestern UniversityChicago60611NCT06649812Map
ILNorthwestern UniversityChicago60611NCT06672146Map
ILNorthwestern UniversityChicago60611NCT06943872Map
ILRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityChicago60611NCT05735184Map
ILUniversity of ChicagoChicago60637NCT03013998Map
ILUniversity of ChicagoChicago60637NCT06456463Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05554393Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05554406Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT05564390Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT04269902Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT06317662Map
ILUniversity of Chicago Comprehensive Cancer CenterChicago60637NCT06672146Map
ILUniversity of Chicago Medical CenterChicago60637NCT04855695Map
ILUniversity of Chicago Medical CenterChicago60637NCT03331198Map
ILUniversity Of Chicago Medical CenterChicago60637NCT03331198Map
ILUniversity of Chicago MedicineChicago60637NCT06852222Map
ILUniversity of Chicago Medicine Comprehensive Cancer CenterChicago60637NCT07294677Map
ILUniversity of IllinoisChicago60612NCT05564390Map
ILUniversity of IllinoisChicago60612NCT06317649Map
ILUniversity of IllinoisChicago60612NCT06672146Map
ILAMG Crystal Lake - OncologyCrystal Lake60014NCT05564390Map
ILCarle at The RiverfrontDanville61832NCT05564390Map
ILCarle at The RiverfrontDanville61832NCT04840602Map
ILCarle at The RiverfrontDanville61832NCT04269902Map
ILCarle at The RiverfrontDanville61832NCT06317649Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT05554393Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT05554406Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT05564390Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT04840602Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT04269902Map
ILCancer Care Specialists of Illinois - DecaturDecatur62526NCT06317649Map
ILDecatur Memorial HospitalDecatur62526NCT05554393Map
ILDecatur Memorial HospitalDecatur62526NCT05554406Map
ILDecatur Memorial HospitalDecatur62526NCT05564390Map
ILDecatur Memorial HospitalDecatur62526NCT06317649Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT05564390Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT04269902Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT06317649Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT06649812Map
ILNorthwestern Medicine Cancer Center KishwaukeeDeKalb60115NCT06672146Map
ILIllinois CancerCare-DixonDixon61021NCT05554406Map
ILIllinois CancerCare-DixonDixon61021NCT05564390Map
ILAdvocate Good Samaritan HospitalDowners Grove60515NCT05564390Map
ILCarle Physician Group-EffinghamEffingham62401NCT05564390Map
ILCarle Physician Group-EffinghamEffingham62401NCT04840602Map
ILCarle Physician Group-EffinghamEffingham62401NCT04269902Map
ILCarle Physician Group-EffinghamEffingham62401NCT06317649Map
ILCrossroads Cancer CenterEffingham62401NCT05554393Map
ILCrossroads Cancer CenterEffingham62401NCT05554406Map
ILCrossroads Cancer CenterEffingham62401NCT05564390Map
ILCrossroads Cancer CenterEffingham62401NCT04840602Map
ILCrossroads Cancer CenterEffingham62401NCT04269902Map
ILCrossroads Cancer CenterEffingham62401NCT06317649Map
ILAdvocate Sherman HospitalElgin60123NCT05564390Map
ILElmhurst Memorial HospitalElmhurst60126NCT04269902Map
ILIllinois CancerCare-EurekaEureka61530NCT05554406Map
ILIllinois CancerCare-EurekaEureka61530NCT05564390Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT05554393Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT05554406Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT05564390Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT04269902Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT06317649Map
ILNorthShore University HealthSystem-Evanston HospitalEvanston60201NCT06672146Map
ILNorthwestern UniversityEvanston60208NCT03824483Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT05554406Map
ILIllinois CancerCare-GalesburgGalesburg61401NCT05564390Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT05564390Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT04269902Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT06317649Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT06649812Map
ILNorthwestern Medicine Cancer Center DelnorGeneva60134NCT06672146Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT05554393Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT05554406Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT05564390Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT04269902Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT06317649Map
ILNorthShore University HealthSystem-Glenbrook HospitalGlenview60026NCT06672146Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT05564390Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT04269902Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT06317649Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT06649812Map
ILNorthwestern Medicine Glenview Outpatient CenterGlenview60026NCT06672146Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT05564390Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT04269902Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT06317649Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT06649812Map
ILNorthwestern Medicine Grayslake Outpatient CenterGrayslake60030NCT06672146Map
ILIngalls Memorial HospitalHarvey60426NCT04269902Map
ILAdvocate South Suburban HospitalHazel Crest60429NCT05564390Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT05554393Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT05554406Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT05564390Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT04269902Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT06317649Map
ILNorthShore University HealthSystem-Highland Park HospitalHighland Park60035NCT06672146Map
ILEdward Hines Jr VA HospitalHines60141NCT05564390Map
ILEdward Hines Jr VA HospitalHines60141NCT06317649Map
ILHope and Healing Cancer ServicesHinsdale60521NCT05963074Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT05554406Map
ILIllinois CancerCare-Kewanee ClinicKewanee61443NCT05564390Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT05564390Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT04269902Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT06317649Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT06649812Map
ILNorthwestern Medicine Lake Forest HospitalLake Forest60045NCT06672146Map
ILAMG Libertyville - OncologyLibertyville60048NCT05564390Map
ILCondell Memorial HospitalLibertyville60048NCT05564390Map
ILIllinois CancerCare-MacombMacomb61455NCT05554406Map
ILIllinois CancerCare-MacombMacomb61455NCT05564390Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT05564390Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT04840602Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT04269902Map
ILCarle Physician Group-Mattoon/CharlestonMattoon61938NCT06317649Map
ILLoyola University Medical CenterMaywood60153NCT05554393Map
ILLoyola University Medical CenterMaywood60153NCT05554406Map
ILLoyola University Medical CenterMaywood60153NCT05564390Map
ILLoyola University Medical CenterMaywood60153NCT04269902Map
ILLoyola University Medical CenterMaywood60153NCT05735184Map
ILLoyola University Medical CenterMaywood60153NCT06317649Map
ILLoyola University Medical CenterMaywood60153NCT06672146Map
ILSSM Health Good SamaritanMount Vernon62864NCT04269902Map
ILEdward Hospital/Cancer CenterNaperville60540NCT04269902Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT05554393Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT05554406Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT04269902Map
ILUC Comprehensive Cancer Center at Silver CrossNew Lenox60451NCT06672146Map
ILIllinois Cancer SpecialistsNiles60714NCT06852222Map
ILIllinois Cancer Specialists (Niles) UsorNiles60714-5905NCT06943872Map
ILCancer Care Center of O'FallonO'Fallon62269NCT05554393Map
ILCancer Care Center of O'FallonO'Fallon62269NCT05554406Map
ILCancer Care Center of O'FallonO'Fallon62269NCT05564390Map
ILCancer Care Center of O'FallonO'Fallon62269NCT04840602Map
ILCancer Care Center of O'FallonO'Fallon62269NCT04269902Map
ILCancer Care Center of O'FallonO'Fallon62269NCT06317649Map
ILNorthwestern Medicine Oak BrookOak Brook60523NCT06649812Map
ILAdvocate Children's Hospital-Oak LawnOak Lawn60453NCT06317662Map
ILAdvocate Christ Medical CenterOak Lawn60453-2699NCT05564390Map
ILAdvocate Outpatient Center - Oak LawnOak Lawn60453NCT05564390Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT05564390Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT06317649Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT06649812Map
ILNorthwestern Medicine Orland ParkOrland Park60462NCT06672146Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT05554393Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT05554406Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT04269902Map
ILUniversity of Chicago Medicine-Orland ParkOrland Park60462NCT06672146Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT05554406Map
ILIllinois CancerCare-Ottawa ClinicOttawa61350NCT05564390Map
ILAdvocate High Tech Medical ParkPalos Heights60463NCT05564390Map
ILAdvocate Children's Hospital-Park RidgePark Ridge60068NCT06317662Map
ILAdvocate Lutheran General HospitalPark Ridge60068NCT05564390Map
ILIllinois CancerCare-PekinPekin61554NCT05554406Map
ILIllinois CancerCare-PekinPekin61554NCT05564390Map
ILIllinois CancerCare-PeoriaPeoria61615NCT05554406Map
ILIllinois CancerCare-PeoriaPeoria61615NCT05564390Map
ILMethodist Medical Center of IllinoisPeoria61636NCT05554406Map
ILMethodist Medical Center of IllinoisPeoria61636NCT05564390Map
ILOSF Saint Francis Medical CenterPeoria61637NCT05554406Map
ILOSF Saint Francis Medical CenterPeoria61637NCT05564390Map
ILIllinois CancerCare-PeruPeru61354NCT05554406Map
ILIllinois CancerCare-PeruPeru61354NCT05564390Map
ILEdward Hospital/Cancer Center?PlainfieldPlainfield60585NCT04269902Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT05554406Map
ILIllinois CancerCare-PrincetonPrinceton61356NCT05564390Map
ILUW Health Carbone Cancer Center RockfordRockford61114NCT04269902Map
ILMemorial Hospital EastShiloh62269NCT06317649Map
ILMemorial Hospital EastShiloh62269NCT06649812Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05554393Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05554406Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT05564390Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT04840602Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT04269902Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT06317649Map
ILSouthern Illinois University School of MedicineSpringfield62702NCT06317662Map
ILSpringfield ClinicSpringfield62702NCT05554393Map
ILSpringfield ClinicSpringfield62702NCT05554406Map
ILSpringfield ClinicSpringfield62702NCT05564390Map
ILSpringfield ClinicSpringfield62702NCT04840602Map
ILSpringfield ClinicSpringfield62702NCT04269902Map
ILSpringfield ClinicSpringfield62702NCT05963074Map
ILSpringfield ClinicSpringfield62702NCT06317649Map
ILSpringfield Clinic - First /ID# 270145Springfield62702NCT06428019Map
ILSpringfield Memorial HospitalSpringfield62781NCT05554393Map
ILSpringfield Memorial HospitalSpringfield62781NCT05554406Map
ILSpringfield Memorial HospitalSpringfield62781NCT05564390Map
ILSpringfield Memorial HospitalSpringfield62781NCT04840602Map
ILSpringfield Memorial HospitalSpringfield62781NCT06317649Map
ILCarle Cancer CenterUrbana61801NCT05564390Map
ILCarle Cancer CenterUrbana61801NCT04840602Map
ILCarle Cancer CenterUrbana61801NCT04269902Map
ILCarle Cancer CenterUrbana61801NCT06317649Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT05564390Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT04269902Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT06317649Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT06649812Map
ILNorthwestern Medicine Cancer Center WarrenvilleWarrenville60555NCT06672146Map
ILIllinois CancerCare - WashingtonWashington61571NCT05554406Map
ILIllinois CancerCare - WashingtonWashington61571NCT05564390Map
ILRush-Copley Healthcare CenterYorkville60560NCT04269902Map
ILCity of Hope - ChicagoZion60099NCT04588922Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT05554393Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT05554406Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT04269902Map
INUChicago Medicine Northwest IndianaCrown Point46307NCT06672146Map
INNorthwest Cancer Center - Dyer Clinic /ID# 268478Dyer46311NCT06428019Map
INCommunity Health NetworkIndianapolis46227NCT04068597Map
INFranciscan St. Francis Health - Indiana Blood and Marrow Transplantation (IBMT)Indianapolis46237NCT03331198Map
INIndiana University School of MedicineIndianapolis46202NCT05183035Map
INIndiana University/Melvin and Bren Simon Cancer CenterIndianapolis46202NCT05554406Map
INIndiana University/Melvin and Bren Simon Cancer CenterIndianapolis46202NCT05564390Map
INIndiana University/Melvin and Bren Simon Cancer CenterIndianapolis46202NCT04269902Map
INIndiana University/Melvin and Bren Simon Cancer CenterIndianapolis46202NCT06317649Map
INRiley Hospital for ChildrenIndianapolis46202NCT06317662Map
IAMary Greeley Medical CenterAmes50010NCT04840602Map
IAMary Greeley Medical CenterAmes50010NCT04269902Map
IAMary Greeley Medical CenterAmes50010NCT06649812Map
IAMcFarland Clinic - AmesAmes50010NCT04840602Map
IAMcFarland Clinic - AmesAmes50010NCT04269902Map
IAMcFarland Clinic - AmesAmes50010NCT06649812Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT05564390Map
IAUI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny50023NCT04269902Map
IAMercy HospitalCedar Rapids52403NCT06649812Map
IAOncology Associates at Mercy Medical CenterCedar Rapids52403NCT06649812Map
IAPhysicians' Clinic of Iowa PCCedar Rapids52402NCT04269902Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT05564390Map
IAUI Health Care Mission Cancer and Blood - West Des Moines ClinicClive50325NCT04269902Map
IABlank Children's HospitalDes Moines50309NCT06317662Map
IABroadlawns Medical CenterDes Moines50314NCT04269902Map
IAIowa Methodist Medical CenterDes Moines50309NCT05564390Map
IAIowa Methodist Medical CenterDes Moines50309NCT04269902Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT05564390Map
IAMercy Medical Center - Des MoinesDes Moines50314NCT04269902Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT05564390Map
IAUI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines50309NCT04269902Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT05564390Map
IAUI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines50314NCT04269902Map
IAUniversity of Iowa Health Care /ID# 267206Des Moines50314-3017NCT06428019Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT04840602Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT04269902Map
IAMcFarland Clinic - Trinity Cancer CenterFort Dodge50501NCT06649812Map
IAIowa City VA Health Care SystemIowa City52246NCT05963074Map
IAUniversity of IowaIowa City52246NCT07007312Map
IAUniversity of Iowa Health CareIowa City52242NCT07177079Map
IAUniversity of Iowa Hospitals & ClinicsIowa City52242NCT05735184Map
IAUniversity of Iowa Stead Family Children's HospitalIowa City52242NCT05183035Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT05554393Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT05554406Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT05564390Map
IAUniversity of Iowa/Holden Comprehensive Cancer CenterIowa City52242NCT06317649Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT04840602Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT04269902Map
IAMcFarland Clinic - MarshalltownMarshalltown50158NCT06649812Map
IAUI Healthcare Mission Cancer and Blood - PellaPella50219NCT05564390Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT05564390Map
IAUI Health Care Mission Cancer and Blood - Waukee ClinicWaukee50263NCT04269902Map
IAThe Iowa Clinic PCWest Des Moines50266NCT05564390Map
KSThe University of Kansas Cancer Center ,Investigational Drug ServicesFairway66205NCT04227847Map
KSThe University of Kansas Clinical Research CenterFairway66205NCT04227847Map
KSThe University of Kansas Medical Center Research InstituteFairway66205NCT05735184Map
KSUniversity of KansasFairway66205NCT06634394Map
KSUniversity of Kansas Clinical Research CenterFairway66205NCT05554393Map
KSUniversity of Kansas Clinical Research CenterFairway66205NCT05554406Map
KSUniversity of Kansas Clinical Research CenterFairway66205NCT05564390Map
KSUniversity of Kansas Clinical Research CenterFairway66205NCT03013998Map
KSUniversity of Kansas Clinical Research CenterFairway66205NCT06317649Map
KSUniversity of Kansas Clinical Research CenterFairway66205NCT06672146Map
KSHaysMedHays67601NCT05564390Map
KSHaysMedHays67601NCT04269902Map
KSThe University of Kansas HospitalKansas City66160NCT04227847Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT05554393Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT05554406Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT05564390Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT04269902Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT06311227Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT06317649Map
KSUniversity of Kansas Cancer CenterKansas City66160NCT06672146Map
KSUniversity of Kansas Hospital Cambridge North Tower AKansas City66160NCT04227847Map
KSUniversity of Kansas Medical center Medical office buildingKansas City66160NCT04227847Map
KSUniversity of Kansas Medical Center Research InstituteKansas City66160NCT04227847Map
KSLawrence Memorial HospitalLawrence66044NCT05564390Map
KSLawrence Memorial HospitalLawrence66044NCT04269902Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT05564390Map
KSThe University of Kansas Cancer Center - OlatheOlathe66061NCT04269902Map
KSThe University of Kansas Cancer Center - Indian Creek CampusOverland Park66211NCT04227847Map
KSThe University of Kansas Cancer Center - Overland ParkOverland Park66210NCT04227847Map
KSUniversity of Kansas Cancer Center-Overland ParkOverland Park66210NCT05564390Map
KSUniversity of Kansas Cancer Center-Overland ParkOverland Park66210NCT04269902Map
KSUniversity of Kansas Cancer Center-Overland ParkOverland Park66210NCT06311227Map
KSUniversity of Kansas Hospital-Indian Creek CampusOverland Park66211NCT05554393Map
KSUniversity of Kansas Hospital-Indian Creek CampusOverland Park66211NCT05554406Map
KSUniversity of Kansas Hospital-Indian Creek CampusOverland Park66211NCT05564390Map
KSUniversity of Kansas Hospital-Indian Creek CampusOverland Park66211NCT06317649Map
KSSalina Regional Health CenterSalina67401NCT05564390Map
KSSalina Regional Health CenterSalina67401NCT04269902Map
KSCotton O'Neil Cancer Center / Stormont Vail HealthTopeka66606NCT06317649Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT05564390Map
KSUniversity of Kansas Health System Saint Francis CampusTopeka66606NCT04269902Map
KSThe University of Kansas Cancer CenterWestwood66205NCT04227847Map
KSThe University of Kansas Medical CenterWestwood66205NCT06445959Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT05554393Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT05554406Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT05564390Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT04269902Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT06311227Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT06317649Map
KSUniversity of Kansas Hospital-Westwood Cancer CenterWestwood66205NCT06672146Map
KYUniversity of KentuckyLexington40536NCT07007312Map
KYUniversity of Kentucky Markey Cancer CenterLexington40536NCT06852222Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT05554393Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT05554406Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT05564390Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT06317649Map
KYUniversity of Kentucky/Markey Cancer CenterLexington40536NCT06317662Map
KYNorton Cancer InstituteLouisville40207NCT06852222Map
KYNorton Cancer Institute - St. MatthewsLouisville40207NCT05735184Map
KYNorton Cancer Institute, St. Matthews CampusLouisville40207NCT04227847Map
KYNorton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmDLouisville40207NCT04227847Map
KYNorton Children's HospitalLouisville40202NCT05183035Map
KYNorton Children's HospitalLouisville40202NCT06317662Map
KYNorton Healthcare - Norton Cancer InstituteLouisville40202NCT03331198Map
KYNorton Hospitals, IncLouisville40202NCT04227847Map
KYNorton Women & Children's HospitalLouisville40207NCT04227847Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT05554393Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT05554406Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT05564390Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT06317649Map
KYThe James Graham Brown Cancer Center at University of LouisvilleLouisville40202NCT06672146Map
KYUniversity of Kentucky Markey Cancer CenterLouisville40202NCT05735184Map
KYUniversity of Louisville, Brown Cancer CenterLouisville40202NCT06943872Map
KYUofL Health Brown Cancer CenterLouisville40202NCT06852222Map
KYUofL Health Medical Center NortheastLouisville40245NCT05554393Map
KYUofL Health Medical Center NortheastLouisville40245NCT05554406Map
KYUofL Health Medical Center NortheastLouisville40245NCT05564390Map
KYUofL Health Medical Center NortheastLouisville40245NCT06317649Map
KYUofL Health Medical Center NortheastLouisville40245NCT06672146Map
LALSU Health Baton Rouge-North ClinicBaton Rouge70805NCT05554393Map
LALSU Health Baton Rouge-North ClinicBaton Rouge70805NCT05554406Map
LALSU Health Baton Rouge-North ClinicBaton Rouge70805NCT05564390Map
LALSU Health Baton Rouge-North ClinicBaton Rouge70805NCT06317649Map
LAMary Bird Perkins Cancer CenterBaton Rouge70809NCT06852222Map
LAMary Bird Perkins Cancer CenterBaton Rouge70809-3738NCT06943872Map
LAOur Lady of The LakeBaton Rouge70808NCT05554393Map
LAOur Lady of The LakeBaton Rouge70808NCT05554406Map
LAOur Lady of The LakeBaton Rouge70808NCT05564390Map
LAOur Lady of The LakeBaton Rouge70808NCT06317649Map
LAOur Lady of The LakeBaton Rouge70808NCT06672146Map
LAOur Lady of the Lake HospitalBaton Rouge70808-4365NCT06846671Map
LAOur Lady of the Lake Physician GroupBaton Rouge70808NCT05554393Map
LAOur Lady of the Lake Physician GroupBaton Rouge70808NCT05554406Map
LAOur Lady of the Lake Physician GroupBaton Rouge70808NCT05564390Map
LAOur Lady of the Lake Physician GroupBaton Rouge70808NCT06317649Map
LAOur Lady of the Lake Physician GroupBaton Rouge70808NCT06672146Map
LAOchsner MD Anderson Cancer CenterJefferson70121NCT05735184Map
LAChildren's Hospital New OrleansNew Orleans70118NCT06317662Map
LAOchsner Medical Center JeffersonNew Orleans70121NCT06317662Map
LAOchsner Medical Center JeffersonNew Orleans70121NCT06649812Map
MEHarold Alfond Center for Cancer CareAugusta04330NCT04269902Map
MEMaineHealth Cancer Care and IV Therapy - BrunswickBrunswick04011NCT05564390Map
MEMaineHealth Cancer Care and IV Therapy - BrunswickBrunswick04011NCT04269902Map
MEMaineHealth Cancer Care and IV Therapy - BrunswickBrunswick04011NCT06317649Map
MEMaineHealth Cancer Care and IV Therapy - BrunswickBrunswick04011NCT06672146Map
MEMid Coast HospitalBrunswick04011NCT05564390Map
MEMid Coast HospitalBrunswick04011NCT04269902Map
MEMid Coast HospitalBrunswick04011NCT06317649Map
MEMid Coast HospitalBrunswick04011NCT06672146Map
MEMaineHealth LincolnHealth HospitalDamariscotta04543NCT04269902Map
MEMaineHealth Maine Medical Center - PortlandPortland04102NCT05554393Map
MEMaineHealth Maine Medical Center - PortlandPortland04102NCT05554406Map
MEMaineHealth Maine Medical Center - PortlandPortland04102NCT05564390Map
MEMaineHealth Maine Medical Center - PortlandPortland04102NCT04269902Map
MEMaineHealth Maine Medical Center - PortlandPortland04102NCT06317649Map
MEMaineHealth Maine Medical Center - PortlandPortland04102NCT06672146Map
MEMaine Children's Cancer ProgramScarborough04074NCT06317662Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT05554393Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT05554406Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT05564390Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT04269902Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT06317649Map
MEMaineHealth Maine Medical Center- ScarboroughScarborough04074NCT06672146Map
MENew England Cancer SpecialistsScarborough04074NCT05168930Map
MEMaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland04106NCT05554393Map
MEMaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland04106NCT05554406Map
MEMaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland04106NCT05564390Map
MEMaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland04106NCT04269902Map
MEMaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland04106NCT06317649Map
MEMaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland04106NCT06672146Map
MDJohns Hopkins Main CenterBaltimore21287NCT04988555Map
MDJohns Hopkins School of MedicineBaltimore21205NCT05735184Map
MDJohns Hopkins UniversityBaltimore21218NCT06284486Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT05554406Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT05564390Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT04269902Map
MDJohns Hopkins University/Sidney Kimmel Cancer CenterBaltimore21287NCT06317662Map
MDSibley Memorial HospitalBaltimore20016NCT04988555Map
MDSinai Hospital of BaltimoreBaltimore21215NCT06317662Map
MDUniversity of MarylandBaltimore21201NCT04988555Map
MDUniversity of Maryland Greenebaum Comprehensive Cancer CenterBaltimore21201-1544NCT06943872Map
MDUniversity of Maryland Medical CenterBaltimore21201NCT03013998Map
MDUniversity of Maryland/Greenebaum Cancer CenterBaltimore21201NCT06311227Map
MDAmerican Oncology Partners of Maryland PaBethesda20817-7847NCT06846671Map
MDCenter for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 266445Bethesda20817NCT06428019Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT03986034Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT03223610Map
MDNational Institutes of Health Clinical CenterBethesda20892NCT06649812Map
MDNCI - Center for Cancer ResearchBethesda20892NCT06311227Map
MDThe Center for Cancer and Blood Disorders (CCBD)Bethesda20817NCT04068597Map
MDWalter Reed National Military Medical CenterBethesda20889-5600NCT05554393Map
MDWalter Reed National Military Medical CenterBethesda20889-5600NCT05554406Map
MDWalter Reed National Military Medical CenterBethesda20889-5600NCT05564390Map
MDWalter Reed National Military Medical CenterBethesda20889-5600NCT04269902Map
MDWalter Reed National Military Medical CenterBethesda20889-5600NCT06317649Map
MDMaryland Oncology Hematology - Silver Spring /ID# 267557Silver Spring20904NCT06428019Map
MABeth Israel Deaconess Medical CenterBoston02215NCT05554406Map
MABeth Israel Deaconess Medical CenterBoston02215NCT05564390Map
MABeth Israel Deaconess Medical CenterBoston02215NCT04855695Map
MABeth Israel Deaconess Medical CenterBoston02215NCT04227847Map
MABeth Israel Deaconess Medical CenterBoston02215NCT03331198Map
MABeth Israel Deaconess Medical CenterBoston02215NCT05168930Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06317649Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06456463Map
MABeth Israel Deaconess Medical CenterBoston02215NCT06510309Map
MABeth Israel Deaconess Medical CenterBoston02215NCT07374029Map
MABoston Medical CenterBoston02118NCT05451771Map
MABrigham and Women's HospitalBoston02215NCT06152809Map
MABrigham and Women's HospitalBoston02115NCT07148180Map
MADana Farber Cancer InstituteBoston02215NCT03113643Map
MADana Farber Cancer InstituteBoston02115NCT06852222Map
MADana Farber Cancer InstituteBoston02215-5418NCT06943872Map
MADana Farber Cancer Institute (Data Collection and Specimen Analysis)Boston02115NCT07231952Map
MADana Farber Cancer Institute (DFCI)Boston02114NCT06456463Map
MADana Farber/Mass General Brigham Cancer Care, IncBoston02215NCT04227847Map
MADana-Farber Cancer CenterBoston02215NCT06284486Map
MADana-Farber Cancer InstituteBoston02215NCT05292664Map
MADana-Farber Cancer InstituteBoston02215NCT05554393Map
MADana-Farber Cancer InstituteBoston02215NCT05554406Map
MADana-Farber Cancer InstituteBoston02215NCT05564390Map
MADana-Farber Cancer InstituteBoston02215NCT04855695Map
MADana-Farber Cancer InstituteBoston02114NCT04256317Map
MADana-Farber Cancer InstituteBoston02215NCT04269902Map
MADana-Farber Cancer InstituteBoston02215NCT03471260Map
MADana-Farber Cancer InstituteBoston02215NCT05168930Map
MADana-Farber Cancer InstituteBoston02215NCT05183035Map
MADana-Farber Cancer InstituteBoston02215NCT06152809Map
MADana-Farber Cancer InstituteBoston02215NCT06317649Map
MADana-Farber Cancer InstituteBoston02215NCT06317662Map
MADana-Farber Cancer InstituteBoston02115NCT06644183Map
MADana-Farber Cancer InstituteBoston02215NCT07148180Map
MADana-Farber Cancer Institute /ID# 230061Boston02215NCT04895436Map
MAMassachusetts General HospitalBoston02114NCT04988555Map
MAMassachusetts General HospitalBoston02114NCT04227847Map
MAMassachusetts General HospitalBoston02114NCT05735184Map
MAMassachusetts General HospitalBoston02114NCT03331198Map
MAMassachusetts General HospitalBoston02114NCT06419634Map
MAMassachusetts General HospitalBoston02114NCT06456463Map
MAMassachusetts General Hospital (Data Collection and Specimen Analysis)Boston02114NCT03824483Map
MAMassachusetts General Hospital Cancer CenterBoston02114NCT04560322Map
MATufts Medical CenterBoston02111NCT05554393Map
MATufts Medical CenterBoston02111NCT05554406Map
MATufts Medical CenterBoston02111NCT05564390Map
MATufts Medical CenterBoston02111NCT04269902Map
MATufts Medical CenterBoston02111NCT06317649Map
MATufts Medical CenterBoston02111NCT06672146Map
MALahey Hospital and Medical CenterBurlington01805NCT05554393Map
MALahey Hospital and Medical CenterBurlington01805NCT05554406Map
MALahey Hospital and Medical CenterBurlington01805NCT06317649Map
MALahey Medical Center-PeabodyPeabody01960NCT05554393Map
MALahey Medical Center-PeabodyPeabody01960NCT05554406Map
MALahey Medical Center-PeabodyPeabody01960NCT06317649Map
MASouth Shore HospitalSouth Weymouth02190NCT05168930Map
MATufts Medical Center Cancer Center StonehamStoneham02180NCT04269902Map
MAUMass Chan Medical SchoolWorcester01655NCT05735184Map
MAUMass Memorial Medical Center - University CampusWorcester01655NCT05564390Map
MAUMass Memorial Medical Center - University CampusWorcester01655NCT06317662Map
MAUMass Memorial Medical Center /ID# 270023Worcester01655NCT06428019Map
MAUniversity of MassachusettsWorcester01605NCT07007312Map
MIC S Mott Children's HospitalAnn Arbor48109NCT06317662Map
MIC.S. Mott Children's HospitalAnn Arbor48109-4259NCT05183035Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT05554406Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT05564390Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT04840602Map
MITrinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor48106NCT04269902Map
MIUniversity of MichiganAnn Arbor48109NCT03523975Map
MIUniversity of MichiganAnn Arbor48109NCT07007312Map
MIUniversity of Michigan Comprehensive Cancer CenterAnn Arbor48109NCT05735184Map
MIUniversity of Michigan Comprehensive Cancer CenterAnn Arbor48109-5362NCT03331198Map
MIUniversity Of Michigan Comprehensive Cancer CenterAnn Arbor48109NCT03331198Map
MIBronson Battle CreekBattle Creek49017NCT04269902Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05554393Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05554406Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT05564390Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT04840602Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT04269902Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT06317649Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT06672146Map
MITrinity Health IHA Medical Group Hematology Oncology - BrightonBrighton48114NCT06917911Map
MITrinity Health Medical Center - BrightonBrighton48114NCT04840602Map
MITrinity Health Medical Center - BrightonBrighton48114NCT04269902Map
MIHenry Ford Cancer Institute-DownriverBrownstown48183NCT04269902
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05554393Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05554406Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT05564390Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT04840602Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT04269902Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT06317649Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT06672146Map
MITrinity Health IHA Medical Group Hematology Oncology - CantonCanton48188NCT06917911Map
MITrinity Health Medical Center - CantonCanton48188NCT04840602Map
MITrinity Health Medical Center - CantonCanton48188NCT04269902Map
MIChelsea HospitalChelsea48118NCT04840602Map
MIChelsea HospitalChelsea48118NCT04269902Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05554393Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05554406Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT05564390Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT04840602Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT04269902Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT06317649Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT06672146Map
MITrinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea48118NCT06917911Map
MIHematology Oncology Consultants-ClarkstonClarkston48346NCT04840602Map
MIHematology Oncology Consultants-ClarkstonClarkston48346NCT04269902Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT05554393Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT05554406Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT05564390Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT04840602Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT04269902Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT06317649Map
MIHenry Ford Macomb Hospital-Clinton TownshipClinton Township48038NCT06672146Map
MIHenry Ford Medical Center-FairlaneDearborn48126NCT04269902Map
MIBarbara Ann Karmanos Cancer InstituteDetroit48201NCT03331198Map
MIChildren's Hospital of MichiganDetroit48201NCT05183035Map
MIHenry Ford Health Saint John HospitalDetroit48236NCT04269902Map
MIHenry Ford Health SystemDetroit48202NCT06852222Map
MIHenry Ford Health System Brigitte Harris Cancer PavillionDetroit48202NCT06456463Map
MIHenry Ford HospitalDetroit48202NCT05554393Map
MIHenry Ford HospitalDetroit48202NCT05554406Map
MIHenry Ford HospitalDetroit48202NCT05564390Map
MIHenry Ford HospitalDetroit48202NCT04840602Map
MIHenry Ford HospitalDetroit48202NCT04269902Map
MIHenry Ford HospitalDetroit48202NCT06317649Map
MIHenry Ford HospitalDetroit48202NCT06672146Map
MIHenry Ford Hospital /ID# 270973Detroit48202NCT06428019Map
MIKarmanos Cancer InstituteDetroit48201NCT04227847Map
MIKarmanos Cancer InstituteDetroit48201NCT05735184Map
MIWayne State University School of MedicineDetroit48201NCT07007312Map
MIWayne State University/Karmanos Cancer InstituteDetroit48201NCT05554406Map
MIWayne State University/Karmanos Cancer InstituteDetroit48201NCT05564390Map
MIHenry Ford River District HospitalEast China Township48054NCT04269902
MIOSF Saint Francis Hospital and Medical GroupEscanaba49829NCT06672146Map
MIKarmanos Cancer Institute Weisberg Cancer Treatment CenterFarmington Hills48334NCT04227847Map
MIWeisberg Cancer Treatment CenterFarmington Hills48334NCT05554406Map
MIWeisberg Cancer Treatment CenterFarmington Hills48334NCT05564390Map
MICancer Hematology Centers - FlintFlint48503NCT05554393Map
MICancer Hematology Centers - FlintFlint48503NCT05554406Map
MICancer Hematology Centers - FlintFlint48503NCT05564390Map
MICancer Hematology Centers - FlintFlint48503NCT04840602Map
MICancer Hematology Centers - FlintFlint48503NCT04269902Map
MICancer Hematology Centers - FlintFlint48503NCT06317649Map
MICancer Hematology Centers - FlintFlint48503NCT06672146Map
MIGenesys Hurley Cancer InstituteFlint48503NCT05554393Map
MIGenesys Hurley Cancer InstituteFlint48503NCT05554406Map
MIGenesys Hurley Cancer InstituteFlint48503NCT05564390Map
MIGenesys Hurley Cancer InstituteFlint48503NCT04840602Map
MIGenesys Hurley Cancer InstituteFlint48503NCT04269902Map
MIGenesys Hurley Cancer InstituteFlint48503NCT06317649Map
MIGenesys Hurley Cancer InstituteFlint48503NCT06672146Map
MIHurley Medical CenterFlint48503NCT05554393Map
MIHurley Medical CenterFlint48503NCT05554406Map
MIHurley Medical CenterFlint48503NCT05564390Map
MIHurley Medical CenterFlint48503NCT04840602Map
MIHurley Medical CenterFlint48503NCT04269902Map
MIHurley Medical CenterFlint48503NCT06317649Map
MICorewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids49503NCT04269902Map
MICorewell Health Grand Rapids Hospitals - Helen DeVos Children's HospitalGrand Rapids49503NCT06317662Map
MIThe Cancer and Hematology CentersGrand Rapids49503-2563NCT06943872Map
MITrinity Health Grand Rapids HospitalGrand Rapids49503NCT04269902Map
MIHenry Ford Saint John Hospital - AcademicGrosse Pointe Woods48236NCT04269902Map
MIHenry Ford Saint John Hospital - Van ElslanderGrosse Pointe Woods48236NCT04269902Map
MIAllegiance HealthJackson49201NCT05554393Map
MIAllegiance HealthJackson49201NCT05554406Map
MIAllegiance HealthJackson49201NCT05564390Map
MIAllegiance HealthJackson49201NCT04269902Map
MIAllegiance HealthJackson49201NCT06317649Map
MIAllegiance HealthJackson49201NCT06672146Map
MIBeacon Kalamazoo Cancer CenterKalamazoo49009NCT04269902Map
MIBronson Methodist HospitalKalamazoo49007NCT04269902Map
MIBronson Methodist HospitalKalamazoo49007NCT06317662Map
MIWest Michigan Cancer CenterKalamazoo49007NCT04269902Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT04840602Map
MIUniversity of Michigan Health - Sparrow LansingLansing48912NCT04269902Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05554393Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05554406Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT05564390Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT04840602Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT04269902Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT06317649Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT06672146Map
MITrinity Health Saint Mary Mercy Livonia HospitalLivonia48154NCT06917911Map
MIHenry Ford Saint John Hospital - Macomb MedicalMacomb48044NCT04269902Map
MITrinity Health Muskegon HospitalMuskegon49444NCT04269902Map
MICorewell Health Lakeland Hospitals - Niles HospitalNiles49120NCT04269902Map
MICancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores49444NCT04269902Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT05554393Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT05554406Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT05564390Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT04840602Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT04269902Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT06317649Map
MIHenry Ford Medical Center-ColumbusNovi48377NCT06672146Map
MIMichigan Healthcare Professionals PontiacPontiac48341NCT04840602Map
MIMichigan Healthcare Professionals PontiacPontiac48341NCT04269902Map
MINewland Medical Associates-PontiacPontiac48341NCT04840602Map
MINewland Medical Associates-PontiacPontiac48341NCT04269902Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT05554393Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT05554406Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT05564390Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT04840602Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT04269902Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT06317649Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT06672146Map
MITrinity Health Saint Joseph Mercy Oakland HospitalPontiac48341NCT06917911Map
MICorewell Health Reed City HospitalReed City49677NCT04269902Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT04840602Map
MIMyMichigan Medical Center SaginawSaginaw48601NCT04269902Map
MICorewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph49085NCT04269902Map
MIHenry Ford Health Providence Southfield HospitalSouthfield48075NCT04269902Map
MIMyMichigan Medical Center TawasTawas City48764NCT04840602Map
MIMyMichigan Medical Center TawasTawas City48764NCT04269902Map
MIMunson Medical CenterTraverse City49684NCT04269902Map
MIHenry Ford Health Warren HospitalWarren48093NCT04269902Map
MIHenry Ford Warren Hospital - GLCMSWarren48093NCT04269902Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT05554393Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT05554406Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT05564390Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT04840602Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT04269902Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT06317649Map
MIHenry Ford West Bloomfield HospitalWest Bloomfield48322NCT06672146Map
MIHenry Ford Wyandotte HospitalWyandotte48192NCT04269902Map
MIUniversity of Michigan Health - WestWyoming49519NCT04269902Map
MIHuron Gastroenterology PCYpsilanti48106NCT04840602Map
MIHuron Gastroenterology PCYpsilanti48106NCT04269902Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05554393Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05554406Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT05564390Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT04840602Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT04269902Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT06317649Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT06672146Map
MITrinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti48197NCT06917911Map
MITrinity Health Michigan Heart - Ann Arbor CampusYpsilanti48106NCT06852222Map
MNEssentia Health Saint Joseph's Medical CenterBrainerd56401NCT06649812Map
MNMercy HospitalCoon Rapids55433NCT05554393Map
MNMercy HospitalCoon Rapids55433NCT05554406Map
MNMercy HospitalCoon Rapids55433NCT05564390Map
MNMercy HospitalCoon Rapids55433NCT04269902Map
MNMercy HospitalCoon Rapids55433NCT06317649Map
MNMercy HospitalCoon Rapids55433NCT06672146Map
MNEssentia Health - Deer River ClinicDeer River56636NCT05554393Map
MNEssentia Health - Deer River ClinicDeer River56636NCT05554406Map
MNEssentia Health - Deer River ClinicDeer River56636NCT05564390Map
MNEssentia Health - Deer River ClinicDeer River56636NCT04269902Map
MNEssentia Health - Deer River ClinicDeer River56636NCT06317649Map
MNEssentia Health - Deer River ClinicDeer River56636NCT06649812Map
MNEssentia Health - Deer River ClinicDeer River56636NCT06672146Map
MNEssentia Health Cancer CenterDuluth55805NCT05554393Map
MNEssentia Health Cancer CenterDuluth55805NCT05554406Map
MNEssentia Health Cancer CenterDuluth55805NCT05564390Map
MNEssentia Health Cancer CenterDuluth55805NCT04269902Map
MNEssentia Health Cancer CenterDuluth55805NCT06317649Map
MNEssentia Health Cancer CenterDuluth55805NCT06649812Map
MNEssentia Health Cancer CenterDuluth55805NCT06672146Map
MNSt. Lukes Hospital of Duluth /ID# 250021Duluth55805NCT04895436Map
MNFairview Southdale HospitalEdina55435NCT05554393Map
MNFairview Southdale HospitalEdina55435NCT05554406Map
MNFairview Southdale HospitalEdina55435NCT05564390Map
MNFairview Southdale HospitalEdina55435NCT06317649Map
MNFairview Southdale HospitalEdina55435NCT06672146Map
MNEssentia Health Hibbing ClinicHibbing55746NCT05554393Map
MNEssentia Health Hibbing ClinicHibbing55746NCT05554406Map
MNEssentia Health Hibbing ClinicHibbing55746NCT05564390Map
MNEssentia Health Hibbing ClinicHibbing55746NCT04269902Map
MNEssentia Health Hibbing ClinicHibbing55746NCT06317649Map
MNEssentia Health Hibbing ClinicHibbing55746NCT06649812Map
MNEssentia Health Hibbing ClinicHibbing55746NCT06672146Map
MNSaint John's Hospital - HealtheastMaplewood55109NCT04269902Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05554393Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05554406Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT05564390Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT06317649Map
MNAbbott-Northwestern HospitalMinneapolis55407NCT06672146Map
MNHennepin County Medical CenterMinneapolis55415NCT04840602Map
MNMasonic Cancer CenterMinneapolis55455NCT05183035Map
MNMinneapolis VA Medical CenterMinneapolis55417NCT04269902Map
MNMinnesota Oncology Hematology P AMinneapolis55404NCT05963074Map
MNUniversity of MinnesotaMinneapolis55455NCT05735184Map
MNUniversity of MinnesotaMinneapolis55455NCT07007312Map
MNUniversity of Minnesota/Masonic Cancer CenterMinneapolis55455NCT06317662Map
MNMayo ClinicRochester55905NCT03331198Map
MNMayo ClinicRochester55905NCT03331198Map
MNMayo Clinic - RochesterRochester55905NCT05735184Map
MNMayo Clinic in RochesterRochester55905NCT05388006Map
MNMayo Clinic in RochesterRochester55905NCT05554406Map
MNMayo Clinic in RochesterRochester55905NCT05564390Map
MNMayo Clinic in RochesterRochester55905NCT04840602Map
MNMayo Clinic in RochesterRochester55905NCT05910801Map
MNMayo Clinic in RochesterRochester55905NCT06042725Map
MNMayo Clinic RochesterRochester55905NCT05451771Map
MNMayo Clinic RochesterRochester55902NCT05091424Map
MNMayo Clinic RochesterRochester55905-0001NCT06943872Map
MNCoborn Cancer Center at Saint Cloud HospitalSaint Cloud56303NCT04269902Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05554393Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05554406Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT05564390Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT04840602Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT04269902Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT06317649Map
MNPark Nicollet Clinic - Saint Louis ParkSaint Louis Park55416NCT06672146Map
MNRegions HospitalSaint Paul55101NCT05554393Map
MNRegions HospitalSaint Paul55101NCT05554406Map
MNRegions HospitalSaint Paul55101NCT05564390Map
MNRegions HospitalSaint Paul55101NCT04840602Map
MNRegions HospitalSaint Paul55101NCT06317649Map
MNRegions HospitalSaint Paul55101NCT06672146Map
MNUnited HospitalSaint Paul55102NCT05554393Map
MNUnited HospitalSaint Paul55102NCT05554406Map
MNUnited HospitalSaint Paul55102NCT05564390Map
MNUnited HospitalSaint Paul55102NCT06317649Map
MNUnited HospitalSaint Paul55102NCT06672146Map
MNEssentia Health SandstoneSandstone55072NCT05554393Map
MNEssentia Health SandstoneSandstone55072NCT05554406Map
MNEssentia Health SandstoneSandstone55072NCT04269902Map
MNEssentia Health SandstoneSandstone55072NCT06317649Map
MNEssentia Health SandstoneSandstone55072NCT06649812Map
MNEssentia Health SandstoneSandstone55072NCT06672146Map
MNSaint Francis Regional Medical CenterShakopee55379NCT04269902Map
MNEssentia Health Virginia ClinicVirginia55792NCT05554393Map
MNEssentia Health Virginia ClinicVirginia55792NCT05554406Map
MNEssentia Health Virginia ClinicVirginia55792NCT05564390Map
MNEssentia Health Virginia ClinicVirginia55792NCT04269902Map
MNEssentia Health Virginia ClinicVirginia55792NCT06317649Map
MNEssentia Health Virginia ClinicVirginia55792NCT06649812Map
MNEssentia Health Virginia ClinicVirginia55792NCT06672146Map
MNRidgeview Medical CenterWaconia55387NCT04269902Map
MSBaptist Memorial Hospital and Cancer Center-Golden TriangleColumbus39705NCT05554393Map
MSBaptist Memorial Hospital and Cancer Center-Golden TriangleColumbus39705NCT05554406Map
MSBaptist Memorial Hospital and Cancer Center-Golden TriangleColumbus39705NCT05564390Map
MSBaptist Memorial Hospital and Cancer Center-Golden TriangleColumbus39705NCT04269902Map
MSBaptist Memorial Hospital and Cancer Center-Golden TriangleColumbus39705NCT06317649Map
MSBaptist Memorial Hospital and Cancer Center-Golden TriangleColumbus39705NCT06917911Map
MSBaptist Cancer Center-GrenadaGrenada38901NCT05554393Map
MSBaptist Cancer Center-GrenadaGrenada38901NCT05554406Map
MSBaptist Cancer Center-GrenadaGrenada38901NCT05564390Map
MSBaptist Cancer Center-GrenadaGrenada38901NCT04269902Map
MSBaptist Cancer Center-GrenadaGrenada38901NCT06317649Map
MSBaptist Cancer Center-GrenadaGrenada38901NCT06917911Map
MSHattiesburg Clinic /ID# 233443Hattiesburg39401NCT04895436Map
MSUniversity of Mississippi Medical CenterJackson39216NCT05183035Map
MSUniversity of Mississippi Medical CenterJackson39216NCT06317662Map
MSBaptist Memorial Hospital and Cancer Center-Union CountyNew Albany38652NCT05554393Map
MSBaptist Memorial Hospital and Cancer Center-Union CountyNew Albany38652NCT05554406Map
MSBaptist Memorial Hospital and Cancer Center-Union CountyNew Albany38652NCT05564390Map
MSBaptist Memorial Hospital and Cancer Center-Union CountyNew Albany38652NCT04269902Map
MSBaptist Memorial Hospital and Cancer Center-Union CountyNew Albany38652NCT06317649Map
MSBaptist Memorial Hospital and Cancer Center-Union CountyNew Albany38652NCT06917911Map
MSBaptist Memorial Hospital and Cancer Center-OxfordOxford38655NCT05554393Map
MSBaptist Memorial Hospital and Cancer Center-OxfordOxford38655NCT05554406Map
MSBaptist Memorial Hospital and Cancer Center-OxfordOxford38655NCT05564390Map
MSBaptist Memorial Hospital and Cancer Center-OxfordOxford38655NCT06317649Map
MSBaptist Memorial Hospital and Cancer Center-OxfordOxford38655NCT06917911Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT05554393Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT05554406Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT05564390Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT04269902Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT06317649Map
MSBaptist Memorial Hospital and Cancer Center-DesotoSouthhaven38671NCT06917911Map
MOSaint Francis Medical CenterCape Girardeau63703NCT04840602Map
MOSaint Francis Medical CenterCape Girardeau63703NCT04269902Map
MOSaint Luke's HospitalChesterfield63017NCT04269902Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT05554393Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT05554406Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT05564390Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT06317649Map
MOSiteman Cancer Center at Saint Peters HospitalCity of Saint Peters63376NCT06649812Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT05554393Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT05554406Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT05564390Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT06317649Map
MOSiteman Cancer Center at West County HospitalCreve Coeur63141NCT06649812Map
MOParkland Health Center - FarmingtonFarmington63640NCT05564390Map
MOParkland Health Center - FarmingtonFarmington63640NCT04269902Map
MOChildren's Mercy Hospital of Kansas CityKansas City64108NCT06177067Map
MOChildren's Mercy Hospitals and ClinicsKansas City64108NCT06317662Map
MOKansas City VA Medical Center, Kansas City, MOKansas City64128-2226NCT06520098Map
MOKansas City Veterans Affairs Medical CenterKansas City64128NCT04269902Map
MOResearch Medical CenterKansas City64132NCT05963074Map
MOSaint Lukes Hospital of Kansas City /ID# 267270Kansas City64111NCT06428019Map
MOThe Children's Mercy Hospital - Adele Hall CampusKansas City64108NCT05183035Map
MOThe University of Kansas Cancer Center - Medical Oncology ClinicKansas City64116NCT04227847Map
MOThe University of Kansas Cancer Center - Radiation Oncology ClinicKansas City64116NCT04227847Map
MOThe University of Kansas Cancer Center -NorthKansas City64154NCT04227847Map
MOUniversity Health Truman Medical CenterKansas City64108NCT05564390Map
MOUniversity Health Truman Medical CenterKansas City64108NCT04269902Map
MOUniversity of Kansas Cancer Center - BriarcliffKansas City64116NCT05564390Map
MOUniversity of Kansas Cancer Center - BriarcliffKansas City64116NCT04269902Map
MOUniversity of Kansas Cancer Center - BriarcliffKansas City64116NCT06311227Map
MOUniversity of Kansas Cancer Center - NorthKansas City64154NCT05564390Map
MOUniversity of Kansas Cancer Center - NorthKansas City64154NCT04269902Map
MOUniversity of Kansas Cancer Center - NorthKansas City64154NCT06311227Map
MOThe University of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT04227847Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT05564390Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT04269902Map
MOUniversity of Kansas Cancer Center - Lee's SummitLee's Summit64064NCT06311227Map
MOPhelps Health Delbert Day Cancer InstituteRolla65401NCT04269902Map
MOHeartland Regional Medical CenterSaint Joseph64506NCT05564390Map
MOHeartland Regional Medical CenterSaint Joseph64506NCT04840602Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT05564390Map
MOSainte Genevieve County Memorial HospitalSainte Genevieve63670NCT04269902Map
MOOncology Hematology AssociatesSpringfield65807-5288NCT06846671Map
MOMercy Hospital Saint LouisSt Louis63141NCT04269902Map
MOMercy Hospital Saint LouisSt Louis63141NCT06317662Map
MOMercy Hospital SouthSt Louis63128NCT04840602Map
MOMercy Hospital SouthSt Louis63128NCT04269902Map
MOMissouri Baptist Medical CenterSt Louis63131NCT05564390Map
MOMissouri Baptist Medical CenterSt Louis63131NCT04269902Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT05554393Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT05554406Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT05564390Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT06317649Map
MOSiteman Cancer Center at Christian HospitalSt Louis63136NCT06649812Map
MOSiteman Cancer Center-South CountySt Louis63129NCT05554393Map
MOSiteman Cancer Center-South CountySt Louis63129NCT05554406Map
MOSiteman Cancer Center-South CountySt Louis63129NCT05564390Map
MOSiteman Cancer Center-South CountySt Louis63129NCT06317649Map
MOSiteman Cancer Center-South CountySt Louis63129NCT06649812Map
MOWashington University - Siteman Cancer CenterSt Louis63110NCT06456463Map
MOWashington University in St LouisSt Louis63130NCT06852222Map
MOWashington University School of MedicineSt Louis63110NCT05554393Map
MOWashington University School of MedicineSt Louis63110NCT05554406Map
MOWashington University School of MedicineSt Louis63110NCT05564390Map
MOWashington University School of MedicineSt Louis63110NCT06317649Map
MOWashington University School of MedicineSt Louis63110NCT06317662Map
MOWashington University School of MedicineSt Louis63110NCT06649812Map
MOWashington University School of Medicine in St. LouisSt Louis63110NCT05183035Map
MOWashington University School of Medicine, Siteman Cancer CenterSt Louis63108NCT06419634Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT05564390Map
MOMissouri Baptist Sullivan HospitalSullivan63080NCT04269902Map
MOBJC Outpatient Center at Sunset HillsSunset Hills63127NCT05564390Map
MOBJC Outpatient Center at Sunset HillsSunset Hills63127NCT04269902Map
MTCommunity Hospital of AnacondaAnaconda59711NCT05554393Map
MTCommunity Hospital of AnacondaAnaconda59711NCT05554406Map
MTCommunity Hospital of AnacondaAnaconda59711NCT05564390Map
MTCommunity Hospital of AnacondaAnaconda59711NCT04269902Map
MTCommunity Hospital of AnacondaAnaconda59711NCT06317649Map
MTCommunity Hospital of AnacondaAnaconda59711NCT06672146Map
MTBillings Clinic Cancer CenterBillings59101NCT05554393Map
MTBillings Clinic Cancer CenterBillings59101NCT05554406Map
MTBillings Clinic Cancer CenterBillings59101NCT05564390Map
MTBillings Clinic Cancer CenterBillings59101NCT04269902Map
MTBillings Clinic Cancer CenterBillings59101NCT06317649Map
MTBillings Clinic Cancer CenterBillings59101NCT06672146Map
MTSaint Vincent Frontier Cancer CenterBillings59102NCT04840602Map
MTBozeman Health Deaconess HospitalBozeman59715NCT05554393Map
MTBozeman Health Deaconess HospitalBozeman59715NCT05554406Map
MTBozeman Health Deaconess HospitalBozeman59715NCT05564390Map
MTBozeman Health Deaconess HospitalBozeman59715NCT04269902Map
MTBozeman Health Deaconess HospitalBozeman59715NCT06317649Map
MTBozeman Health Deaconess HospitalBozeman59715NCT06672146Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT05554393Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT05554406Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT05564390Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT04269902Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT06317649Map
MTBenefis Sletten Cancer InstituteGreat Falls59405NCT06672146Map
MTLogan Health Medical CenterKalispell59901NCT05554393Map
MTLogan Health Medical CenterKalispell59901NCT05554406Map
MTLogan Health Medical CenterKalispell59901NCT05564390Map
MTLogan Health Medical CenterKalispell59901NCT04269902Map
MTLogan Health Medical CenterKalispell59901NCT06317649Map
MTLogan Health Medical CenterKalispell59901NCT06672146Map
MTCommunity Medical CenterMissoula59804NCT05554393Map
MTCommunity Medical CenterMissoula59804NCT05554406Map
MTCommunity Medical CenterMissoula59804NCT05564390Map
MTCommunity Medical CenterMissoula59804NCT04269902Map
MTCommunity Medical CenterMissoula59804NCT06317649Map
MTCommunity Medical CenterMissoula59804NCT06672146Map
MTSaint Patrick Hospital - Community HospitalMissoula59802NCT05564390Map
NENebraska Medicine-BellevueBellevue68123NCT05554393Map
NENebraska Medicine-BellevueBellevue68123NCT05554406Map
NENebraska Medicine-BellevueBellevue68123NCT05564390Map
NENebraska Medicine-BellevueBellevue68123NCT06649812Map
NEChildren's Hospital and Medical Center of OmahaOmaha68114NCT06317662Map
NENebraska Cancer SpecialistsOmaha68130NCT04068597Map
NENebraska Cancer SpecialistsOmaha68130NCT06115135Map
NENebraska Medicine-Village PointeOmaha68118NCT05554393Map
NENebraska Medicine-Village PointeOmaha68118NCT05554406Map
NENebraska Medicine-Village PointeOmaha68118NCT05564390Map
NENebraska Medicine-Village PointeOmaha68118NCT06649812Map
NEOncology Hematology West, Pc Dba Nebraska Cancer SpecialistsOmaha68130-2042NCT06846671Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT05554393Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT05554406Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT05564390Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT03331198Map
NEUniversity of Nebraska Medical CenterOmaha68198-6846NCT04068597Map
NEUniversity of Nebraska Medical CenterOmaha68198NCT06649812Map
NEUniversity Of Nebraska Medical CenterOmaha68198NCT03331198Map
NVAlliance for Childhood Diseases dba Cure 4 The Kids FoundationLas Vegas89135NCT05183035Map
NVAlliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas89135NCT06317662Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT05554393Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT05554406Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT05564390Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT04269902Map
NVOptumCare Cancer Care at CharlestonLas Vegas89102NCT06317649Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT05554393Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT05554406Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT05564390Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT04269902Map
NVOptumCare Cancer Care at Fort ApacheLas Vegas89183NCT06317649Map
NHDartmouth Hitchcock Medical CenterLebanon03756NCT06852222Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT05554393Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT05564390Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT04269902Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT06317649Map
NHDartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon03756NCT06317662Map
NJMemoral Sloan Kettering at Basking Ridge (Limited Protocol Activities)Basking Ridge07920NCT07392242Map
NJMemorial Sloan Kettering at Basking RidgeBasking Ridge07920NCT03824483Map
NJMemorial Sloan Kettering at Basking Ridge (All Protocol Activities)Basking Ridge07920NCT06773208Map
NJMemorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)Basking Ridge07920NCT06903702Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT05554393Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT05554406Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT05564390Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT04840602Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT04269902Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT06317649Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT06672146Map
NJMemorial Sloan Kettering Basking RidgeBasking Ridge07920NCT07231952Map
NJMemorial Sloan-Kettering Cancer Center (MSKCC) - Basking RidgeBasking Ridge07920NCT03331198Map
NJCooper Hospital University Medical CenterCamden08103NCT05554406Map
NJCooper Hospital University Medical CenterCamden08103NCT05564390Map
NJCooper Hospital University Medical CenterCamden08103NCT04269902Map
NJAstera Cancer CareEdison08820NCT03331198Map
NJHunterdon Hematology OncologyFlemington08822NCT05963074Map
NJHackensack University Medical CenterHackensack07601NCT05735184Map
NJHackensack University Medical CenterHackensack07601NCT03331198Map
NJHackensack University Medical CenterHackensack07601NCT06317662Map
NJHackensack University Medical Center, HMHHackensack07601NCT05183035Map
NJJohn Theurer Cancer CenterHackensack07601-2191NCT03331198Map
NJJohn Theurer Cancer Center - Hackensack Meridian HealthHackensack07601NCT06456463Map
NJJohn Theurer Cancer Center / Hackensack UniversityHackensack07601NCT04256317Map
NJJohn Theurer Cancer Center at Hackensack University Medical CenterHackensack07601NCT06419634Map
NJJohn Theurer Cancer Center at Hackensack University Medical CenterHackensack07601NCT06852222Map
NJRegional Cancer Care Associates /ID# 244620Hackensack07601-7015NCT04895436Map
NJJersey City Medical CenterJersey City07302NCT04269902Map
NJMonmouth Medical Center Southern CampusLakewood08701NCT04269902Map
NJSaint Barnabas Medical CenterLivingston07039NCT05554393Map
NJSaint Barnabas Medical CenterLivingston07039NCT05554406Map
NJSaint Barnabas Medical CenterLivingston07039NCT05564390Map
NJSaint Barnabas Medical CenterLivingston07039NCT06317649Map
NJSaint Barnabas Medical CenterLivingston07039NCT06672146Map
NJMonmouth Medical CenterLong Branch07740NCT05554393Map
NJMonmouth Medical CenterLong Branch07740NCT05554406Map
NJMonmouth Medical CenterLong Branch07740NCT05564390Map
NJMonmouth Medical CenterLong Branch07740NCT04269902Map
NJMonmouth Medical CenterLong Branch07740NCT06317649Map
NJMonmouth Medical CenterLong Branch07740NCT06672146Map
NJMemoral Sloan Kettering MonmouthMiddletown07748NCT07231952Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT05554393Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT05554406Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT05564390Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT04840602Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT04269902Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT03824483Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT06317649Map
NJMemorial Sloan Kettering MonmouthMiddletown07748NCT06672146Map
NJMemorial Sloan Kettering Monmouth (All Protocol Activities)Middletown07748NCT06773208Map
NJMemorial Sloan Kettering Monmouth (Consent and Follow-up)Middletown07748NCT06903702Map
NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown07748NCT06903702Map
NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown07748NCT07392242Map
NJMemorial Sloan Kettering BergenMontvale07645NCT05554393Map
NJMemorial Sloan Kettering BergenMontvale07645NCT05554406Map
NJMemorial Sloan Kettering BergenMontvale07645NCT05564390Map
NJMemorial Sloan Kettering BergenMontvale07645NCT04840602Map
NJMemorial Sloan Kettering BergenMontvale07645NCT04269902Map
NJMemorial Sloan Kettering BergenMontvale07645NCT06317649Map
NJMemorial Sloan Kettering BergenMontvale07645NCT06672146Map
NJMemorial Sloan Kettering BergenMontvale07645NCT07231952Map
NJMemorial Sloan Kettering Bergen (All Protocol Activities)Montvale07645NCT06773208Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT06903702Map
NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale07645NCT07392242Map
NJAtlantic HealthMorristown07960NCT04988555Map
NJAtlantic Health System / Morristown Medical CenterMorristown07960NCT03331198Map
NJMorristown Medical CenterMorristown07960NCT05183035Map
NJMorristown Medical CenterMorristown07960NCT06317662Map
NJRutgers Biomedical and Health SciencesNew Brunswick08903NCT07007312Map
NJRutgers Cancer InstituteNew Brunswick08903NCT05735184Map
NJRutgers Cancer InstituteNew Brunswick08901NCT06456463Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT05554393Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT05554406Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT05564390Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08901NCT04988555Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT04269902Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT03331198Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT06317649Map
NJRutgers Cancer Institute of New JerseyNew Brunswick08903NCT06672146Map
NJRutgers Cancer Institute of New Jersey-Robert Wood Johnson University HospitalNew Brunswick08903NCT06317662Map
NJThe Valley Hospital - Luckow PavilionParamus07652NCT05554393Map
NJThe Valley Hospital - Luckow PavilionParamus07652NCT05554406Map
NJThe Valley Hospital - Luckow PavilionParamus07652NCT05564390Map
NJThe Valley Hospital - Luckow PavilionParamus07652NCT06317649Map
NJSaint Joseph's Regional Medical CenterPaterson07503NCT06317662Map
NJValley Health System Ridgewood CampusRidgewood07450NCT05554393Map
NJValley Health System Ridgewood CampusRidgewood07450NCT05554406Map
NJValley Health System Ridgewood CampusRidgewood07450NCT05564390Map
NJValley Health System Ridgewood CampusRidgewood07450NCT06317649Map
NJSidney Kimmel Comprehensive Cancer Center Washington TwpSewell08080NCT06943872Map
NJCommunity Medical CenterToms River08755NCT05554393Map
NJCommunity Medical CenterToms River08755NCT05554406Map
NJCommunity Medical CenterToms River08755NCT05564390Map
NJCommunity Medical CenterToms River08755NCT04269902Map
NJCommunity Medical CenterToms River08755NCT06317649Map
NJCommunity Medical CenterToms River08755NCT06672146Map
NJMD Anderson Cancer Center at Cooper-VoorheesVoorhees Township08043NCT04269902Map
NMUniversity of New MexicoAlbuquerque87131NCT07007312Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT05554393Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT05554406Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT05564390Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT04269902Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT06317649Map
NMUniversity of New Mexico Cancer CenterAlbuquerque87106NCT06672146Map
NMMemorial Medical Center-Las CrucesLas Cruces88011NCT04269902Map
NMPresbyterian Rust Medical Center/Jorgensen Cancer CenterRio Rancho87124NCT04269902Map
NMChristus St Vincent Regional Cancer CenterSanta Fe87505NCT06943872Map
NYAlbany Medical CenterAlbany12208NCT06317662Map
NYRoswell ParkBuffalo14263NCT06445959Map
NYRoswell Park Cancer InstituteBuffalo14263NCT05442216Map
NYRoswell Park Cancer InstituteBuffalo14263NCT05554393Map
NYRoswell Park Cancer InstituteBuffalo14263NCT05554406Map
NYRoswell Park Cancer InstituteBuffalo14263NCT05564390Map
NYRoswell Park Cancer InstituteBuffalo14263NCT06317649Map
NYRoswell Park Cancer InstituteBuffalo14263NCT06317662Map
NYRoswell Park Cancer InstituteBuffalo14203NCT06456463Map
NYRoswell Park Cancer InstituteBuffalo14263NCT06501196Map
NYRoswell Park Cancer InstituteBuffalo14263NCT06672146Map
NYRoswell Park Comprehensive Cancer CenterBuffalo14203NCT04988555Map
NYRoswell Park Comprehensive Cancer CenterBuffalo14263NCT04256317Map
NYRoswell Park Comprehensive Cancer CenterBuffalo14203NCT05735184Map
NYRoswell Park Comprehensive Cancer CenterBuffalo14263NCT06852222Map
NYState University of New York at BuffaloBuffalo14263NCT07007312Map
NYHematology Oncology Associates of CNY at CamillusCamillus13031NCT04269902Map
NYMemorial Sloan Kettering Cancer Center - Suffolk (Limited Protocol Activities)Commack11725NCT06903702Map
NYMemorial Sloan Kettering CommackCommack11725NCT05554393Map
NYMemorial Sloan Kettering CommackCommack11725NCT05554406Map
NYMemorial Sloan Kettering CommackCommack11725NCT05564390Map
NYMemorial Sloan Kettering CommackCommack11725NCT04840602Map
NYMemorial Sloan Kettering CommackCommack11725NCT04269902Map
NYMemorial Sloan Kettering CommackCommack11725NCT03824483Map
NYMemorial Sloan Kettering CommackCommack11725NCT06317649Map
NYMemorial Sloan Kettering CommackCommack11725NCT06672146Map
NYMemorial Sloan Kettering Suffolk - CommackCommack11725NCT07231952Map
NYMemorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)Commack11725NCT07392242Map
NYMemorial Sloan Kettering Suffolk-Commack (All Protocol Activities)Commack11725NCT06773208Map
NYHematology Oncology Associates of Central New York-East SyracuseEast Syracuse13057NCT04269902Map
NYGlens Falls HospitalGlens Falls12801NCT04269902Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT05554406Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT04840602Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT04269902Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT03824483Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT06672146Map
NYMemorial Sloan Kettering WestchesterHarrison10604NCT07231952Map
NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison10604NCT06773208Map
NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison10604NCT06903702Map
NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison10604NCT07392242Map
NYNorthwell Health/Center for Advanced MedicineLake Success11042NCT05554406Map
NYNorthwell Health/Center for Advanced MedicineLake Success11042NCT06317649Map
NYNorth Shore University HospitalManhasset11030NCT05554406Map
NYNorth Shore University HospitalManhasset11030NCT06317649Map
NYNorth Shore University HospitalManhasset11030NCT06456463Map
NYNew York University Langone Hospital - Long IslandMineola11501NCT04256317Map
NYThe Steven and Alexandra Cohen Children's Medical Center of New YorkNew Hyde Park11040NCT06317662Map
NYZuckerberg Cancer CenterNew Hyde Park11042NCT07163793Map
NYColumbia UniversityNew York10032NCT07007312Map
NYColumbia University Irving Medical CenterNew York10032NCT04227847Map
NYColumbia University Irving Medical CenterNew York10032NCT05183035Map
NYColumbia University Irving Medical CenterNew York10032NCT06456463Map
NYColumbia University Medical CenterNew York10032NCT05735184Map
NYCUIMC Research PharmacyNew York10032NCT04227847Map
NYIcahn School of Medicine at Mount SinaiNew York10029NCT04256317Map
NYIcahn School of Medicine at Mount SinaiNew York10003NCT07007312Map
NYIcahn School of Medicine at Mount SinaiNew York10029NCT07320235Map
NYIcahn School of Medicine at Mount Sinai /ID# 266328New York10029NCT06428019Map
NYLaura and Isaac Perlmutter Cancer Center at NYU LangoneNew York10016NCT06317662Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05554393Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05554406Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT05564390Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT04840602Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT04269902Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT03824483Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT03013998Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06284486Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06317649Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06317662Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06501196Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06672146Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT06903702Map
NYMemorial Sloan Kettering Cancer CenterNew York10065NCT07231952Map
NYMemorial Sloan Kettering Cancer Center - New YorkNew York10065NCT05183035Map
NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)New York10065NCT06773208Map
NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)New York10065NCT07392242Map
NYMemorial Sloan Kettering Cancer Center MskccNew York10065-6800NCT06846671Map
NYMemorial Sloan Kettering Cancer Center MskccNew York10065-6800NCT06943872Map
NYMemorial Sloan- Kettering Cancer CenterNew York10065NCT06177067Map
NYMount Sinai - Ruttenberg Treatment CenterNew York10029NCT05735184Map
NYMount Sinai HospitalNew York10029NCT05554393Map
NYMount Sinai HospitalNew York10029NCT05554406Map
NYMount Sinai HospitalNew York10029NCT05564390Map
NYNew York - Presbyterian / Weill Cornell MedicineNew York10021NCT05735184Map
NYNew York Presbyterian - Weill CornellNew York10065NCT06852222Map
NYNew York Presbyterian Hospital/Columbia University Irving Medical CenterNew York10032NCT05451771Map
NYNYP/Weill Cornell Medical CenterNew York10065NCT06317662Map
NYNYU Langone HealthNew York10016NCT06456463Map
NYPerlmutter Cancer Center - 34th StreetNew York10016NCT04256317Map
NYThe New York and Presbyterian HospitalNew York10032NCT04227847Map
NYWeill Cornell Medical CenterNew York10065NCT07007312Map
NYWeill Cornell Medical CollegeNew York10065NCT03331198Map
NYHematology Oncology Associates of RocklandNyack10960NCT05963074Map
NYUpstate Cancer Center at OswegoOswego13126NCT04269902Map
NYCohen Children's Medical CenterQueens11040NCT05183035Map
NYRochester General HospitalRochester14621NCT05564390Map
NYUniversity of RochesterRochester14642NCT05554393Map
NYUniversity of RochesterRochester14642NCT05554406Map
NYUniversity of RochesterRochester14642NCT05564390Map
NYUniversity of RochesterRochester14642NCT04840602Map
NYUniversity of RochesterRochester14642NCT04269902Map
NYUniversity of RochesterRochester14642NCT06317649Map
NYUniversity of RochesterRochester14642NCT06317662Map
NYUniversity of RochesterRochester14642NCT06672146Map
NYUniversity of Rochester Medical CenterRochester14642NCT06852222Map
NYMemorial Sloan Kettering Nassau (All Protocol Activities)Rockville Centre11553NCT06773208Map
NYMemorial Sloan Kettering Nassau (Limited Protocol Activites)Rockville Centre11553NCT07392242Map
NYStony Brook UniversityStony Brook11794-8160NCT03331198Map
NYStony Brook University HospitalStony Brook11794NCT05735184Map
NYStony Brook University Medical CenterStony Brook11794NCT05554393Map
NYStony Brook University Medical CenterStony Brook11794NCT05554406Map
NYStony Brook University Medical CenterStony Brook11794NCT05564390Map
NYStony Brook University Medical CenterStony Brook11794NCT06317649Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT05554406Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT05564390Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT04269902Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT06317649Map
NYState University of New York Upstate Medical UniversitySyracuse13210NCT06317662Map
NYSUNY Upstate Medical Center-Community CampusSyracuse13215NCT04269902Map
NYEinstein-Montefiore Medical CenterThe Bronx10467NCT06852222Map
NYMontefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM)The Bronx10467NCT05342584Map
NYMontefiore Medical CenterThe Bronx10467NCT04256317Map
NYMontefiore Medical CenterThe Bronx10467NCT05986240Map
NYMontefiore Medical CenterThe Bronx10467NCT05184842Map
NYMontefiore Medical CenterThe Bronx10467NCT07283094Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT05554393Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT05554406Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT05564390Map
NYMontefiore Medical Center - Moses CampusThe Bronx10467NCT06317662Map
NYMemorial Sloan Kettering NassauUniondale11553NCT05554393Map
NYMemorial Sloan Kettering NassauUniondale11553NCT05554406Map
NYMemorial Sloan Kettering NassauUniondale11553NCT05564390Map
NYMemorial Sloan Kettering NassauUniondale11553NCT04840602Map
NYMemorial Sloan Kettering NassauUniondale11553NCT04269902Map
NYMemorial Sloan Kettering NassauUniondale11553NCT03824483Map
NYMemorial Sloan Kettering NassauUniondale11553NCT06672146Map
NYMemorial Sloan Kettering NassauUniondale11553NCT07231952Map
NYNew York Medical CollegeValhalla10595NCT06317662Map
NYUpstate Cancer Center at VeronaVerona13478NCT04269902Map
NYWilmot Cancer Institute at WebsterWebster14580NCT04269902Map
NYClinical Research Alliance, IncWestbury11590-5119NCT06846671Map
NYClinical Research Alliance, IncWestbury11590-5119NCT06943872Map
NYWhite Plains HospitalWhite Plains10601NCT05184842Map
NCUNC HospitalChapel Hill27514NCT04988555Map
NCUNC Hospitals, University of North Carolina at Chapel HillChapel Hill27514NCT05401097Map
NCUNC Hospitals, University of North Carolina at Chapel HillChapel Hill27514NCT03013998Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT05564390Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT04269902Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT06317649Map
NCUNC Lineberger Comprehensive Cancer CenterChapel Hill27599NCT06317662Map
NCUNC School of Medicine, Division of HematologyChapel Hill27599NCT04588922Map
NCUniversity of North Carolina /ID# 233313Chapel Hill27514NCT04895436Map
NCUniversity of North Carolina at Chapel HillChapel Hill27599NCT05442216Map
NCUniversity of North Carolina At Chapel HillChapel Hill27514-4220NCT06943872Map
NCUniversity of North Carolina, Chapel HillChapel Hill27514NCT07007312Map
NCAtrium HealthCharlotte28204NCT06852222Map
NCAtrium Health /ID# 267219Charlotte28204-2963NCT06428019Map
NCCarolina Oncology SpecialistsCharlotte28207NCT06852222Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT05554393Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT05554406Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT05564390Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT04840602Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT06317649Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT06317662Map
NCCarolinas Medical Center/Levine Cancer InstituteCharlotte28203NCT06672146Map
NCLevine Cancer CenterCharlotte28204-2990NCT06943872Map
NCNovant Health CharlotteCharlotte28204NCT06852222Map
NCNovant Health Presbyterian Medical CenterCharlotte28204NCT05554393Map
NCNovant Health Presbyterian Medical CenterCharlotte28204NCT05564390Map
NCNovant Health Presbyterian Medical CenterCharlotte28204NCT06456463Map
NCNovant Health Presbyterian Medical Center /ID# 230201Charlotte28204NCT04895436Map
NCSoutheastern Medical Oncology Center-ClintonClinton28328NCT04840602Map
NCSoutheastern Medical Oncology Center-ClintonClinton28328NCT04269902Map
NCDuke Blood Cancer CenterDurham27705NCT05735184Map
NCDuke UniversityDurham27705NCT04988555Map
NCDuke UniversityDurham27705NCT04256317Map
NCDuke University Medical CenterDurham27710NCT05554393Map
NCDuke University Medical CenterDurham27710NCT05554406Map
NCDuke University Medical CenterDurham27710NCT05564390Map
NCDuke University Medical CenterDurham27710NCT04269902Map
NCDuke University Medical CenterDurham27705NCT03331198Map
NCDuke University Medical CenterDurham27710NCT03331198Map
NCDuke University Medical CenterDurham27705NCT03850574Map
NCDuke University Medical CenterDurham27710NCT06317649Map
NCDuke University Medical CenterDurham27710NCT06317662Map
NCDuke University Medical CenterDurham27710NCT06649812Map
NCDuke University Medical CenterDurham27710NCT06672146Map
NCDuke University Medical CenterDurham27710NCT07007312Map
NCDurham VA Medical Center, Durham, NCDurham27705-3875NCT06520098Map
NCLevine Cancer Institute-GastonGastonia28054NCT04840602Map
NCSoutheastern Medical Oncology Center-GoldsboroGoldsboro27534NCT04840602Map
NCSoutheastern Medical Oncology Center-GoldsboroGoldsboro27534NCT04269902Map
NCEast Carolina UniversityGreenville27834NCT05554393Map
NCEast Carolina UniversityGreenville27834NCT05554406Map
NCEast Carolina UniversityGreenville27834NCT05564390Map
NCEast Carolina UniversityGreenville27834NCT04269902Map
NCEast Carolina UniversityGreenville27834NCT06317649Map
NCEast Carolina UniversityGreenville27834NCT06317662Map
NCEast Carolina UniversityGreenville27834NCT06672146Map
NCMargaret R Pardee Memorial HospitalHendersonville28791NCT04269902Map
NCUniversity of North Carolina-Hillsborough CampusHillsborough27278NCT04269902Map
NCSoutheastern Medical Oncology Center-JacksonvilleJacksonville28546NCT04840602Map
NCSoutheastern Medical Oncology Center-JacksonvilleJacksonville28546NCT04269902Map
NCECU Health Oncology KinstonKinston28501NCT04269902Map
NCAtrium Health Union/LCI-UnionMonroe28112NCT04840602Map
NCNovant Health New Hanover Regional Medical CenterWilmington28401NCT05564390Map
NCAtrium Health Wake Forest BaptistWinston-Salem27157NCT06943872Map
NCAtrium Health Wake Forest Baptist Comprehensive Cancer CenterWinston-Salem27157NCT05442216Map
NCAtrium Health Wake Forest Baptist Comprehensive Cancer CenterWinston-Salem27157NCT06382168Map
NCAtrium Health Wake Forest Baptist Comprehensive Cancer CenterWinston-Salem27157NCT06852222Map
NCAtrium Health Wake Forest Baptist Medical Center /ID# 273142Winston-Salem27157NCT06428019Map
NCAtrium Wake Forest Baptist Medical CenterWinston-Salem27157NCT04988555Map
NCNovant Health Derrick L Davis Cancer CenterWinston-Salem27103NCT06456463Map
NCNovant Health Forsyth Medical CenterWinston-Salem27103NCT05554393Map
NCNovant Health Forsyth Medical CenterWinston-Salem27103NCT05564390Map
NCNovant Health Forsyth Medical Center /ID# 249533Winston-Salem27103NCT04895436Map
NCNovant Health Winston SalemWinston-Salem27106NCT06852222Map
NCWake Forest University Health SciencesWinston-Salem27157NCT05554393Map
NCWake Forest University Health SciencesWinston-Salem27157NCT05554406Map
NCWake Forest University Health SciencesWinston-Salem27157NCT05564390Map
NCWake Forest University Health SciencesWinston-Salem27157NCT06317649Map
NCWake Forest University Health SciencesWinston-Salem27157NCT06317662Map
NCWake Forest University Health SciencesWinston-Salem27157NCT06672146Map
NDEssentia Health Cancer Center-South University ClinicFargo58103NCT06649812Map
NDSanford Broadway Medical CenterFargo58122NCT06317662Map
OHChildren's Hospital Medical Center of AkronAkron44308NCT06317662Map
OHStrecker Cancer Center-BelpreBelpre45714NCT04269902Map
OHGabrail Cancer CenterCanton44718NCT06634394Map
OHGabrail Cancer CenterCanton44718NCT06852222Map
OHCincinnati Children's Hospital Medical CenterCincinnati45229NCT03826992Map
OHCincinnati Children's Hospital Medical CenterCincinnati45229NCT06177067Map
OHCincinnati Children's Hospital Medical CenterCincinnati45229NCT06317662Map
OHCincinnati Children's Hospital Medical CenterCincinnati45229NCT06863259Map
OHOncology Hematology CareCincinnati45242NCT05963074Map
OHOncology Hematology CareCincinnati45226NCT06634394Map
OHOncology Hematology CareCincinnati45226NCT06852222Map
OHOncology Hematology Care Clinical Trials, LlcCincinnati45245-1995NCT06943872Map
OHUniversity of CincinnatiCincinnati45219NCT07014917Map
OHUniversity of Cincinnati Medical CenterCincinnati45219NCT03013998Map
OHCase Western Reserve UniversityCleveland44106NCT05554393Map
OHCase Western Reserve UniversityCleveland44106NCT05554406Map
OHCase Western Reserve UniversityCleveland44106NCT05564390Map
OHCase Western Reserve UniversityCleveland44106NCT05834244Map
OHCase Western Reserve UniversityCleveland44106NCT06317649Map
OHCleveland ClinicCleveland44195NCT04227847Map
OHCleveland ClinicCleveland44195NCT06852222Map
OHCleveland Clinic Cancer Center/Fairview HospitalCleveland44111NCT04269902Map
OHCleveland Clinic FoundationCleveland44195NCT04269902Map
OHCleveland Clinic FoundationCleveland44195NCT06456463Map
OHCleveland Clinic Main Campus /ID# 271292Cleveland44195NCT06428019Map
OHCleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer CenterCleveland44106NCT06129734Map
OHCleveland Clinic Taussig Cancer InstituteCleveland44195NCT05735184Map
OHCleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer CenterCleveland44195NCT03471260Map
OHRainbow Babies and Childrens HospitalCleveland44106NCT06317662Map
OHUniversity HospitalsCleveland44106-1716NCT06846671Map
OHUniversity Hospitals Cleveland Medical CenterCleveland44106NCT04227847Map
OHUniversity Hospitals Cleveland Medical CenterCleveland44106NCT05735184Map
OHUniversity Hospitals Cleveland Medical CenterCleveland44106NCT03331198Map
OHUniversity Hospitals Cleveland Medical CenterCleveland44106NCT06852222Map
OHUniversity Hospitals Seidman Cancer Center (Case Western)Cleveland44106-5061NCT03331198Map
OHUniversity Hospitals Seidman Cancer, Case Comprehensive Cancer CenterCleveland44106NCT06129734Map
OHNationwide Children's HospitalColumbus43205NCT05183035Map
OHOhio State UniversityColumbus43210NCT03013998Map
OHOhio State UniversityColumbus43210NCT07007312Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05336812Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05401097Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05554406Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT05564390Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT04269902Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT06317649Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT06466122Map
OHOhio State University Comprehensive Cancer CenterColumbus43210NCT06649812Map
OHOhio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research InstituteColumbus43210NCT04256317Map
OHThe James Cancer Hospital and Solove Research InstituteColumbus43210NCT05735184Map
OHThe James Cancer Hospital and Solove Research InstituteColumbus43210NCT05091424Map
OHThe Mark H Zangmeister CenterColumbus43219NCT04269902Map
OHThe Ohio State University /ID# 230439Columbus43210NCT04895436Map
OHThe Ohio State University Comprehensive Cancer CenterColumbus43210NCT04988555Map
OHThe Ohio State University Comprehensive Cancer CenterColumbus43210NCT03331198Map
OHThe Ohio State University Wexner Medical CenterColumbus43210NCT03850574Map
OHThe Ohio State University Wexner Medical Center - James Cancer HospColumbus43210NCT06501196Map
OHThe Ohio State University Wexner Medical Center/James Cancer HospitalColumbus43210NCT04227847Map
OHDayton Children's HospitalDayton45404NCT06317662Map
OHDayton Physician NetworkDayton45415NCT06846671Map
OHMarietta Memorial HospitalMarietta45750NCT04269902Map
OHMemorial HospitalMarysville43040NCT04269902Map
OHHillcrest Hospital Cancer CenterMayfield Heights44124NCT04269902Map
OHLicking Memorial HospitalNewark43055NCT04840602Map
OHLicking Memorial HospitalNewark43055NCT04269902Map
OHSouthern Ohio Medical CenterPortsmouth45662NCT04269902Map
OHSpringfield Regional Cancer CenterSpringfield45504NCT04269902Map
OHProMedica Flower HospitalSylvania43560NCT04269902Map
OHProMedica Toledo Hospital/Russell J Ebeid Children's HospitalToledo43606NCT06317662Map
OHGenesis Healthcare System Cancer Care CenterZanesville43701NCT04269902Map
OKOU Health Stephenson Cancer CenterOklahoma City73104NCT05735184Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05554393Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05554406Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT05564390Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT04269902Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT06317649Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT06317662Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT06649812Map
OKUniversity of Oklahoma Health Sciences CenterOklahoma City73104NCT06672146Map
OKUniversity of Oklahoma Health Sciences Center (Stephenson Cancer Center)Oklahoma City73104NCT03331198Map
OKUniversity of Oklahoma Peggy and Charles Stephenson Cancer CenterOklahoma City73104NCT03331198Map
OKOklahoma Cancer Specialists and Research Institute /ID# 267643Tulsa74146NCT06428019Map
OKSaint Francis Children's HospitalTulsa74136NCT06390319Map
ORSaint Charles Health SystemBend97701NCT04269902Map
ORClackamas Radiation Oncology CenterClackamas97015NCT04269902Map
OROncology Associates of OregonEugene97401NCT04988555Map
OROncology Associates of Oregon Willamette Valley Cancer CenterEugene97401NCT06846671Map
OROncology Associates of Oregon Willamette Valley Cancer CenterEugene97401NCT06943872Map
ORWillamette Valley Cancer InstituteEugene97401NCT07007312Map
ORWillamette Valley Cancer Institute and Research CenterEugene97401NCT05963074Map
ORWillamette Valley Cancer Institute and Research Center /ID# 266326Eugene97401NCT06428019Map
ORProvidence Newberg Medical CenterNewberg97132NCT05564390Map
ORProvidence Newberg Medical CenterNewberg97132NCT04840602Map
ORProvidence Newberg Medical CenterNewberg97132NCT04269902Map
ORProvidence Newberg Medical CenterNewberg97132NCT06317649Map
ORProvidence Newberg Medical CenterNewberg97132NCT06649812Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT05554393Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT05554406Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT05564390Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT04269902Map
ORSaint Alphonsus Cancer Care Center-OntarioOntario97914NCT06317649Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT05564390Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT04840602Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT04269902Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT06317649Map
ORProvidence Willamette Falls Medical CenterOregon City97045NCT06649812Map
ORDoernbecher Children's HospitalPortland97239NCT05183035Map
OROHSU Knight Cancer InstitutePortland97239NCT05963074Map
OROHSU Knight Cancer InstitutePortland97239NCT03874052Map
OROHSU Knight Cancer InstitutePortland97239NCT06357182Map
OROHSU Knight Cancer InstitutePortland97239NCT06504459Map
OROHSU Knight Cancer InstitutePortland97239NCT07228273Map
OROregon Health & Science UniversityPortland97239NCT03013998Map
OROregon Health and Science UniversityPortland97239NCT04256317Map
OROregon Health and Science UniversityPortland97239NCT03471260Map
OROregon Health and Science University ( Site 5425)Portland97239-3011NCT05947851Map
ORProvidence Oncology and Hematology Care Clinic WestsidePortland97225NCT06852222Map
ORProvidence Portland Medical CenterPortland97213NCT05554393Map
ORProvidence Portland Medical CenterPortland97213NCT05554406Map
ORProvidence Portland Medical CenterPortland97213NCT05564390Map
ORProvidence Portland Medical CenterPortland97213NCT04840602Map
ORProvidence Portland Medical CenterPortland97213NCT04269902Map
ORProvidence Portland Medical CenterPortland97213NCT06317649Map
ORProvidence Portland Medical CenterPortland97213NCT06649812Map
ORProvidence Portland Medical CenterPortland97213NCT06852222Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05554393Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05554406Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT05564390Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT04840602Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT04269902Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT06317649Map
ORProvidence Saint Vincent Medical CenterPortland97225NCT06649812Map
OROregon Oncology SpecialistsSalem97301NCT04256317Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT05554393Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT05554406Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT05564390Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT04269902Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT06317649Map
PALehigh Valley Hospital-Cedar CrestAllentown18103NCT06317662Map
PALehigh Valley Hospital - MuhlenbergBethlehem18017NCT04269902Map
PAGeisinger Medical CenterDanville17822NCT05554393Map
PAGeisinger Medical CenterDanville17822NCT05554406Map
PAGeisinger Medical CenterDanville17822NCT05564390Map
PAGeisinger Medical CenterDanville17822NCT04269902Map
PAGeisinger Medical CenterDanville17822NCT06317649Map
PAGeisinger Medical CenterDanville17822NCT06317662Map
PAGeisinger Medical CenterDanville17822NCT06672146Map
PAPenn State Milton S Hershey Medical CenterHershey17033-0850NCT05554393Map
PAPenn State Milton S Hershey Medical CenterHershey17033-0850NCT05554406Map
PAPenn State Milton S Hershey Medical CenterHershey17033-0850NCT05564390Map
PAPenn State Milton S Hershey Medical CenterHershey17033-0850NCT06317649Map
PAPenn State Milton S Hershey Medical CenterHershey17033NCT06943872Map
PALewistown HospitalLewistown17044NCT05554393Map
PALewistown HospitalLewistown17044NCT05554406Map
PALewistown HospitalLewistown17044NCT05564390Map
PAChildren's Hospital of PhiladelphiaPhiladelphia19104NCT05183035Map
PAChildren's Hospital of PhiladelphiaPhiladelphia19104NCT06177067Map
PAChildren's Hospital of PhiladelphiaPhiladelphia19104NCT06317662Map
PAFox Chase Cancer CenterPhiladelphia19111NCT06852222Map
PAHospital of the University of PennsylvaniaPhiladelphia19104NCT05735184Map
PAJefferson Torresdale HospitalPhiladelphia19114NCT04269902Map
PAPenn Medicine - Abramson Cancer Center PerelmanPhiladelphia19104NCT04068597Map
PAPenn Medicine Abramson Cancer CenterPhiladelphia19104NCT05442216Map
PAPennsylvania Oncology Hematolo /ID# 249637Philadelphia19106NCT04895436Map
PASidney Kimmel Comprehensive Cancer CenterPhiladelphia19107NCT04988555Map
PASydney Kimmel (Thomas Jefferson University)Philadelphia19107NCT06456463Map
PAThomas Jefferson UniversityPhiladelphia19107NCT03331198Map
PAThomas Jefferson UniversityPhiladelphia19107NCT06852222Map
PAThomas Jefferson UniversityPhiladelphia19107-4216NCT06943872Map
PAThomas Jefferson University - Clinical Research InstitutePhiladelphia19107NCT03331198Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT05554406Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT05564390Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT04269902Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT06649812Map
PAThomas Jefferson University HospitalPhiladelphia19107NCT06672146Map
PAUniversity of PennsylvaniaPhiladelphia19104NCT07007312Map
PAUniversity of Pennsylvania - Perelman Center for Advanced MedicinePhiladelphia19104NCT03331198Map
PAUniversity of Pennsylvania Perelman Center for Advanced MedicinePhiladelphia19104NCT03331198Map
PAUniversity of Pennsylvania/Abramson Cancer CenterPhiladelphia19104NCT05554406Map
PAUniversity of Pennsylvania/Abramson Cancer CenterPhiladelphia19104NCT05564390Map
PAUniversity of Pennsylvania/Abramson Cancer CenterPhiladelphia19104NCT06317649Map
PAAllegheny Health NetworkPittsburgh15224NCT04988555Map
PAChildren's Hospital of Pittsburgh of UPMCPittsburgh15224NCT06317662Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05554393Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05554406Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT05564390Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT06317649Map
PAUniversity of Pittsburgh Cancer Institute (UPCI)Pittsburgh15232NCT06672146Map
PAUniversity of Pittsburgh Medical CenterPittsburgh15260NCT06852222Map
PAUPMC Hillman Cancer CenterPittsburgh15232NCT03331198Map
PAUpmc Hillman Cancer Center(Univ of Pittsburgh)Pittsburgh15232-1309NCT06943872Map
PAWest Penn HospitalPittsburgh15224NCT06846671Map
PAReading HospitalWest Reading19611NCT05554393Map
PAReading HospitalWest Reading19611NCT05554406Map
PAReading HospitalWest Reading19611NCT05564390Map
PAReading HospitalWest Reading19611NCT06317649Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT05554393Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT05554406Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT05564390Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT04269902Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT06317649Map
PAGeisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre18711NCT06672146Map
PACancer Care Associates of YorkYork17403-5049NCT06846671Map
RILifespan Cancer Institute - Providence /ID# 266550Providence02903NCT06428019Map
RILifespan Health System Rhode Island HospitalProvidence46278NCT05442216Map
RIRhode Island HospitalProvidence02903NCT05554406Map
RIRhode Island HospitalProvidence02903NCT05564390Map
RIRhode Island HospitalProvidence02903NCT06317649Map
RIRhode Island HospitalProvidence02903NCT06317662Map
RIRhode Island HospitalProvidence02903NCT06672146Map
SCPrisma Health Cancer Institute - SpartanburgBoiling Springs29316NCT05554393Map
SCPrisma Health Cancer Institute - SpartanburgBoiling Springs29316NCT05554406Map
SCPrisma Health Cancer Institute - SpartanburgBoiling Springs29316NCT05564390Map
SCPrisma Health Cancer Institute - SpartanburgBoiling Springs29316NCT04269902Map
SCPrisma Health Cancer Institute - SpartanburgBoiling Springs29316NCT06317649Map
SCPrisma Health Cancer Institute - SpartanburgBoiling Springs29316NCT06672146Map
SCHollings Cancer CenterCharleston29425NCT04227847Map
SCHollings Cancer CenterCharleston29425NCT04256317Map
SCMedical University of South CarolinaCharleston29425NCT05564390Map
SCMedical University of South CarolinaCharleston29425NCT04988555Map
SCMedical University of South CarolinaCharleston29425NCT04269902Map
SCMedical University of South CarolinaCharleston29425NCT06317649Map
SCMedical University of South Carolina- Ashley River TowerCharleston29425NCT04227847Map
SCMedical University of South Carolina- Investigational Drug ServicesCharleston29425NCT04227847Map
SCMedical University of South Carolina- University HospitalCharleston29425NCT04227847Map
SCRalph H Johnson VA Medical CenterCharleston29401NCT04269902Map
SCPrisma Health Richland HospitalColumbia29203NCT05183035Map
SCPrisma Health Richland HospitalColumbia29203NCT06317662Map
SCPrisma Health Cancer Institute - EasleyEasley29640NCT05554393Map
SCPrisma Health Cancer Institute - EasleyEasley29640NCT05554406Map
SCPrisma Health Cancer Institute - EasleyEasley29640NCT05564390Map
SCPrisma Health Cancer Institute - EasleyEasley29640NCT04269902Map
SCPrisma Health Cancer Institute - EasleyEasley29640NCT06317649Map
SCPrisma Health Cancer Institute - EasleyEasley29640NCT06672146Map
SCBI-LO Charities Children's Cancer CenterGreenville29605NCT06317662Map
SCBon Secours St. Francis Cancer CenterGreenville29607NCT04588922Map
SCPrisma Health Cancer Institute - ButternutGreenville29605NCT05554393Map
SCPrisma Health Cancer Institute - ButternutGreenville29605NCT05554406Map
SCPrisma Health Cancer Institute - ButternutGreenville29605NCT05564390Map
SCPrisma Health Cancer Institute - ButternutGreenville29605NCT04269902Map
SCPrisma Health Cancer Institute - ButternutGreenville29605NCT06317649Map
SCPrisma Health Cancer Institute - ButternutGreenville29605NCT06672146Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT05554393Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT05554406Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT05564390Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT04269902Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT06317649Map
SCPrisma Health Cancer Institute - EastsideGreenville29615NCT06672146Map
SCPrisma Health Cancer Institute - FarisGreenville29605NCT05554393Map
SCPrisma Health Cancer Institute - FarisGreenville29605NCT05554406Map
SCPrisma Health Cancer Institute - FarisGreenville29605NCT05564390Map
SCPrisma Health Cancer Institute - FarisGreenville29605NCT04269902Map
SCPrisma Health Cancer Institute - FarisGreenville29605NCT06317649Map
SCPrisma Health Cancer Institute - FarisGreenville29605NCT06672146Map
SCPrisma Health Cancer Institute - GreerGreer29650NCT05554393Map
SCPrisma Health Cancer Institute - GreerGreer29650NCT05554406Map
SCPrisma Health Cancer Institute - GreerGreer29650NCT05564390Map
SCPrisma Health Cancer Institute - GreerGreer29650NCT04269902Map
SCPrisma Health Cancer Institute - GreerGreer29650NCT06317649Map
SCPrisma Health Cancer Institute - GreerGreer29650NCT06672146Map
SCPrisma Health Cancer Institute - SenecaSeneca29672NCT05554393Map
SCPrisma Health Cancer Institute - SenecaSeneca29672NCT05554406Map
SCPrisma Health Cancer Institute - SenecaSeneca29672NCT05564390Map
SCPrisma Health Cancer Institute - SenecaSeneca29672NCT04269902Map
SCPrisma Health Cancer Institute - SenecaSeneca29672NCT06317649Map
SCPrisma Health Cancer Institute - SenecaSeneca29672NCT06672146Map
SDSanford Cancer Center Oncology ClinicSioux Falls57104NCT05564390Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT05564390Map
SDSanford USD Medical Center - Sioux FallsSioux Falls57117-5134NCT06317662Map
TNTennessee Oncology Greco Hainsworth Centers For Research ChattanoogaChattanooga37404NCT06943872Map
TNBaptist Memorial Hospital and Cancer Center-ColliervilleCollierville38017NCT05554393Map
TNBaptist Memorial Hospital and Cancer Center-ColliervilleCollierville38017NCT05554406Map
TNBaptist Memorial Hospital and Cancer Center-ColliervilleCollierville38017NCT05564390Map
TNBaptist Memorial Hospital and Cancer Center-ColliervilleCollierville38017NCT06317649Map
TNBaptist Memorial Hospital and Cancer Center-ColliervilleCollierville38017NCT06917911Map
TNBallad Health Cancer Care - KingsportKingsport37660NCT04269902Map
TNEast Tennessee Childrens HospitalKnoxville37916NCT06317662Map
TNUniversity of TennesseeKnoxville37920NCT06852222Map
TNUniversity of Tennessee - KnoxvilleKnoxville37920NCT05554406Map
TNUniversity of Tennessee - KnoxvilleKnoxville37920NCT05564390Map
TNUniversity of Tennessee - KnoxvilleKnoxville37920NCT06317649Map
TNBaptist Clinical Research InstituteMemphis38120NCT07007312Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT05554393Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT05554406Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT05564390Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT04269902Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT06317649Map
TNBaptist Memorial Hospital and Cancer Center-MemphisMemphis38120NCT06917911Map
TNSaint Jude Children's Research HospitalMemphis38105NCT06317662Map
TNSt. Jude Children's Research HospitalMemphis38105-3678NCT05183035Map
TNSt. Jude Children's Research HospitalMemphis38105NCT06177067Map
TNSt. Jude Children's Research HospitalMemphis38105NCT06390319Map
TNMonroe Carell Jr. Children's Hospital at VanderbiltNashville37232NCT05183035Map
TNSarah Cannon Research InstituteNashville37203NCT06501196Map
TNSarah Cannon Research Institute - Tennessee OncologyNashville37203NCT03331198Map
TNSarah Cannon, the Cancer Institute of HCA HealthcareNashville37203NCT06456463Map
TNTennessee OncologyNashville37203NCT06456463Map
TNTennessee OncologyNashville37205NCT06943872Map
TNTennessee OncologyNashville37203NCT07007312Map
TNThe Children's Hospital at TriStar CentennialNashville37203NCT06317662Map
TNTriStar Bone Marrow TransplantNashville37203NCT05735184Map
TNTriStar Centennial Medical CenterNashville37203NCT04988555Map
TNTriStar Centennial Medical CenterNashville37203NCT07007312Map
TNVanderbilt Ingram Cancer CenterNashville37232NCT06852222Map
TNVanderbilt University Medical CenterNashville37232NCT04256317Map
TNVanderbilt University/Ingram Cancer CenterNashville37232NCT06317662Map
TNVanderbilt University/Ingram Cancer CenterNashville37203NCT06399640Map
TXDell Children's Medical Center of Central TexasAustin78723NCT06317662Map
TXSarah Cannon Research Institute - St. David's South Austin Medical Center / Texas Oncology South AustinAustin78704NCT05735184Map
TXTexas Oncology - Austin Midtown /ID# 268152Austin78705NCT06428019Map
TXTexas Oncology-Austin MidtownAustin78705NCT07007312Map
TXDriscoll Children's HospitalCorpus Christi78411NCT06317662Map
TXBaylor Research InstituteDallas75204NCT04227847Map
TXBaylor Scott & White HealthDallas75246NCT04588922Map
TXBaylor Scott & White HealthDallas75246NCT06456463Map
TXBaylor University Medical CenterDallas75246NCT04227847Map
TXBaylor University Medical CenterDallas75246NCT03331198Map
TXBaylor University Medical CenterDallas75246NCT06852222Map
TXBaylor University Medical Center, Investigational Drug Services, Department of PharmacyDallas75246NCT04227847Map
TXHarold C. Simmons Comprehensive Cancer CenterDallas75235NCT05183035Map
TXMedical City Dallas HospitalDallas75230NCT06317662Map
TXTexas Oncology Baylorcharles A Sammons Cancer CenterDallas75246-2003NCT06943872Map
TXTexas Oncology-Presbyterian Cancer CenterDallas75231NCT07007312Map
TXUniversity of Texas - Southwestern Medical Center /ID# 266528Dallas75235NCT06428019Map
TXUniversity of Texas SouthwesternDallas75390NCT03013998Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT04256317Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT03331198Map
TXUniversity of Texas Southwestern Medical CenterDallas75390NCT06634394Map
TXUT Southwestern - Simmons Cancer CenterDallas75235NCT05735184Map
TXUT Southwestern Medical Center at DallasDallas75235NCT05401097Map
TXUT Southwestern/Simmons Cancer CenterDallas75390NCT06177067Map
TXUT Southwestern/Simmons Cancer Center-DallasDallas75390NCT06317662Map
TXSTCC at DHR Health Institute for Research and DevelopmentEdinburg78539NCT04269902Map
TXEl Paso Children's HospitalEl Paso79905NCT06317662Map
TXCook Children's Medical CenterFort Worth76104NCT06177067Map
TXCook Children's Medical CenterFort Worth76104NCT06317662Map
TXTexas Oncology-Fort Worth Cancer CenterFort Worth76104NCT05963074Map
TXBaylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston77030NCT05554393Map
TXBaylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston77030NCT05564390Map
TXBaylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston77030NCT06317649Map
TXBaylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston77030NCT06317662Map
TXBen Taub General HospitalHouston77030NCT05554393Map
TXBen Taub General HospitalHouston77030NCT05564390Map
TXBen Taub General HospitalHouston77030NCT06317649Map
TXHouston Methodist HospitalHouston77030NCT04227847Map
TXM D Anderson Cancer CenterHouston77030NCT05360160Map
TXM D Anderson Cancer CenterHouston77030NCT05365035Map
TXM D Anderson Cancer CenterHouston77030NCT05529069Map
TXM D Anderson Cancer CenterHouston77030NCT05536349Map
TXM D Anderson Cancer CenterHouston77030NCT04708054Map
TXM D Anderson Cancer CenterHouston77030NCT04774393Map
TXM D Anderson Cancer CenterHouston77030NCT04216524Map
TXM D Anderson Cancer CenterHouston77030NCT03471260Map
TXM D Anderson Cancer CenterHouston77030NCT03586609Map
TXM D Anderson Cancer CenterHouston77030NCT03629171Map
TXM D Anderson Cancer CenterHouston77030NCT02392572Map
TXM D Anderson Cancer CenterHouston77030NCT03661307Map
TXM D Anderson Cancer CenterHouston77030NCT00501826Map
TXM D Anderson Cancer CenterHouston77030NCT02115295Map
TXM D Anderson Cancer CenterHouston77030NCT03128879Map
TXM D Anderson Cancer CenterHouston77030NCT03214562Map
TXM D Anderson Cancer CenterHouston77030NCT04140487Map
TXM D Anderson Cancer CenterHouston77030NCT04169737Map
TXM D Anderson Cancer CenterHouston77030NCT05010122Map
TXM D Anderson Cancer CenterHouston77030NCT05010772Map
TXM.D. Anderson Cancer CenterHouston77030NCT05834244Map
TXM.D. Anderson Cancer Center, Department of LeukemiaHouston77030NCT05986240Map
TXMD AndersonHouston77091NCT04588922Map
TXMD Anderson Cancer CenterHouston77030NCT04256317Map
TXMD Anderson Cancer CenterHouston77030NCT05735184Map
TXMD Anderson Cancer CenterHouston77030NCT03113643Map
TXMD Anderson Cancer CenterHouston77030NCT06191978Map
TXMD Anderson Cancer CenterHouston77030NCT06284486Map
TXMD Anderson Cancer CenterHouston77030NCT06397027Map
TXMD Anderson Cancer CenterHouston77030NCT06445959Map
TXMD Anderson Cancer CenterHouston77030NCT06448013Map
TXMD Anderson Cancer CenterHouston77030NCT06466395Map
TXMD Anderson Cancer CenterHouston77030NCT06548230Map
TXMD Anderson Cancer CenterHouston77090NCT06561074Map
TXMD Anderson Cancer CenterHouston77030NCT06634394Map
TXMD Anderson Cancer CenterHouston77030NCT06852222Map
TXMD Anderson Cancer CenterHouston77030NCT06967610Map
TXMD Anderson Cancer CenterHouston77030NCT07032727Map
TXMDACCHouston77030NCT04988555Map
TXTexas Children's Cancer and Hematology CenterHouston77030NCT07059975Map
TXTexas Children's HospitalHouston77030NCT05183035Map
TXThe University of Texas - MD Anderson Cancer CenterHouston77030NCT03331198Map
TXThe University of Texas M.D. Anderson Cancer CenterHouston77030NCT06501196Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT05963074Map
TXThe University of Texas MD Anderson Cancer CenterHouston77030NCT03331198Map
TXUniversity of TexasHouston77030NCT07007312Map
TXUniversity of Texas MD Anderson Cancer CenterHouston77030NCT06419634Map
TXUniversity of Texas MD Anderson Cancer CenterHouston77030NCT06456463Map
TXMD Anderson Cancer CenterHuston77030NCT03850574
TXChildren's Hospital of San AntonioSan Antonio78207NCT06317662Map
TXMethodist Children's Hospital of South TexasSan Antonio78229NCT06317662Map
TXTexas Oncology - San Antonio Medical CenterSan Antonio78240NCT07007312Map
TXTexas Oncology San Antonio Medical Center UsorSan Antonio78240-5251NCT06943872Map
TXTexas Oncology-Gulf CoastThe Woodlands77380NCT05963074Map
TXTexas Oncology - NortheastTyler75702NCT06852222Map
TXTexas Oncology TylerTyler75702-7522NCT06846671Map
TXTexas Oncology TylerTyler75702-7522NCT06943872Map
UTCommunity Cancer Trials of UtahOgden84405NCT05963074Map
UTGeorge E Wahlen Department of Veterans Affairs Medical CenterSalt Lake City84148NCT05564390Map
UTGeorge E Wahlen Department of Veterans Affairs Medical CenterSalt Lake City84148NCT06317649Map
UTHuntsman Cancer InstituteSalt Lake City84112NCT04988555Map
UTHuntsman Cancer InstituteSalt Lake City84112NCT05861050Map
UTHuntsman Cancer InstituteSalt Lake City84112NCT03331198Map
UTHuntsman Cancer Institute at The University of UtahSalt Lake City84112NCT05091424Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05554393Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05554406Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT05564390Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT04269902Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT06317649Map
UTHuntsman Cancer Institute/University of UtahSalt Lake City84112NCT06672146Map
UTIntermountain HealthcareSalt Lake City84143NCT04988555Map
UTPrimary Children's HospitalSalt Lake City84113NCT05183035Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT05554393Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT05554406Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT05564390Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT06317649Map
VTUniversity of Vermont and State Agricultural CollegeBurlington05405NCT06649812Map
VTUniversity of Vermont Cancer CenterBurlington05401NCT06382168Map
VTUniversity of Vermont Medical CenterBurlington05401NCT05554393Map
VTUniversity of Vermont Medical CenterBurlington05401NCT05554406Map
VTUniversity of Vermont Medical CenterBurlington05401NCT05564390Map
VTUniversity of Vermont Medical CenterBurlington05401NCT06317649Map
VTUniversity of Vermont Medical CenterBurlington05401NCT06649812Map
VTUniversity of Vermont Medical CenterBurlington05401NCT07007312Map
VABallad Health Cancer Care - BristolBristol24201NCT04269902Map
VAUniversity of VirginiaCharlottesville22908NCT04988555Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT05554393Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT05554406Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT05564390Map
VAUniversity of Virginia Cancer CenterCharlottesville22903NCT03523975Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT06317649Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT06317662Map
VAUniversity of Virginia Cancer CenterCharlottesville22911NCT06382168Map
VAUniversity of Virginia Cancer CenterCharlottesville22908NCT06649812Map
VAUniversity of Virginia School of MedicineCharlottesville22903NCT07007312Map
VAInova Schar Cancer InstituteFairfax22031NCT05554393Map
VAInova Schar Cancer InstituteFairfax22031NCT05554406Map
VAInova Schar Cancer InstituteFairfax22031NCT05564390Map
VAVirginia Cancer SpecialistsFairfax22031NCT04988555Map
VAVirginia Cancer Specialists - Fairfax /ID# 268155Fairfax22031NCT06428019Map
VAInova Fairfax HospitalFalls Church22042NCT05554393Map
VAInova Fairfax HospitalFalls Church22042NCT05554406Map
VAInova Fairfax HospitalFalls Church22042NCT05564390Map
VAVirginia Cancer SpecialistsManassas20110NCT05963074Map
VAVirginia Cancer SpecialistsManassas20110NCT07007312Map
VAChildren's Hospital of The King's DaughtersNorfolk23507NCT06317662Map
VAVirginia Oncology AssociatesNorfolk23502NCT04988555Map
VABallad Health Cancer Care - NortonNorton24273NCT04269902Map
VAChildren's Hospital of Richmond at Virginia Commonwealth UniversityRichmond23219NCT05183035Map
VAVCU Massey Cancer Center at Stony PointRichmond23235NCT04269902Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT05564390Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT04840602Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT04269902Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT06317649Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT06317662Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT06649812Map
VAVCU Massey Comprehensive Cancer CenterRichmond23298NCT06672146Map
VAVirginia Commonwealth University - Massey Cancer CenterRichmond23298NCT06852222Map
VACarilion Children'sRoanoke24014NCT06317662Map
VAVirginia Oncology AssociatesVirginia Beach23456NCT05963074Map
WAFHCC OverlakeBellevue98004NCT04269902Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT05554393Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT05554406Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT05564390Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT04840602Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT04269902Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT06317649Map
WASwedish Cancer Institute-EdmondsEdmonds98026NCT06672146Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT05554393Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT05554406Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT05564390Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT04840602Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT04269902Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT06317649Map
WASwedish Cancer Institute-IssaquahIssaquah98029NCT06672146Map
WAKadlec Clinic Hematology and OncologyKennewick99336NCT04269902Map
WAFHCC at EvergreenHealthKirkland98034NCT04269902Map
WAVista Oncology - East Olympia /ID# 267337Olympia98506NCT06428019Map
WAFHCC at Northwest HospitalSeattle98133NCT04269902Map
WAFred Hutch/University of Washington Cancer ConsortiumSeattle98109NCT04797767Map
WAFred Hutch/University of Washington Cancer ConsortiumSeattle98109NCT04941716Map
WAFred Hutchinson Cancer CenterSeattle98109NCT05564390Map
WAFred Hutchinson Cancer CenterSeattle98109NCT04269902Map
WAFred Hutchinson Cancer CenterSeattle98109NCT06317649Map
WAFred Hutchinson Cancer CenterSeattle98109NCT06501196Map
WAFred Hutchinson Cancer CenterSeattle98109NCT06852222Map
WAFred Hutchinson Cancer Research CenterSeattle98109NCT03331198Map
WAFred Hutchinson Cancer Research CenterSeattle98109-4433NCT07277231Map
WASeattle Cancer Care AllianceSeattle98109NCT04256317Map
WASeattle Cancer Center AllianceSeattle98109NCT03331198Map
WASeattle Children's HospitalSeattle98105NCT05183035Map
WASeattle Children's HospitalSeattle98105NCT06317662Map
WASwedish Cancer InstituteSeattle98104NCT04227847Map
WASwedish Cancer InstituteSeattle98104NCT06852222Map
WASwedish Medical CenterSeattle98122NCT04227847Map
WASwedish Medical Center-First HillSeattle98122NCT05554393Map
WASwedish Medical Center-First HillSeattle98122NCT05554406Map
WASwedish Medical Center-First HillSeattle98122NCT05564390Map
WASwedish Medical Center-First HillSeattle98122NCT04840602Map
WASwedish Medical Center-First HillSeattle98122NCT04269902Map
WASwedish Medical Center-First HillSeattle98122NCT06317649Map
WASwedish Medical Center-First HillSeattle98122NCT06649812Map
WASwedish Medical Center-First HillSeattle98122NCT06672146Map
WAUniversity of Washington Medical Center - MontlakeSeattle98195NCT05564390Map
WAUniversity of Washington Medical Center - MontlakeSeattle98195NCT04269902Map
WAUniversity of Washington Medical Center - MontlakeSeattle98195NCT06317649Map
WAVA Puget Sound Health Care System Seattle Division, Seattle, WASeattle98108-1532NCT06520098Map
WAVA Puget Sound Healthcare SystemSeattle98108NCT05963074Map
WAMedical Oncology Associates, PS ( Site 5406)Spokane99208NCT05947851Map
WAProvidence Sacred Heart Medical Center and Children's HospitalSpokane99204NCT06317662Map
WANorthwest Medical Specialties Tacoma /ID# 266327Tacoma98405NCT06428019Map
WANorthwest Cancer Specialist, Pc(Us Oncology Research)Vancouver98684-6930NCT06943872Map
WANorthwest Cancer Specialists PCVancouver98684NCT05963074Map
WVWest Virginia University School of Medicine /ID# 267645Morgantown26506NCT06428019Map
WVWVU Medicine Wheeling HospitalWheeling26003NCT07007312Map
WIThedaCare Regional Cancer CenterAppleton54911NCT05554406Map
WIThedaCare Regional Cancer CenterAppleton54911NCT05564390Map
WIThedaCare Regional Cancer CenterAppleton54911NCT04840602Map
WIThedaCare Regional Cancer CenterAppleton54911NCT06317649Map
WIThedaCare Regional Medical Center - AppletonAppleton54911NCT05554406Map
WIDuluth Clinic AshlandAshland54806NCT05554393Map
WIDuluth Clinic AshlandAshland54806NCT05554406Map
WIDuluth Clinic AshlandAshland54806NCT05564390Map
WIDuluth Clinic AshlandAshland54806NCT04269902Map
WIDuluth Clinic AshlandAshland54806NCT06317649Map
WIDuluth Clinic AshlandAshland54806NCT06649812Map
WIDuluth Clinic AshlandAshland54806NCT06672146Map
WIAurora Cancer Care-Southern Lakes VLCCBurlington53105NCT05564390Map
WIAurora Saint Luke's South ShoreCudahy53110NCT05564390Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT05564390Map
WIMarshfield Medical Center-EC Cancer CenterEau Claire54701NCT04269902Map
WIAurora Health Care Germantown Health CenterGermantown53022NCT05564390Map
WIAurora Cancer Care-GraftonGrafton53024NCT05564390Map
WIAurora BayCare Medical CenterGreen Bay54311NCT05564390Map
WIBellin Memorial HospitalGreen Bay54301NCT04269902Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT05554393Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT05554406Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT05564390Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT06317649Map
WISaint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay54303NCT06672146Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT05554393Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT05554406Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT05564390Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT06317649Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT06317662Map
WISaint Vincent Hospital Cancer Center Green BayGreen Bay54301NCT06672146Map
WIMercyhealth Hospital and Cancer Center - JanesvilleJanesville53548NCT05564390Map
WIMercyhealth Hospital and Cancer Center - JanesvilleJanesville53548NCT06649812Map
WIAurora Cancer Care-Kenosha SouthKenosha53142NCT05564390Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT05554393Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT05554406Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT05564390Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT04840602Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT06317649Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT06649812Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT06672146Map
WIGundersen Lutheran Medical CenterLa Crosse54601NCT06917911Map
WIUniversity of WisconsinMadison53792NCT07007312Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT05554406Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT05564390Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT04269902Map
WIUniversity of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison53718NCT06317649Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT05554406Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT05564390Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT04269902Map
WIUniversity of Wisconsin Carbone Cancer Center - University HospitalMadison53792NCT06317649Map
WIUniversity of Wisconsin Clinical Science CenterMadison53792NCT06501196Map
WIUniversity of Wisconsin Hospital and ClinicsMadison53792NCT05735184Map
WIWilliam S Middleton VA Medical CenterMadison53705NCT05564390Map
WIWilliam S Middleton VA Medical CenterMadison53705NCT06317649Map
WIWilliam S Middleton VA Medical CenterMadison53705NCT06672146Map
WIAurora Bay Area Medical Group-MarinetteMarinette54143NCT05564390Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT05564390Map
WIMarshfield Medical Center-MarshfieldMarshfield54449NCT04269902Map
WIFroedtert Menomonee Falls HospitalMenomonee Falls53051NCT05564390Map
WIFroedtert Menomonee Falls HospitalMenomonee Falls53051NCT06649812Map
WIAurora Cancer Care-MilwaukeeMilwaukee53209NCT05564390Map
WIAurora Saint Luke's Medical CenterMilwaukee53215NCT05564390Map
WIAurora Sinai Medical CenterMilwaukee53233NCT05564390Map
WIChildren's Hospital of WisconsinMilwaukee53226NCT06317662Map
WIChildren's WisconsinMilwaukee53226NCT05317403Map
WIFroedtert & Medical College of WisconsinMilwaukee53226NCT04256317Map
WIFroedtert & Medical College of WisconsinMilwaukee53226NCT07007312Map
WIFroedtert Hospital & the Medical College of WisconsinMilwaukee53226NCT05451771Map
WIFroedtert Hospital BMT Medical College of WisconsinMilwaukee53226NCT03331198Map
WIMedical College of WisconsinMilwaukee53226NCT05554393Map
WIMedical College of WisconsinMilwaukee53226NCT05554406Map
WIMedical College of WisconsinMilwaukee53226NCT05564390Map
WIMedical College of WisconsinMilwaukee53226NCT03331198Map
WIMedical College of WisconsinMilwaukee53226NCT06317649Map
WIMedical College of WisconsinMilwaukee53226NCT06649812Map
WIMedical College of WisconsinMilwaukee53226NCT06672146Map
WIMedical College of Wisconsin Cancer CenterMilwaukee53226NCT05735184Map
WIZablocki Veterans Administration Medical CenterMilwaukee53295NCT04269902Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT05564390Map
WIMarshfield Medical Center - MinocquaMinocqua54548NCT04269902Map
WIProHealth D N Greenwald CenterMukwonago53149NCT05564390Map
WIFroedtert and MCW Moorland Reserve Health CenterNew Berlin53151NCT05564390Map
WIFroedtert and MCW Moorland Reserve Health CenterNew Berlin53151NCT06649812Map
WICancer Center of Western WisconsinNew Richmond54017NCT04269902Map
WIDrexel Town Square Health CenterOak Creek53154NCT05564390Map
WIDrexel Town Square Health CenterOak Creek53154NCT06649812Map
WIProHealth Oconomowoc Memorial HospitalOconomowoc53066NCT05564390Map
WISaint Vincent Hospital Cancer Center at Oconto FallsOconto Falls54154NCT05564390Map
WISaint Vincent Hospital Cancer Center at Oconto FallsOconto Falls54154NCT06317649Map
WISaint Vincent Hospital Cancer Center at Oconto FallsOconto Falls54154NCT06672146Map
WIVince Lombardi Cancer Clinic - OshkoshOshkosh54904NCT05564390Map
WIAurora Cancer Care-RacineRacine53406NCT05564390Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT05564390Map
WIMarshfield Medical Center-Rice LakeRice Lake54868NCT04269902Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT05564390Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT06317649Map
WISaint Vincent Hospital Cancer Center at SheboyganSheboygan53081NCT06672146Map
WISheboygan Physicians GroupSheboygan53081NCT06672146Map
WIVince Lombardi Cancer Clinic-SheboyganSheboygan53081NCT05564390Map
WIEssentia Health-Spooner ClinicSpooner54801NCT06649812Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05554393Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05554406Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT05564390Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT04269902Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT06317649Map
WIMarshfield Medical Center-River Region at Stevens PointStevens Point54482NCT06672146Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT05564390Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT06317649Map
WISaint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay54235-1495NCT06672146Map
WIAurora Medical Center in SummitSummit53066NCT05564390
WIEssentia Health Saint Mary's Hospital - SuperiorSuperior54880NCT06649812Map
WIVince Lombardi Cancer Clinic-Two RiversTwo Rivers54241NCT05564390Map
WIProHealth Waukesha Memorial HospitalWaukesha53188NCT05564390Map
WIUW Cancer Center at ProHealth CareWaukesha53188NCT05564390Map
WIAurora Cancer Care-Milwaukee WestWauwatosa53226NCT05564390Map
WIAurora West Allis Medical CenterWest Allis53227NCT05564390Map
WIFroedtert West Bend Hospital/Kraemer Cancer CenterWest Bend53095NCT05564390Map
WIFroedtert West Bend Hospital/Kraemer Cancer CenterWest Bend53095NCT06649812Map
WIMarshfield Medical Center - WestonWeston54476NCT05554393Map
WIMarshfield Medical Center - WestonWeston54476NCT05554406Map
WIMarshfield Medical Center - WestonWeston54476NCT05564390Map
WIMarshfield Medical Center - WestonWeston54476NCT04269902Map
WIMarshfield Medical Center - WestonWeston54476NCT06317649Map
WIMarshfield Medical Center - WestonWeston54476NCT06672146Map

Venetoclax clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingenrolling by invitationcompletedterminatedwithdrawnsuspendednot yet recruitingunknownno longer availableavailableTotal
Early P112216
P14127145277532158
P1/P2442013239178125
P21195037171011916269
P2/P310211519
P317161347259
P42125
N/A203161292145

Recruiting Venetoclax clinical trials (303)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT05725200EVIDENTStudy to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerP2Metastatic Colorectal Cancer40Sep 2022
NCT05947851VRA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).P3Leukemia, Lymphocytic, Chronic, B-Cell735Aug 2023
NCT07320235IMAGINEImetelstat Combinations in Relapsed AMLP1Relapsed Acute Myeloid Leukemia36Jan 2026
NCT06390319ALLAdding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)P2T-cell Acute Lymphoblastic Leukemia100Dec 2024
NCT07604233Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLP1/P2Myeloid Leukemia30Nov 2026
NCT06967610PVOPhase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).P2Chronic Lymphocytic Leukemia40Jul 2025
NCT07520006Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesP1/P2B-cell Lymphoma150May 2026
NCT05099471VIWA-1Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaP2Waldenstrom Macroglobulinemia80Mar 2025
NCT04523428REVEALREtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)P2CLL/SLL60Dec 2020
NCT05791409AETHERVenetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLLP1/P2CLL/SLL112Apr 2024
NCT07175415HEM-iSMART EHEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesP1/P2Acute Lymphoblastic Leukemia42Oct 2026
NCT06644183IOA-244Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)P1/P2Leukemia64Mar 2025
NCT07581002REVIVALA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)P2/P3Acute Myeloid Leukemia660Jul 2026
NCT07014917ESR-23-22182Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLP2Chronic Lymphocytic Leukemia62Dec 2025
NCT06991920Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous LineageN/AAdult ALL50Jun 2026
NCT07294677CAVALRYCApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLP1/P2Leukemia104Mar 2026
NCT06558604GLOASISPhase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell LymphomaP2Lymphoma, Mantle-Cell100Feb 2025
NCT04628026Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2P3Acute Myeloid Leukemia650Sep 2022
NCT05091424A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaP1Chronic Lymphocytic Leukemia137Mar 2022
NCT05745714HEM-iSMART CHEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesP1/P2Acute Lymphoblastic Leukemia, in Relapse26Oct 2025
NCT07425808FIT-AMLFLT3-ITD Targeted Therapy in Fit AML PatientsP2/P3AML (Acute Myeloid Leukemia)230Dec 2026
NCT05751044HEM-iSMART BHEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesP1/P2Acute Lymphoblastic Leukemia26Oct 2025
NCT02416388BIG-1Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CRP2/P3Acute Myeloid Leukemia (AML)3,100Jan 2015
NCT07513129Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic LymphomaP1T-cell Acute Lymphoblastic Leukemia18Sep 2026
NCT06561074T-ALLA Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)P2T-cell Acute Lymphoblastic Leukemia22Sep 2025
NCT06943872CELESTIAL-RRCLLA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)P3Chronic Lymphocytic Leukemia630Jun 2025
NCT06466395A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated LeukemiasP1Refractory Acute Leukemia22Feb 2025
NCT07277231BGB-11417A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaP3Chronic Lymphocytic Leukemia500Jan 2026
NCT07007312Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLP3Acute Myeloid Leukemia (AML)1,300Sep 2025
NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaP2Lymphoma33Feb 2026
NCT07007052TAGVENPhase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm PatientsP2Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)33Dec 2025
NCT05431257LD-VenExAzacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML ProfilingP2Acute Myeloid Leukemia117May 2022
NCT07059975UPDATE AMLUPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLEarly P1Acute Myeloid Leukemia36Oct 2025
NCT04941716Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialP2Recurrent Chronic Lymphocytic Leukemia20May 2023
NCT05442216TAGALONGTagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating AgentsP2Acute Myeloid Leukemia53May 2024
NCT07238686Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDSP2Myelodysplastic Syndromes40Jun 2025
NCT07078591Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AMLP2Acute Myeloid Leukemia50Jun 2025
NCT06855810CCCG-TALL-2025Newly-diagnosed Pediatric T-cell ALL ProtocolP2/P3Acute Lymphoblastic Leukemia610Mar 2025
NCT06764238CCCG-I/HR-ALLNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolP2/P3Acute Lymphoblastic Leukemia ALL1,800Jan 2025
NCT06810778PTCLDuvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)P1/P2T-cell-prolymphocytic Leukemia12May 2025
NCT05183035AMLVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)P3Acute Myeloid Leukemia130Oct 2022
NCT07539818Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AMLP3AML788Apr 2026
NCT07082452SEVENAZAA Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive InductionP3Leukemia, B-Cell, Chronic262Sep 2025
NCT07311746Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaP1/P2T-cell Prolymphocytic Leukemia36Jun 2026
NCT07407140VAG-3+7-GVAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLP3AML, Adult300Apr 2026
NCT07148180A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and VenetoclaxP1/P2Acute Myeloid Leukaemia (AML)31Feb 2026
NCT06520098Benefit VAA Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)P2Chronic Lymphocytic Leukemia100Oct 2025
NCT06448013A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaP1Acute Myeloid Leukemia22Mar 2025
NCT06397027A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute LeukemiasP1Refractory Acute Leukemia22Dec 2024
NCT05910801V-MINDTafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaP2Recurrent Mantle Cell Lymphoma100Jan 2024
NCT06841952Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid LeukemiaN/AAML, Adult158Feb 2025
NCT07374029Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AMLP1Acute Myeloid Leukemia30Feb 2026
NCT06598384VA as Maintenance Therapy Post Allo-HSCT in MDS and AMLP2Acute Myeloid Leukemia40Sep 2024
NCT06419634ORM-6151Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeP1Acute Myeloid Leukemia105May 2024
NCT07159620Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsP2Adult T-cell Leukemia/Lymphoma27Sep 2025
NCT06471946VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDSP1/P2Higher-risk Myelodysplastic Syndromes54Oct 2024
NCT07511062Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLP1Acute Myeloid Leukemia32Aug 2026
NCT03868722Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early TreatmentP2/P3CLL212Oct 2019
NCT05292664Venetoclax Basket Trial for High Risk Hematologic MalignanciesP1Myelodysplastic Syndromes, de Novo30Mar 2023
NCT07396480Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 TrialP3Venentoclax186Mar 2026
NCT05404906AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First RemissionP2/P3Acute Myeloid Leukemia (AML) in Remission124Jun 2022
NCT02115295Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaP2Acute Biphenotypic Leukemia508May 2014
NCT07478991VENP-A-QUIAzacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)P3Acute Myeloid Leukemia, Adult376Mar 2026
NCT06696183SEQUENCEGilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentP2AML - Acute Myeloid Leukemia60Apr 2025
NCT05735184A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLP1Acute Myeloid Leukemia420Jul 2023
NCT07153497Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)P2Acute Myeloid Leukemia132May 2026
NCT06972641Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationP2/P3AML126Jun 2025
NCT05986240Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AMLP1AML/MDS38May 2024
NCT07493161Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLN/APh+ ALL110Apr 2026
NCT05530421SELVEDgeSelinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple MyelomaP2Relapsed and Refractory Multiple Myeloma33Mar 2023
NCT07522801ALL-TARGETA Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALLP2LAL93Sep 2026
NCT07454226ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALLN/APh-Like92May 2026
NCT07495631Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaN/AAcute Lymphoblastic Leukemia, Adult43Apr 2026
NCT07283094FHD-286FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid LeukemiaP1Acute Myeloid Leukemia33Feb 2026
NCT06846671CaDAnCe-302A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsP3CLL250Apr 2025
NCT06456463TRILLIUMA Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyP2Acute Myeloid Leukemia83Jan 2025
NCT07407660Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus VenetoclaxP3Acute Myeloid Leukemia250Feb 2026
NCT07481175INITIATEInhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)P1HIV-138Apr 2026
NCT07154264TAI-SHAN10A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)P2Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma66Sep 2025
NCT06084819Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaP2Relapsed/Refractory Acute Myeloid Leukemia200Aug 2023
NCT07358195Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney TransplantationEarly P1Kidney Failure Chronic3Jul 2026
NCT07060001Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease MarkerP2Acute Myeloid Leukemia (AML)112Apr 2026
NCT07177079HDAHigh-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)P1Acute Myeloid Leukemia30Mar 2026
NCT07052422VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCTP2/P3Older Patients160Jul 2025
NCT06221683GMCAIIClinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLP2AML, Childhood500Jan 2024
NCT06548230MDSA Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)P1/P2Myelodysplastic Syndrome(MDS)40Mar 2025
NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaP2Acute Myeloid Leukemia102Dec 2025
NCT06852222cAMeLot-2A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)P3Leukemia, Myeloid, Acute600Jun 2025
NCT07014462DLIT-AMLA Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AMLP1AML - Acute Myeloid Leukemia20Sep 2025
NCT07047183Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic SyndromesP2Myelodysplastic Neoplasms46Jul 2025
NCT06445959Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibP1/P2Mutant IDH1 Inhibitor Olutasidenib78Aug 2024
NCT05401097IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)P2Acute Myeloid Leukemia125Sep 2022
NCT07218510Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity TrialP2Chronic Lymphocytic Leukemia33Jan 2026
NCT07032727Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsP2Targeted Therapy68Sep 2025
NCT07437950Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)P2Acute Myeloid Leukemia126Oct 2026
NCT07023588Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual DiseaseP2Acute Myeloid Leukemia (AML)70Jun 2025
NCT02966756A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaP2Chronic Lymphocytic Leukemia (CLL)110Oct 2017
NCT07024706MAVRiCPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± ObinutuzumabP2Chronic Lymphocytic Leukemia (CLL)80Jan 2026
NCT06317649AMLVenetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)P2Acute Myeloid Leukemia147Sep 2024
NCT05564390MYELOMATCHMYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)P2Acute Myeloid Leukemia2,000Jun 2024
NCT07582159Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaP2Chronic Lymphocytic Leukemia35Dec 2026
NCT06516978A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLP2Diffuse Large B Cell Lymphoma528Oct 2024
NCT07469046VAH vs VA in Newly Diagnosed Elderly AMLP3Acute Myeloid Leukemia (AML)308Apr 2026
NCT06782542OLUVENAZAOlutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyP2Acute Myeloid Leukemia16Mar 2026
NCT07507825VHAGExploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)P2Acute Myeloid Leukemia (AML)61Mar 2026
NCT07075016EVOLVE 1Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive ChemotherapyP3Acute Myeloid Leukemia227Aug 2025
NCT05287568CC-486 and Venetoclax for Acute Myeloid LeukemiaP1AML35Dec 2022
NCT05963074TAILORA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic LeukemiaP2Leukemia, Lymphocytic, Chronic, B-Cell320May 2024
NCT07490288Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AMLN/AAML27May 2026
NCT04560322Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLP2Chronic Lymphocytic Leukemia40Oct 2020
NCT07439211GAVELAssessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid LeukemiaP1Leukemia, Myeloid48Jul 2026
NCT04895436ReVenGStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)P2Chronic Lymphocytic Leukemia (CLL)75Mar 2022
NCT06863259Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALLP1B-cell Acute Lymphoblastic Leukemia28May 2025
NCT07514832VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm TrialP2AML (Acute Myeloid Leukemia)48Apr 2026
NCT06317662Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaP2Acute Leukemia of Ambiguous Lineage153Jun 2025
NCT06470841CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AMLP2Acute Myeloid Leukemia85Sep 2024
NCT06387121Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLP2Precursor Cell Lymphoblastic Leukemia-Lymphoma53Apr 2024
NCT06191978ASTX727A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)P1Acute Myeloid Leukemia40Mar 2024
NCT05853965BELI(E)VECombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple MyelomaP1/P2Multiple Myeloma45Jun 2023
NCT05342584Venetoclax AMLVenetoclax Plus Intensive Chemotherapy in AML and Advanced MDSP1Acute Myeloid Leukemia99May 2022
NCT04797767Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsP1/P2Acute Biphenotypic Leukemia62Feb 2022
NCT03013998Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaP1/P2Previously Untreated Relapsed Refractory Acute Myeloid Leukemia3,000Nov 2016
NCT07264010Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical StudyP2/P3Acute Myeloid Leukaemia (AML)87Dec 2025
NCT06284486A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibP1/P2Acute Myeloid Leukemia8Sep 2024
NCT06757855Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CMLP1/P2CML,Blast Phase29Jan 2025
NCT06042725MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaP1Multiple Myeloma100Mar 2024
NCT06651229A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsP1Leukemia, Myeloid, Acute155Mar 2025
NCT06557421STOP VENDe-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding PatientsP2Acute Myeloid Leukemia50Feb 2026
NCT04256317A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)P2/P3Myelodysplastic Syndromes316May 2020
NCT07486726Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid LeukemiaP1/P2Acute Myeloid Leukemia (AML)112Mar 2026
NCT07163793Pilot Study of Reduced Venetoclax ExposureP2Acute Myeloid Leukemia in Remission41Oct 2024
NCT06686108Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse PreventionP2T-cell Acute Lymphoblastic Leukemia59Oct 2024
NCT05168930ZANU-VENZanubrutinib and Venetoclax in CLL (ZANU-VEN)P2Chronic Lymphocytic Leukemia (CLL)45Feb 2022
NCT06611839IDH1-AML-2024Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AMLP1/P2AML23Oct 2025
NCT06635681DAV-AML-2024Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AMLP2AML (Acute Myelogenous Leukemia)380Sep 2024
NCT04269902CLLTesting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyP3Chronic Lymphocytic Leukemia247Mar 2021
NCT05904106VINCENTVenetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AMLP2Acute Myeloid Leukemia146Apr 2024
NCT04140487Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmP1/P2Recurrent Acute Myeloid Leukemia97Dec 2019
NCT06712121Venetoclax and Decitabine in R/R T-ALLP2T Lymphoblastic Leukemia/Lymphoma28Jan 2025
NCT06511882Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRDP2Acute Myeloid Leukemia37Nov 2024
NCT07132684Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia PatientsP3AML, Adult240Aug 2025
NCT07183878Ven-BUCYVenetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)N/AAcute Myeloid Leukemia138Aug 2025
NCT06544109Ven APLVenetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsP2/P3Acute Promyelocytic Leukemia98Aug 2023
NCT07605949RAVENRevumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AMLP2Leukemia Acute Myeloid88Jul 2026
NCT07387471WMStudy to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)P2Waldenstrom Macroglobulinemia14Mar 2026
NCT06668558VERDIVenetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaP2Acute Myeloid Leukemia29Dec 2024
NCT06536010Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AMLN/AAcute Myeloid Leukemia50Nov 2021
NCT04227847A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesP1Myelodysplastic Syndrome178Aug 2020
NCT06483906Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.P2Acute Myeloid Leukemia56Jul 2024
NCT06537843VenCMSafety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid LeukemiaP2Acute Myeloid Leukemia100Dec 2023
NCT06742463VHAG in Treating R/R T-ALL/LBLP2Acute T Lymphpblastic Leukemia/Lymphoma50Dec 2024
NCT06481241Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLN/APhiladelphia Chromosome Negative ALL77Jun 2024
NCT05834244ADVENT-AMLA Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)P1Acute Myeloid Leukemia32Oct 2023
NCT07133997Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaP1Recurrent B Acute Lymphoblastic Leukemia26Jun 2026
NCT06481228Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLN/APhiladelphia Positive Acute Lymphoblastic Leukemia82Jun 2024
NCT05197192A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLP3Chronic Lymphocytic Leukemia202Apr 2022
NCT06954987Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)P2Acute Myeloid Leukemia244Jul 2026
NCT07012447Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid MutationsP2Early T Acute Lymphoblastic Leukemia32Apr 2025
NCT06504459Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLP2Acute Monocytic Leukemia40Jan 2025
NCT07131059MRD-positive AML Clinical StudyN/AAML, Adult120May 2024
NCT05536349CLLTime-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)P2Leukemia60Dec 2022
NCT07231952WMA Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)P2Waldenstrom Macroglobulinemia40Nov 2025
NCT06634394APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AMLP1Acute Myeloid Leukemia (AML)39Oct 2024
NCT06428019TLSA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)P3Chronic Lymphocytic Leukemia170Aug 2024
NCT06014489HO171A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AMLP2AML, Adult142Jan 2024
NCT04840602Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaP2Lymphoplasmacytic Lymphoma92Jan 2022
NCT05805098VHAVenetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLP2/P3Acute Myeloid Leukemia60Mar 2023
NCT06571825RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CRP4Acute Myeloid Leukemia118Jul 2024
NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyP2Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)79Dec 2025
NCT07392242A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaP2Acute Myeloid Leukemia45Jan 2026
NCT03826992CPX-351Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute LeukemiaP1Leukemia21Dec 2018
NCT05807932FLAMSAVenetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLP1/P2Myelodysplastic Syndromes38Jun 2023
NCT05010122ASTX727ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeP1/P2Acute Myeloid Leukemia42Jul 2021
NCT06765928Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCTP2MDS73Jan 2025
NCT03661307Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeP1/P2Acute Myeloid Leukemia73Oct 2018
NCT07557056Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2Chronic Lymphocytic Leukemia25May 2026
NCT07255872A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaP2/P3Acute Myeloid Leukemia216Mar 2026
NCT07486479Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLP3Acute Myeloid Leukemia (AML)204Mar 2026
NCT07451912Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AMLP1/P2Acute Myeloid Leukemia (AML)29Sep 2025
NCT06783790Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTP2AML (Acute Myelogenous Leukemia)20Jan 2025
NCT07514936Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaP2Newly Diagnosed Acute Myeloid Leukemia (AML)120Nov 2024
NCT05554393Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)P2Acute Myeloid Leukemia153Sep 2024
NCT06621199Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AMLP2Acute Myeloid Leukemia42Jul 2024
NCT06621212Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AMLP2Relapsed/Refractory Acute Myeloid Leukaemia72Jul 2024
NCT06115135A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple MyelomaP2Multiple Myeloma in Relapse39Jun 2024
NCT06429098Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AMLP2Acute Myeloid Leukemia40Jan 2024
NCT05365035A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsP2Myelodysplastic Syndromes60Sep 2022
NCT04988555DSP-5336A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)P1/P2Leukemia, Myeloid, Acute606Feb 2022
NCT04708054Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSP2/P3Acute Myeloid Leukemia324Oct 2021
NCT04855695Avo In R/R And Previously Untreated MCLP1/P2Mantle Cell Lymphoma72Jul 2021
NCT04588922Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLP1/P2Hematologic Malignancies160May 2021
NCT03874052Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaP1Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome51Aug 2019
NCT06754267Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLP2Precursor B-Cell Acute Lymphoblastic Leukemia36Dec 2024
NCT06386302Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaN/AAML184Aug 2024
NCT06232694Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AMLN/AAcute Myeloid Leukemia54Jan 2024
NCT04758975VALUABLEVenetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)P2Chronic Lymphocytic Leukemia (CLL)55Sep 2022
NCT05660473Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaP2Precursor Cell Lymphoblastic Leukemia-Lymphoma100Aug 2022
NCT06328179Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.N/AAcute Myeloid Leukemia34May 2022
NCT06390306The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBPChronic Myeloid Leukemia30Jul 2024
NCT03223610Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaP1/P2Lymphoma155Feb 2018
NCT07044687SCStudy to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in IndiaP4Acute Myeloid Leukemia100Jul 2025
NCT06660368BCL2i CLAG-M in R/R Acute Myeloid LeukemiaP2Relapsed or Refractory Acute Myeloid Leukemia (AML)52Nov 2024
NCT06429449Mitoxantrone for Venetoclax Resistant Acute Myeloid LeukemiaP1Leukemia30Jul 2024
NCT06152809CIML NK Cells With Venetoclax for AMLP1Acute Myeloid Leukemia10Feb 2024
NCT04774393Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaP1/P2Acute Myeloid Leukemia84May 2021
NCT03331198CLLStudy Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)P1/P2Leukemia, Lymphocytic, Chronic, B-Cell320Nov 2017
NCT06917911GOTesting the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)P2Core Binding Factor Acute Myeloid Leukemia162Feb 2027
NCT06643962Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction TherapyN/ALeukemia83Oct 2024
NCT06232655Cladribine Venetoclax in Monocytic AMLP2Acute Myeloid Leukemia20Feb 2024
NCT06399640Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaP1Relapsed Myelodysplastic Syndrome60Aug 2024
NCT05939180VA vs DA for Newly Diagnosed Hig-risk AMLP2/P3Acute Myeloid Leukemia116Apr 2024
NCT03471260Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesP1/P2Acute Myeloid Leukemia96Mar 2018
NCT03214562Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaP1/P2High Risk Myelodysplastic Syndrome116Sep 2017
NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaP2High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements120Oct 2025
NCT07244367Maintenance Venetoclax in AML Fit PatientsN/AAcute Myeloid Leukaemia (AML)80Sep 2025
NCT06237192MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult PatientsN/APrecursor Cell Lymphoblastic Leukemia-Lymphoma200Apr 2023
NCT06561880FLT3AML-2024The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 MutationP1/P2FLT3 Gene Mutation66Oct 2024
NCT06554626Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLP2Precursor B-Cell Lymphoblastic Leukemia20Aug 2024
NCT06129734Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantP1/P2Myeloid Malignancy20Jul 2025
NCT06536959VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSP2Relapsed Acute Myeloid Leukemia67Jul 2024
NCT06496308Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentP3Mantle Cell Lymphoma (MCL)78Jul 2024
NCT03969446Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractoryP1Acute Myeloid Leukemia54May 2020
NCT06903702A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid LeukemiaP2Acute Myeloid Leukemia100Jun 2025
NCT06746519BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid LeukemiaP1/P2Acute Myeloid Leukemia135Dec 2024
NCT06652685Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid LeukemiaP2Acute Myeloid Leukemia (AML)218Oct 2024
NCT06451861Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AMLP2Acute Myeloid Leukemia240Aug 2024
NCT06501196A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic SyndromeP1Leukemia170Jun 2024
NCT05305859VCAVenetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AMLP2Leukemia, Myeloid, Acute30Jan 2022
NCT03523975Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaP1/P2Mantle Cell Lymphoma28Dec 2018
NCT06471738Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaP2Ann Arbor Stage II Follicular Lymphoma30Jul 2024
NCT03113643AMLSL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)P1Acute Myeloid Leukemia72Jun 2017
NCT03128879Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLP2Chronic Lymphocytic Leukemia90Jun 2017
NCT06311227Venetoclax for the Treatment of Patients With Relapsed Hairy Cell LeukemiaP2Recurrent Hairy Cell Leukemia20Dec 2024
NCT06372717A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDSP1Acute Myeloid Leukemia Refractory100Jun 2024
NCT06387420A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid LeukemiaP1/P2ACUTE MYELOID LEUKEMIA; AML180Apr 2024
NCT06177067Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaP1Refractory Acute Myeloid Leukemia24Apr 2024
NCT05736965SAVA Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid LeukemiaP2AML, Adult58Feb 2023
NCT03850574TUSCANYClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaP1/P2Leukemia, Myeloid, Acute240Mar 2019
NCT03586609Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaP2Acute Myeloid Leukemia145Oct 2018
NCT05529069Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsP2Mantle Cell Lymphoma30Jan 2023
NCT06393985Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALLP2B-cell Acute Lymphoblastic Leukemia30Apr 2024
NCT06672146Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)P2Acute Myeloid Leukemia93May 2025
NCT05554406Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)P2Acute Myeloid Leukemia335Sep 2024
NCT06361329Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALLP3ETP-ALL81Apr 2024
NCT06192979Optimize First-line Treatment for AL Amyloidosis With t (11; 14)N/AAmyloidosis; Systemic41Jan 2024
NCT06156579VenSwitchCombination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AMLP2AML27Nov 2023
NCT05184842Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLP2Myelodysplastic Syndromes91Mar 2022
NCT04068597Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesP1/P2Haematological Malignancy250Aug 2019
NCT05736978AVSAdaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD ResultsP2AML58Mar 2023
NCT05628623ERASETesting the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial TreatmentP2Leukemia, Myeloid, Acute184Oct 2024
NCT03824483CLLStudy of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)P2Chronic Lymphocytic Leukemia (CLL)230Feb 2019
NCT05388006Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2Chronic Lymphocytic Leukemia27Jan 2023
NCT05861050Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaP1/P2Blastoid Variant Mantle Cell Lymphoma50Aug 2023
NCT07044544Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid MalignanciesP1Myeloid Malignancy20Jul 2025
NCT06773208AMLA Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)P2Acute Myeloid Leukemia (AML)30Jan 2025
NCT05317403Venetoclax to Augment Epigenetic Modification and ChemotherapyP1Acute Myeloid Leukemia, in Relapse40Mar 2023
NCT06763341A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaP1Recurrent Acute Myeloid Leukemia12Jul 2025
NCT06990321Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid LeukemiaP3Acute Myeloid Leukemia (AML)68Jun 2025
NCT07007949a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid LeukemiaP2Acute Myeloid Leukemia42Jun 2025
NCT06466122LOXO-305Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKiP2Chronic Lymphocytic Leukemia30Nov 2024
NCT05074355Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative NeoplasmsP2Myeloproliferative Neoplasm40Nov 2023
NCT04790045LymBIOLymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based RegimensP4Chronic Lymphocytic Leukemia30Nov 2023
NCT05603884AMLVCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)P2Leukemia, Myeloid, Acute66Dec 2022
NCT05506332Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid LeukemiaP1Acute Myeloid Leukemia, in Relapse10Jul 2022
NCT05211570AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaP1/P2Acute Myeloid Leukemia Refractory78Jun 2022
NCT05010772Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionP1Acute Myeloid Leukemia125Oct 2021
NCT04581512Study to Evaluate the Safety and Tolerability of EP0042P1/P2Acute Myeloid Leukemia70Nov 2020
NCT04216524Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmP2Blastic Plasmacytoid Dendritic Cell Neoplasm40May 2020
NCT03629171Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaP2Recurrent Acute Myeloid Leukemia52Oct 2018
NCT06394011Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML PatientsP2Intermediate Risk Acute Myeloid Leukemia60Feb 2024
NCT06324994Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.P2Mantle Cell Lymphoma10May 2024
NCT05668026AMBERAdministration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ARTP1/P2HIV-1-infection18Apr 2024
NCT06220162VAC Regimen for AML Patients Who Failed to Response to VA RegimenP2Acute Myeloid Leukemia32Feb 2024
NCT05360160ASTX727A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)P1/P2Acute Myeloid Leukemia43Oct 2022
NCT05376111Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL PatientsP2T-cell Acute Lymphoblastic Leukemia28Apr 2022
NCT02392572ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic SyndromeP1/P2Recurrent Acute Lymphoblastic Leukemia120Nov 2015
NCT05597306VenBomVenetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaP1Acute Myeloid Leukemia18Nov 2022
NCT06082934Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic LeukemiaP1/P2Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia30Nov 2023
NCT05657652CAV Regimen for R/R Ph- B-ALLN/AAcute Lymphoblastic Leukemia36Oct 2022
NCT05336812Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic LeukemiaP2Chronic Lymphocytic Leukemia52Sep 2022
NCT00501826Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaP2T Acute Lymphoblastic Leukemia160Jul 2007
NCT06629818Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)P2Light Chain (AL) Amyloidosis36Oct 2024
NCT06191263RIVER-81Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AMLP2Acute Myeloid Leukemia98Jan 2024
NCT05451771Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisP1/P2AL Amyloidosis53Oct 2022
NCT05566054VACVenetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic LeukemiaP2Acute Monocytic Leukemia92Mar 2022
NCT06928376A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML PatientsP2Acute Myeloid Leukemia160Apr 2024
NCT05554419Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)P2Acute Myeloid Leukemia184Jul 2026
NCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLN/ALeukemia, Myeloid, Acute94Feb 2025
NCT05054465ITALLI001A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALLP1/P2Acute Lymphoblastic Leukemia48Oct 2021
NCT04169737Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2Recurrent Chronic Lymphocytic Leukemia168Jul 2020
NCT03986034CLLEarly Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)P2Chronic Lymphocytic Leukemia75Jun 2019
NCT06382168DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaP1/P2Leukemia, Myeloid, Acute39Jun 2024
NCT06434662Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AMLP2Relapsed/Refractory Acute Myeloid Leukaemia34Feb 2024
NCT06265545Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaN/AAML120Feb 2024
NCT06357182Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid LeukemiaP1Acute Myeloid Leukemia24Aug 2024
NCT07039877Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL PatientsP2Acute Lymphobkastic Leukemia12Jan 2025
NCT03557619A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological MalignanciesP1Hematologic Malignancies12Jul 2019
NCT05901974Venetoclax Combined With Azactidine in the Treatment of ALALP2Acute Leukemia of Ambiguous Lineage23Jul 2023
NCT06045819PREDICLAXRelation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)Adult Acute Myeloid Leukemia100Apr 2024
NCT05881265Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic LeukemiaP2APL30May 2023
NCT06763666CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AMLP4Relapsed/Refractory AML172Feb 2025
NCT05841771Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.P2Hypomethylating Agent78Jan 2023
NCT04905810Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent FailureP2Acute Myeloid Leukemia20Feb 2022

Venetoclax clinical trials by indication

Acute Myeloid Leukemia (147)

NCTAcronymPhaseStatusTitle
NCT05955261P2suspendedA Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
NCT07581002REVIVALP2/P3not yet recruitingA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT04628026P3recruitingPhase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
NCT05431257LD-VenExP2recruitingAzacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
NCT07059975UPDATE AMLEarly P1recruitingUPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
NCT05442216TAGALONGP2recruitingTagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
NCT07078591P2recruitingVenetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
NCT05183035AMLP3recruitingVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
+ 139 more, see All trials below.

Chronic Lymphocytic Leukemia (53)

NCTAcronymPhaseStatusTitle
NCT06967610PVOP2recruitingPhase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
NCT07014917ESR-23-22182P2recruitingIntermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
NCT05091424P1recruitingA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT06943872CELESTIAL-RRCLLP3recruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT07277231BGB-11417P3recruitingA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT06520098Benefit VAP2recruitingA Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05677919P2active not recruitingPirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
NCT04843904SAVEP1active not recruitingSafe Accelerated Venetoclax Escalation in CLL
+ 45 more, see All trials below.

Acute Myeloid Leukemia (AML) (29)

NCTAcronymPhaseStatusTitle
NCT02416388BIG-1P2/P3recruitingStudy to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
NCT07007312P3recruitingStudies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT03613532P1active not recruitingVenetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
NCT07060001P2not yet recruitingEfficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
NCT07023588P2recruitingStudy on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
NCT07469046P3not yet recruitingVAH vs VA in Newly Diagnosed Elderly AML
NCT07507825VHAGP2not yet recruitingExploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
NCT07486726P1/P2not yet recruitingAclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
+ 21 more, see All trials below.

Leukemia, Myeloid, Acute (24)

NCTAcronymPhaseStatusTitle
NCT06852222cAMeLot-2P3recruitingA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06651229P1recruitingA Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT04988555DSP-5336P1/P2recruitingA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT06384261P2active not recruitingA Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT05305859VCAP2recruitingVenetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
NCT06770257P2withdrawnDaunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
NCT04150887ELEVATEP1active not recruitingCusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
NCT03850574TUSCANYP1/P2recruitingClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
+ 16 more, see All trials below.

Chronic Lymphocytic Leukemia (CLL) (15)

NCTAcronymPhaseStatusTitle
NCT02966756P2recruitingA Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07024706MAVRiCP2not yet recruitingPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
NCT04895436ReVenGP2recruitingStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT05168930ZANU-VENP2recruitingZanubrutinib and Venetoclax in CLL (ZANU-VEN)
NCT03580928AVOP2active not recruitingAcalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
NCT04758975VALUABLEP2recruitingVenetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
NCT04419519P2active not recruitingAssessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
NCT03824483CLLP2recruitingStudy of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
+ 7 more, see All trials below.

AML (12)

NCTAcronymPhaseStatusTitle
NCT07539818P3not yet recruitingAzacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML
NCT06972641P2/P3recruitingMolecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
NCT05287568P1recruitingCC-486 and Venetoclax for Acute Myeloid Leukemia
NCT07490288N/ArecruitingVenetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NCT06611839IDH1-AML-2024P1/P2recruitingVenetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
NCT06744556P2active not recruitingHAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
NCT06386302N/ArecruitingChidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
NCT06156579VenSwitchP2recruitingCombination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
+ 4 more, see All trials below.

Leukemia (11)

NCTAcronymPhaseStatusTitle
NCT06644183IOA-244P1/P2recruitingRoginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT07294677CAVALRYP1/P2recruitingCApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
NCT03319901P1/P2active not recruitingVenetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
NCT05536349CLLP2recruitingTime-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
NCT03826992CPX-351P1recruitingVenetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
NCT06429449P1recruitingMitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
NCT06643962N/ArecruitingVenetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
NCT06501196P1recruitingA Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
+ 3 more, see All trials below.

Mantle Cell Lymphoma (10)

NCTAcronymPhaseStatusTitle
NCT04802590P2active not recruitingStudy of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
NCT06522386GATE1P2active not recruitingGATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
NCT04855695P1/P2recruitingAvo In R/R And Previously Untreated MCL
NCT03523975P1/P2recruitingVenetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
NCT05529069P2recruitingPhase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
NCT03710772P2active not recruitingIbrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT06324994P2not yet recruitingLinperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
NCT05025423P2terminatedPhase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
+ 2 more, see All trials below.

Recurrent Acute Myeloid Leukemia (9)

NCTAcronymPhaseStatusTitle
NCT04140487P1/P2recruitingAzacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
NCT05222984P1active not recruitingNavitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
NCT06763341P1recruitingA Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03629171P2recruitingLiposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
NCT05799079P2terminatedDecitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
NCT04487106P2completedAzacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
NCT04655391P1withdrawnGlasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
NCT03390296OX40P1/P2completedOX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
+ 1 more, see All trials below.

Multiple Myeloma (9)

NCTAcronymPhaseStatusTitle
NCT03314181P2active not recruitingA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05853965BELI(E)VEP1/P2recruitingCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
NCT06042725P1recruitingMC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
NCT03539744P3active not recruitingA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT02899052MMP2active not recruitingStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
NCT03312530P1/P2completedA Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
NCT02951117P1withdrawnA Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
NCT03567616P2terminatedA Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
+ 1 more, see All trials below.

Acute Lymphoblastic Leukemia (8)

NCTAcronymPhaseStatusTitle
NCT07175415HEM-iSMART EP1/P2not yet recruitingHEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05751044HEM-iSMART BP1/P2recruitingHEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT06855810CCCG-TALL-2025P2/P3recruitingNewly-diagnosed Pediatric T-cell ALL Protocol
NCT05657652N/ArecruitingCAV Regimen for R/R Ph- B-ALL
NCT05054465ITALLI001P1/P2not yet recruitingA Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
NCT05386576ALLEarly P1active not recruitingA Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
NCT05268003P2terminatedA Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
NCT06087419P1/P2unknownA Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

AML, Adult (8)

NCTAcronymPhaseStatusTitle
NCT07407140VAG-3+7-GP3not yet recruitingVAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML
NCT06841952N/Anot yet recruitingStudy of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia
NCT07132684P3recruitingComparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
NCT07131059N/ArecruitingMRD-positive AML Clinical Study
NCT06014489HO171P2recruitingA Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML
NCT05736965SAVP2recruitingA Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
NCT05503355P1/P2unknownA Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
NCT05177731P3active not recruitingVenetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

Follicular Lymphoma (8)

NCTAcronymPhaseStatusTitle
NCT03980171LEVERAGEP1/P2active not recruitingStudy of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
NCT04599634VENOMP1completedVenetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
NCT04722601P1/P2terminatedA Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
NCT03113422PrE0403P2completedPhase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
NCT03276468P2completedEvaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
NCT02877550P1completedObinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
NCT03135262FLP1/P2terminatedA Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02187861GDC-0199P2completedA Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Myelodysplastic Syndromes (7)

NCTAcronymPhaseStatusTitle
NCT07238686P2recruitingVenetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
NCT04256317P2/P3recruitingA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT05201066MBG453P2active not recruitingRoll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
NCT05807932FLAMSAP1/P2recruitingVenetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
NCT05365035P2recruitingA Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
NCT05184842P2recruitingMetabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
NCT06109064P2unknownSafety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS

Leukemia, Lymphocytic, Chronic, B-Cell (7)

NCTAcronymPhaseStatusTitle
NCT05947851VRP3recruitingA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
NCT03462719GLOWP3active not recruitingA Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05963074TAILORP2recruitingA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05650723CLLP2active not recruitingZanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
NCT03331198CLLP1/P2recruitingStudy Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT02639910COSMOSP2completedStudy to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
NCT03343678P1withdrawnThis Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

Lymphoma (6)

NCTAcronymPhaseStatusTitle
NCT06510309P2recruitingRituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
NCT04739813P1active not recruitingVenetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
NCT03223610P1/P2recruitingVenetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
NCT05371054VVIPP1/P2completedStudy of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
NCT03530683PF-07901801P1terminatedA Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
NCT01742988CUDC-907P1completedStudy to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

T-cell Acute Lymphoblastic Leukemia (5)

NCTAcronymPhaseStatusTitle
NCT06390319ALLP2recruitingAdding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
NCT07513129P1not yet recruitingVenetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
NCT06561074T-ALLP2recruitingA Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
NCT06686108P2recruitingDemethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
NCT05376111P2recruitingStudy of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

Waldenstrom Macroglobulinemia (5)

NCTAcronymPhaseStatusTitle
NCT05099471VIWA-1P2recruitingEfficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
NCT05734495P2active not recruitingPirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
NCT07387471WMP2recruitingStudy to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
NCT07231952WMP2recruitingA Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
NCT04273139P2active not recruitingIbrutinib + Venetoclax in Untreated WM

CLL (5)

NCTAcronymPhaseStatusTitle
NCT06073821BGB-11417P3active not recruitingStudy of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT03868722P2/P3recruitingAcalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
NCT06846671CaDAnCe-302P3recruitingA Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT04639362P2active not recruitingCLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.
NCT05209308CORALP2withdrawnRituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Acute Myeloid Leukemia, Adult (4)

NCTAcronymPhaseStatusTitle
NCT07478991VENP-A-QUIP3not yet recruitingAzacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
NCT06449482P1/P2terminatedSelinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
NCT04752527P2unknownIndividualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
NCT04454580N/AunknownHypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Myeloid Malignancy (4)

NCTAcronymPhaseStatusTitle
NCT06129734P1/P2recruitingDecitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
NCT07044544P1recruitingTrial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
NCT05455294P1active not recruitingCombination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
NCT04214860P1completedAPR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Chronic Myeloid Leukemia (4)

NCTAcronymPhaseStatusTitle
NCT05768711AVENHIRP2active not recruitingAzacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
NCT06390306N/ArecruitingThe Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
NCT05701215VARIANTP2active not recruitingVenetoclax After TKI to Target Persisting Stem Cells in CML
NCT03455517VeRitAsP2completedActivity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia

Chronic Myelomonocytic Leukemia (4)

NCTAcronymPhaseStatusTitle
NCT05600894P2active not recruitingVenetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
NCT04655755P1/P2active not recruitingVenetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT04160052P1/P2terminatedVenetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
NCT06085638P1/P2withdrawnPhase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Recurrent Plasma Cell Myeloma (4)

NCTAcronymPhaseStatusTitle
NCT05391750P1active not recruitingVenetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
NCT03399539P1completedVenetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
NCT03856112P1/P2withdrawnIxazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
NCT03701321P1/P2withdrawnDaratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Chronic Lymphoid Leukemia (4)

NCTAcronymPhaseStatusTitle
NCT03766763P2active not recruitingPreemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
NCT04608318CLL17P3active not recruitingIbrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04515238CLL2-BZAGP2active not recruitingSequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
NCT03787264CLL2-BAAGP2completedSequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

Acute Myeloid Leukaemia (AML) (3)

NCTAcronymPhaseStatusTitle
NCT07148180P1/P2recruitingA Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
NCT07264010P2/P3not yet recruitingSorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
NCT07244367N/ArecruitingMaintenance Venetoclax in AML Fit Patients

Relapsed Acute Myeloid Leukemia (3)

NCTAcronymPhaseStatusTitle
NCT07320235IMAGINEP1recruitingImetelstat Combinations in Relapsed AML
NCT06536959P2recruitingVA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
NCT05362942P2unknownCombination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

B-cell Acute Lymphoblastic Leukemia (3)

NCTAcronymPhaseStatusTitle
NCT06863259P1recruitingStudy of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
NCT06393985P2recruitingDecitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
NCT05016947P1active not recruitingVenetoclax Plus Inotuzumab for B-ALL

AML (Acute Myelogenous Leukemia) (3)

NCTAcronymPhaseStatusTitle
NCT06635681DAV-AML-2024P2recruitingEfficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML
NCT06783790P2recruitingAvapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
NCT06993883AMLN/AcompletedUse of Venetoclax , AML , Sohag , Egypt

MDS (3)

NCTAcronymPhaseStatusTitle
NCT06765928P2not yet recruitingSelinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT
NCT05226455P1/P2active not recruitingVenetoclax in Patients With MDS or AML in Relapse After AHSCT
NCT07318662N/Aactive not recruitingEfficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML

Diffuse Large B Cell Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT06516978P2not yet recruitingA Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
NCT04572763P1/P2active not recruitingCopanlisib Plus Venetoclax in R/R DLBCL
NCT05863845N/AunknownEfficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

Acute Myeloid Leukemia Refractory (3)

NCTAcronymPhaseStatusTitle
NCT06372717P1recruitingA Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
NCT05211570P1/P2recruitingAB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06150040AML-NETP1/P2terminatedAcute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

Mantle Cell Lymphoma (MCL) (3)

NCTAcronymPhaseStatusTitle
NCT05951959TrAVeRseP2active not recruitingA Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
NCT06496308P3recruitingBendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
NCT04477486P2completedStudy to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

B Acute Lymphoblastic Leukemia (3)

NCTAcronymPhaseStatusTitle
NCT04872790P1active not recruitingVenetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
NCT05157971P1active not recruitingVenetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
NCT06078306B-ALLP2unknownCD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

Adult Acute Myeloid Leukemia (3)

NCTAcronymPhaseStatusTitle
NCT06045819PREDICLAXN/ArecruitingRelation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)
NCT05262465N/AunknownMicrotransplantation Combined With Azacytidine to Improve the Efficacy of EAML
NCT03226418P2completedGeriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT06387121P2recruitingEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
NCT05660473P2recruitingPediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
NCT06237192N/ArecruitingMRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

AL Amyloidosis (3)

NCTAcronymPhaseStatusTitle
NCT05486481ALTITUDEP1/P2withdrawnVenetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
NCT05451771P1/P2recruitingVenetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
NCT03000660ABT-199P1terminatedTrial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Recurrent Mantle Cell Lymphoma (3)

NCTAcronymPhaseStatusTitle
NCT05910801V-MINDP2recruitingTafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
NCT04939272P1/P2active not recruitingCopanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
NCT04990778P2withdrawnVenetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

Lymphoma, Non-Hodgkin (3)

NCTAcronymPhaseStatusTitle
NCT05618366P1terminatedTazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT03357627P1completedA Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
NCT02055820NHLP1/P2completedA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Recurrent Chronic Lymphocytic Leukemia (3)

NCTAcronymPhaseStatusTitle
NCT04941716P2recruitingAcalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
NCT04169737P2recruitingAcalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT03045328P2completedVenetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Acute Myelogenous Leukemia (3)

NCTAcronymPhaseStatusTitle
NCT04278768AMLP1/P2suspendedDose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04172844PAVEP1terminatedPevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia
NCT02287233P1/P2completedA Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

AML (Acute Myeloid Leukemia) (2)

NCTAcronymPhaseStatusTitle
NCT07425808FIT-AMLP2/P3not yet recruitingFLT3-ITD Targeted Therapy in Fit AML Patients
NCT07514832P2recruitingVA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

Leukemia, Myeloid (2)

NCTAcronymPhaseStatusTitle
NCT07439211GAVELP1not yet recruitingAssessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
NCT04748848P1terminatedA Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Recurrent B Acute Lymphoblastic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT07133997P1recruitingRecombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
NCT03808610P1/P2terminatedLow-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse (2)

NCTAcronymPhaseStatusTitle
NCT05745714HEM-iSMART CP1/P2recruitingHEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05740449HEM-iSMART AP1/P2withdrawnHEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

AML - Acute Myeloid Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT06696183SEQUENCEP2recruitingGilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
NCT07014462DLIT-AMLP1enrolling by invitationA Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML

Acute Leukemia of Ambiguous Lineage (2)

NCTAcronymPhaseStatusTitle
NCT06317662P2recruitingTesting the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT05901974P2recruitingVenetoclax Combined With Azactidine in the Treatment of ALAL

Lymphoma, Mantle-Cell (2)

NCTAcronymPhaseStatusTitle
NCT06558604GLOASISP2recruitingPhase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
NCT03567876P2completedRituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Refractory Acute Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT06466395P1recruitingA Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
NCT06397027P1recruitingA Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Acute Monocytic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT06504459P2recruitingVenetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
NCT05566054VACP2recruitingVenetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Relapsed or Refractory Acute Myeloid Leukemia (AML) (2)

NCTAcronymPhaseStatusTitle
NCT06660368P2recruitingBCL2i CLAG-M in R/R Acute Myeloid Leukemia
NCT03218683P1terminatedStudy of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Light Chain (AL) Amyloidosis (2)

NCTAcronymPhaseStatusTitle
NCT06629818P2recruitingDaratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)
NCT05996406P2active not recruitingVenetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)

Acute Myeloid Leukemia in Remission (2)

NCTAcronymPhaseStatusTitle
NCT04062266P2active not recruitingAZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
NCT07163793P2recruitingPilot Study of Reduced Venetoclax Exposure

Relapsed Adult AML (2)

NCTAcronymPhaseStatusTitle
NCT06007911P1withdrawnVenetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT04330820RELAXP1/P2unknownTrial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

T Acute Lymphoblastic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT00501826P2recruitingCombination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT06210750T-ALLP2withdrawnAdding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Ann Arbor Stage II Follicular Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT06471738P2recruitingCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
NCT04450173P2active not recruitingObinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Relapsed/Refractory Acute Myeloid Leukaemia (2)

NCTAcronymPhaseStatusTitle
NCT06621212P2recruitingMitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
NCT06434662P2recruitingMitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Secondary Acute Myeloid Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT05513131P2unknownClinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML
NCT05780879G-CSFP2terminatedA Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

CLL/SLL (2)

NCTAcronymPhaseStatusTitle
NCT04523428REVEALP2recruitingREtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
NCT05791409AETHERP1/P2recruitingVenetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

Healthy Volunteers (2)

NCTAcronymPhaseStatusTitle
NCT06070948P1withdrawnA Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants
NCT05909553P1completedStudy to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

Blastoid Variant Mantle Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03946878P2active not recruitingVenetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT05861050P1/P2recruitingGlofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Acute Myeloid Leukemia, in Relapse (2)

NCTAcronymPhaseStatusTitle
NCT05317403P1recruitingVenetoclax to Augment Epigenetic Modification and Chemotherapy
NCT05506332P1recruitingTreatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Myelodysplastic Syndrome (2)

NCTAcronymPhaseStatusTitle
NCT04227847P1recruitingA Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT05564650P1completedNavitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT05057494MAJICP3active not recruitingA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT04981912P1active not recruitingRituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

Relapsed or Refractory Acute Myeloid Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT05522192P1/P2unknownClinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
NCT04666649P1completedPegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Relapsed Non Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT05053659P1active not recruitingLoncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
NCT03505944VALERIAP1/P2unknownVenetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Acute Biphenotypic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT02115295P2recruitingCladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
NCT04797767P1/P2recruitingVenetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Hematopoietic and Lymphoid Cell Neoplasm (2)

NCTAcronymPhaseStatusTitle
NCT04874194P1/P2terminatedOmacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
NCT04752163P1/P2terminatedDS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Hematologic Malignancy (2)

NCTAcronymPhaseStatusTitle
NCT04809181P2unknownAzacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
NCT05084027P2unknownVenetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

Lymphoma, Large B-Cell, Diffuse (2)

NCTAcronymPhaseStatusTitle
NCT04790903RP1terminatedA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02987400P2completedCombination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

Myelodysplastic Syndrome (MDS) (2)

NCTAcronymPhaseStatusTitle
NCT04401748VeronaP3active not recruitingStudy Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04812548STIMULUS-MDS3P2terminatedA Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Hematologic Malignancies (2)

NCTAcronymPhaseStatusTitle
NCT04588922P1/P2recruitingStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
NCT03557619P1recruitingA Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

Recurrent B-Cell Non-Hodgkin Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT04447716P1active not recruitingAn Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
NCT04659044P2terminatedPolatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Relapsed/Refractory Chronic Lymphocytic Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT04623541EPCORE™ CLL-1P1/P2active not recruitingSafety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT03708003P2terminatedIbrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT04298918P1/P2terminatedA Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT04274933P1terminatedA Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (2)

NCTAcronymPhaseStatusTitle
NCT04216524P2recruitingVenetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
NCT03485547BPDCNP1completedStudy of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (2)

NCTAcronymPhaseStatusTitle
NCT04188405P2completedDecitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
NCT03878524SMMARTP1terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Acute Bilineal Leukemia (2)

NCTAcronymPhaseStatusTitle
NCT04128501P2active not recruitingVenetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
NCT02397720P2completedNivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Diffuse Large B-Cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03984448P2/P3active not recruitingTesting the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT03036904V+DA-EPOCH-RP1completedStudy of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Diffuse Large B-cell Lymphoma (2)

NCTAcronymPhaseStatusTitle
NCT03955783P1completedVenetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
NCT03255096P1completedA Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

Cancer (2)

NCTAcronymPhaseStatusTitle
NCT03768063IMbrella BP3active not recruitingA Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT02391480P1completedA Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

Acute Myeloid Leukaemia (2)

NCTAcronymPhaseStatusTitle
NCT03672695P1completedPhase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.
NCT03217838P1terminatedSafety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

Advanced Solid Tumors (2)

NCTAcronymPhaseStatusTitle
NCT03000257ABBV-181P1completedA Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
NCT03082209P1completedA Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Myelodysplastic Syndromes (MDS) (2)

NCTAcronymPhaseStatusTitle
NCT02942290MDSP1active not recruitingA Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
NCT02966782MDSP1completedA Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Relapsed/Refractory Multiple Myeloma (2)

NCTAcronymPhaseStatusTitle
NCT02755597BelliniP3completedA Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
NCT01794520P1/P2completedStudy Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

Lymphocytic Leukemia, Chronic (2)

NCTAcronymPhaseStatusTitle
NCT02242942P3completedComparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
NCT01685892P1completedA Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Core Binding Factor Acute Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06917911GOP2recruitingTesting the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT07604233P1/P2not yet recruitingPhase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

LAL (1)

NCTAcronymPhaseStatusTitle
NCT07522801ALL-TARGETP2not yet recruitingA Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL

Leukemia Acute Myeloid (1)

NCTAcronymPhaseStatusTitle
NCT07605949RAVENP2not yet recruitingRevumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

Kidney Failure Chronic (1)

NCTAcronymPhaseStatusTitle
NCT07358195Early P1not yet recruitingAddition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

Adult ALL (1)

NCTAcronymPhaseStatusTitle
NCT06991920N/Anot yet recruitingImmune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage

T-cell Prolymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT07311746P1/P2not yet recruitingPhase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

B-cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT07520006P1/P2not yet recruitingStudy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Ph-Like (1)

NCTAcronymPhaseStatusTitle
NCT07454226N/ArecruitingABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

HIV-1 (1)

NCTAcronymPhaseStatusTitle
NCT07481175INITIATEP1recruitingInhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)

Ph+ ALL (1)

NCTAcronymPhaseStatusTitle
NCT07493161N/ArecruitingChemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL

Acute Lymphoblastic Leukemia, Adult (1)

NCTAcronymPhaseStatusTitle
NCT07495631N/ArecruitingPediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia

Venentoclax (1)

NCTAcronymPhaseStatusTitle
NCT07396480P3recruitingFludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) (1)

NCTAcronymPhaseStatusTitle
NCT06958705P2recruitingVenetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (1)

NCTAcronymPhaseStatusTitle
NCT07007052TAGVENP2not yet recruitingPhase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements (1)

NCTAcronymPhaseStatusTitle
NCT06649812P2recruitingTesting the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Leukemia, B-Cell, Chronic (1)

NCTAcronymPhaseStatusTitle
NCT07082452SEVENAZAP3not yet recruitingA Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT07154264TAI-SHAN10P2recruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Targeted Therapy (1)

NCTAcronymPhaseStatusTitle
NCT07032727P2recruitingOlutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Adult T-cell Leukemia/Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT07159620P2recruitingVenetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

Older Patients (1)

NCTAcronymPhaseStatusTitle
NCT07052422P2/P3not yet recruitingVEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Myelodysplastic Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT07047183P2recruitingClinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

Acute Promyelocytic Leukemia (APL) (1)

NCTAcronymPhaseStatusTitle
NCT07187505N/Aactive not recruitingVenetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia

B-Cell Acute Lymphoblastic Leukemia, Adult (1)

NCTAcronymPhaseStatusTitle
NCT07199855P2active not recruitingBlinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

Myelodysplastic Syndrome/Acute Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06454409P1suspendedRegorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

T-cell-prolymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06810778PTCLP1/P2recruitingDuvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Early T Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT07012447P2recruitingVenetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations

Myelodysplastic Syndrome(MDS) (1)

NCTAcronymPhaseStatusTitle
NCT06548230MDSP1/P2recruitingA Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Relapsed/Refractory AML (1)

NCTAcronymPhaseStatusTitle
NCT06763666P4not yet recruitingCLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (1)

NCTAcronymPhaseStatusTitle
NCT06563804P1/P2terminatedA Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

T Lymphoblastic Leukemia/Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06712121P2recruitingVenetoclax and Decitabine in R/R T-ALL

CML,Blast Phase (1)

NCTAcronymPhaseStatusTitle
NCT06757855P1/P2recruitingOlverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

Acute Lymphoblastic Leukemia ALL (1)

NCTAcronymPhaseStatusTitle
NCT06764238CCCG-I/HR-ALLP2/P3recruitingNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Acute Lymphobkastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT07039877P2recruitingEfficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

Acute T Lymphpblastic Leukemia/Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT06742463P2recruitingVHAG in Treating R/R T-ALL/LBL

Precursor B-Cell Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06754267P2recruitingVenetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

Healthy Volunteer (1)

NCTAcronymPhaseStatusTitle
NCT06742086P1completedA Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants

Recurrent Hairy Cell Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06311227P2recruitingVenetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Newly Diagnosed Acute Myeloid Leukemia (AML) (1)

NCTAcronymPhaseStatusTitle
NCT07514936P2recruitingVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

FLT3 Gene Mutation (1)

NCTAcronymPhaseStatusTitle
NCT06561880FLT3AML-2024P1/P2recruitingThe Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Higher-risk Myelodysplastic Syndromes (1)

NCTAcronymPhaseStatusTitle
NCT06471946P1/P2recruitingVA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

Mutant IDH1 Inhibitor Olutasidenib (1)

NCTAcronymPhaseStatusTitle
NCT06445959P1/P2recruitingPhase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib

Precursor B-Cell Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06554626P2recruitingBlinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

Relapsed Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT06399640P1recruitingEltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Multiple Myeloma in Relapse (1)

NCTAcronymPhaseStatusTitle
NCT06115135P2recruitingA Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Philadelphia Chromosome Negative ALL (1)

NCTAcronymPhaseStatusTitle
NCT06481241N/ArecruitingEfficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

Philadelphia Positive Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06481228N/ArecruitingEfficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

AML/MDS (1)

NCTAcronymPhaseStatusTitle
NCT05986240P1recruitingDanvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

ACUTE MYELOID LEUKEMIA; AML (1)

NCTAcronymPhaseStatusTitle
NCT06387420P1/P2not yet recruitingA Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06177067P1recruitingStudy of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

ETP-ALL (1)

NCTAcronymPhaseStatusTitle
NCT06361329P3recruitingComparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

HIV-1-infection (1)

NCTAcronymPhaseStatusTitle
NCT05668026AMBERP1/P2recruitingAdministration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART

Recurrent Transformed Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06247540P2withdrawnVenetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Intermediate Risk Acute Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06394011P2recruitingStudy of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

Ph-Positive Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06578546P2unknownChemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL

Amyloidosis; Systemic (1)

NCTAcronymPhaseStatusTitle
NCT06192979N/ArecruitingOptimize First-line Treatment for AL Amyloidosis With t (11; 14)

AML, Childhood (1)

NCTAcronymPhaseStatusTitle
NCT06221683GMCAIIP2recruitingClinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Waldenstrom's Macroglobulinaemia Refractory (1)

NCTAcronymPhaseStatusTitle
NCT06200220N/AunknownPatients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Untreated Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT05782127P1/P2active not recruitingOral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Myeloproliferative Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT05074355P2recruitingStudy of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06082934P1/P2recruitingOlverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

Acute Myelocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06105658P2unknownSafety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML

Idiopathic Pulmonary Fibrosis (1)

NCTAcronymPhaseStatusTitle
NCT05976217Early P1completedSafety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis

Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) (1)

NCTAcronymPhaseStatusTitle
NCT05665530P1completedA Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Mantle Cell Lymphoma Refractory (1)

NCTAcronymPhaseStatusTitle
NCT05864742P2active not recruitingGenetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Acute Promyelocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06544109Ven APLP2/P3enrolling by invitationVenetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

Relapsed/Refractory Acute Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT06084819P2recruitingClinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

APL (1)

NCTAcronymPhaseStatusTitle
NCT05881265P2recruitingTreatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia

Leukemia, Lymphoblastic (1)

NCTAcronymPhaseStatusTitle
NCT05464836P2terminatedPhase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

Myelodysplastic Syndromes, de Novo (1)

NCTAcronymPhaseStatusTitle
NCT05292664P1recruitingVenetoclax Basket Trial for High Risk Hematologic Malignancies

Relapsed and Refractory Multiple Myeloma (1)

NCTAcronymPhaseStatusTitle
NCT05530421SELVEDgeP2recruitingSelinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Refractory/Relapse Acute Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT05807347P2unknownVenetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia

Hypomethylating Agent (1)

NCTAcronymPhaseStatusTitle
NCT05841771P2recruitingHypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

AML, Adult Recurrent (1)

NCTAcronymPhaseStatusTitle
NCT05829226AMLP1completedA Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT05594784P2completedOlverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

Metastatic Colorectal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT05725200EVIDENTP2recruitingStudy to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Refractory Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT05192889P1/P2active not recruitingTrial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Recurrent AL Amyloidosis (1)

NCTAcronymPhaseStatusTitle
NCT04847453P1active not recruitingVenetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Hemophagocytic Lymphohistiocytosis (1)

NCTAcronymPhaseStatusTitle
NCT05546060P1unknownEfficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH

Acute Myeloid Leukemia (AML) in Remission (1)

NCTAcronymPhaseStatusTitle
NCT05404906P2/P3recruitingAZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

Secondary Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT05379166P2active not recruitingVenetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

Relapsed or Refractory Hematologic Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT04926285VEN-OMP1completedSafety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)

Philadelphia Chromosome (1)

NCTAcronymPhaseStatusTitle
NCT05433532P2completedStudy of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Myelodysplastic/Myeloproliferative Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT05282719P2unknownClinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS) (1)

NCTAcronymPhaseStatusTitle
NCT05211336VIPORP1active not recruitingVenetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Lymphoplasmacytic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04840602P2recruitingTesting the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

ALL, Recurrent, Adult (1)

NCTAcronymPhaseStatusTitle
NCT05182385BCP-ALLP1/P2active not recruitingVenetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Acute Leukemia of Ambiguous Lineage in Relapse (1)

NCTAcronymPhaseStatusTitle
NCT04898894P1active not recruitingStudy of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Acute T-Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT05149378P2completedVenetoclax Based Regimen for R/R T-ALL

Recurrent Acute Biphenotypic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT04975919P2active not recruitingVenetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Richter's Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT04939363P2completedA Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;

Renal Impairment (1)

NCTAcronymPhaseStatusTitle
NCT04810598P1completedStudy to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

Relapsed Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04543916P1/P2withdrawnVenetoclax and Irinotecan in Relapsed/Refractory SCLC

Myeloid Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT04778410P2terminatedStudy of Magrolimab Combinations in Participants With Myeloid Malignancies

Marginal Zone Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04416451P2active not recruitingA Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

Non Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04419389R/RP1/P2terminatedAPR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04607772RRP1/P2withdrawnStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04553692IGM-8444P1terminatedPhase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04422210ES-SCLCP1terminatedA Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

AML With Monocytic Differentiation (1)

NCTAcronymPhaseStatusTitle
NCT04372433P1completedIO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Recurrent Chronic Myelomonocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT04550442P1/P2terminatedVenetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Lymphoma, B-Cell (1)

NCTAcronymPhaseStatusTitle
NCT04161248Early P1active not recruitingPhase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Non Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04274907NSCLCP1terminatedA Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Primary CNS Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT04073147VENOBI-CNSP1terminatedVenetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma

High Grade B-Cell Lymphoma, Not Otherwise Specified (1)

NCTAcronymPhaseStatusTitle
NCT04285268P2withdrawnRituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

CTCL (1)

NCTAcronymPhaseStatusTitle
NCT04171791CTCLP1completedA Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

Non-Hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03886649P1terminatedCopanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

CLL Transformation (1)

NCTAcronymPhaseStatusTitle
NCT04082897MOLTOP2active not recruitingObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Intermediate Risk Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT04010968ERADICP2completedEvaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

Breast Neoplasm Female (1)

NCTAcronymPhaseStatusTitle
NCT03900884PALVENP1active not recruitingPalbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT03874052P1recruitingRuxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Haematological Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT04068597P1/P2recruitingStudy to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Castration Levels of Testosterone (1)

NCTAcronymPhaseStatusTitle
NCT03751436P1completedEnzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Refractory Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT03884972P1withdrawnTrabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

CCND1 Positive (1)

NCTAcronymPhaseStatusTitle
NCT03872180P2active not recruitingBendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Relapsed Refractory Multiple Myeloma (1)

NCTAcronymPhaseStatusTitle
NCT03732703MyDRUGP1/P2completedMyeloma-Developing Regimens Using Genomics (MyDRUG)

Non-hodgkin Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03713580P1active not recruitingVenetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma

Relapsed or Refractory Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT03739554P1completedCYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

Acute Myeloid Leukemia With FLT3/ITD Mutation (1)

NCTAcronymPhaseStatusTitle
NCT03735875P1/P2terminatedVenetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

B-Cell Chronic Lymphocytic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT03755947P2completedIbrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

T-Cell Lymphoma Relapsed (1)

NCTAcronymPhaseStatusTitle
NCT03552692P2terminatedUse of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Hematopoietic Cell Transplantation Recipient (1)

NCTAcronymPhaseStatusTitle
NCT03583424P1/P2completedVenetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03584009VeronicaP2terminatedA Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Anaplastic Large Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03534180P2completedVenetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

Recurrent Adult Lymphoblastic Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03504644P1/P2active not recruitingVenetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Cancer - Acute Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT03484520MK7965P1terminatedA Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCTAcronymPhaseStatusTitle
NCT03576547P1/P2terminatedVenetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Follicular Lymphoma (FL) (1)

NCTAcronymPhaseStatusTitle
NCT03547115P1terminatedA Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Acute Lymphoblastic Leukemia (ALL) (1)

NCTAcronymPhaseStatusTitle
NCT03181126P1completedA Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT03236857P1completedA Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

High Risk Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT03214562P1/P2recruitingVenetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Acute Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT03176277P1/P2terminatedA Study of ONO-7475 in Patients With Acute Leukemias

Diffuse Large B-cell-lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03064867P1/P2active not recruitingVenetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Chronic Lymphocytic Leukemia in Relapse (1)

NCTAcronymPhaseStatusTitle
NCT03226301RR-CLLP2active not recruitingA Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Mantle-Cell Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT03112174SYMPATICOP3completedStudy of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

Richter Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT03054896P2active not recruitingA Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

Refractory Follicular Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02956382P1/P2completedIbrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

B-Cell Lymphoma, Unspecified (1)

NCTAcronymPhaseStatusTitle
NCT02992522P1active not recruitingObinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT03013998P1/P2recruitingStudy of Biomarker-Based Treatment of Acute Myeloid Leukemia

Leukemia, Lymphocytic, Chronic (1)

NCTAcronymPhaseStatusTitle
NCT02758665CLL2-GiVeP2completedTrial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Non-Hodgkin's Lymphoma (1)

NCTAcronymPhaseStatusTitle
NCT02611323FLP1/P2completedA Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCTAcronymPhaseStatusTitle
NCT02689440P2active not recruitingDasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Recurrent Acute Lymphoblastic Leukemia (1)

NCTAcronymPhaseStatusTitle
NCT02392572P1/P2recruitingONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Non-Hodgkin Lymphoma (NHL) (1)

NCTAcronymPhaseStatusTitle
NCT02265731P1/P2completedStudy Evaluating Venetoclax in Subjects With Hematological Malignancies

Relapsed Childhood ALL (1)

NCTAcronymPhaseStatusTitle
NCT05215405N/Ano longer availableExpanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

Myelofibrosis (1)

NCTAcronymPhaseStatusTitle
NCT03592576N/Ano longer availableExpanded Access to Navitoclax

Venetoclax pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
SCNCT07044687P4recruitingAcute Myeloid Leukemia100
LymBIONCT04790045P4not yet recruitingChronic Lymphocytic Leukemia30
SCNCT05144243P4active not recruitingAcute Myeloid Leukemia (AML)44
VRNCT05947851P3recruitingLeukemia, Lymphocytic, Chronic, B-Cell735
BGB-11417NCT06073821P3active not recruitingCLL652
CELESTIAL-RRCLLNCT06943872P3recruitingChronic Lymphocytic Leukemia630
BGB-11417NCT07277231P3recruitingChronic Lymphocytic Leukemia500
AMLNCT05183035P3recruitingAcute Myeloid Leukemia130PMID 39368878
SEVENAZANCT07082452P3not yet recruitingLeukemia, B-Cell, Chronic262
VAG-3+7-GNCT07407140P3not yet recruitingAML, Adult300
VENP-A-QUINCT07478991P3not yet recruitingAcute Myeloid Leukemia, Adult376
CaDAnCe-302NCT06846671P3recruitingCLL250
cAMeLot-2NCT06852222P3recruitingLeukemia, Myeloid, Acute600
MAJICNCT05057494P3active not recruitingChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma607PMID 36102212
GLOWNCT03462719P3active not recruitingLeukemia, Lymphocytic, Chronic, B-Cell211PMID 37944541
EVOLVE 1NCT07075016P3recruitingAcute Myeloid Leukemia227
CLLNCT04269902P3recruitingChronic Lymphocytic Leukemia247
IMbrella BNCT03768063P3active not recruitingCancer1,000
TLSNCT06428019P3recruitingChronic Lymphocytic Leukemia170
BRUIN CLL-322NCT04965493P3active not recruitingChronic Lymphocytic Leukemia600
SEQUOIANCT03336333P3active not recruitingChronic Lymphocytic Leukemia590PMID 33054121
CLL17NCT04608318P3active not recruitingChronic Lymphoid Leukemia897PMID 41358601
VeronaNCT04401748P3active not recruitingMyelodysplastic Syndrome (MDS)531PMID 38065202
AMPLIFYNCT03836261P3active not recruitingChronic Lymphocytic Leukemia984PMID 33796237
REGALNCT04229979P3active not recruitingAcute Myeloid Leukemia127PMID 39606837
Viale-aNCT02993523P3active not recruitingAcute Myeloid Leukemia (AML)443PMID 40913104
VIALE-MNCT04102020P3completedAcute Myeloid Leukemia (AML)112PMID 35852098
VIALE-TNCT04161885P3terminatedAcute Myeloid Leukemia (AML)465
CRISTALLONCT04285567P3completedChronic Lymphocytic Leukemia (CLL)166
SYMPATICONCT03112174P3completedMantle-Cell Lymphoma366PMID 34717692
ENHANCE-3NCT05079230P3terminatedAcute Myeloid Leukemia378PMID 37703506
ENHANCE-2NCT04778397P3terminatedAcute Myeloid Leukemia258PMID 40009500
GAIANCT02950051P3completedChronic Lymphocytic Leukemia926PMID 38821083
CLLNCT03406156P3completedChronic Lymphocytic Leukemia (CLL)120
BelliniNCT02755597P3completedRelapsed/Refractory Multiple Myeloma291PMID 33129376
MURANONCT02005471P3completedChronic Lymphocytic Leukemia389PMID 35605176
AMLNCT03941964P3completedAcute Myeloid Leukemia (AML)60PMID 38711253
VENICE INCT02756611P3completedChronic Lymphocytic Leukemia258PMID 38467131
VENICE IINCT02980731P3completedChronic Lymphocytic Leukemia (CLL)210PMID 34632935
LDACNCT04509622P3completedAcute Myeloid Leukemia (AML)14
EVIDENTNCT05725200P2recruitingMetastatic Colorectal Cancer40
ALLNCT06390319P2recruitingT-cell Acute Lymphoblastic Leukemia100
PVONCT06967610P2recruitingChronic Lymphocytic Leukemia40
VIWA-1NCT05099471P2recruitingWaldenstrom Macroglobulinemia80PMID 37348018
REVEALNCT04523428P2recruitingCLL/SLL60
ESR-23-22182NCT07014917P2recruitingChronic Lymphocytic Leukemia62
GLOASISNCT06558604P2recruitingLymphoma, Mantle-Cell100
T-ALLNCT06561074P2recruitingT-cell Acute Lymphoblastic Leukemia22
TAGVENNCT07007052P2not yet recruitingBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)33
LD-VenExNCT05431257P2recruitingAcute Myeloid Leukemia117
TAGALONGNCT05442216P2recruitingAcute Myeloid Leukemia53
Benefit VANCT06520098P2recruitingChronic Lymphocytic Leukemia100
HMANCT05766514P2withdrawnAcute Myeloid Leukemia0
V-MINDNCT05910801P2recruitingRecurrent Mantle Cell Lymphoma100
SEQUENCENCT06696183P2recruitingAML - Acute Myeloid Leukemia60
SELVEDgeNCT05530421P2recruitingRelapsed and Refractory Multiple Myeloma33
ALL-TARGETNCT07522801P2not yet recruitingLAL93
TRILLIUMNCT06456463P2recruitingAcute Myeloid Leukemia83
TAI-SHAN10NCT07154264P2recruitingChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma66
BRAVENCT06524375P2active not recruitingChronic Lymphocytic Leukemia118
GMCAIINCT06221683P2recruitingAML, Childhood500
MAVRiCNCT07024706P2not yet recruitingChronic Lymphocytic Leukemia (CLL)80
AMLNCT06317649P2recruitingAcute Myeloid Leukemia147
MYELOMATCHNCT05564390P2recruitingAcute Myeloid Leukemia2,000PMID 36902217
OLUVENAZANCT06782542P2recruitingAcute Myeloid Leukemia16
VHAGNCT07507825P2not yet recruitingAcute Myeloid Leukemia (AML)61PMID 39531539
TAILORNCT05963074P2recruitingLeukemia, Lymphocytic, Chronic, B-Cell320
GATE1NCT06522386P2active not recruitingMantle Cell Lymphoma50
LAMSA2020NCT04968015P2active not recruitingAcute Myeloid Leukemia134
ReVenGNCT04895436P2recruitingChronic Lymphocytic Leukemia (CLL)75
STOP VENNCT06557421P2recruitingAcute Myeloid Leukemia50
TrAVeRseNCT05951959P2active not recruitingMantle Cell Lymphoma (MCL)108
AVENHIRNCT05768711P2active not recruitingChronic Myeloid Leukemia44
ZANU-VENNCT05168930P2recruitingChronic Lymphocytic Leukemia (CLL)45
DAV-AML-2024NCT06635681P2recruitingAML (Acute Myelogenous Leukemia)380
VINCENTNCT05904106P2recruitingAcute Myeloid Leukemia146
RAVENNCT07605949P2not yet recruitingLeukemia Acute Myeloid88
WMNCT07387471P2recruitingWaldenstrom Macroglobulinemia14
VERDINCT06668558P2recruitingAcute Myeloid Leukemia29
VenCMNCT06537843P2recruitingAcute Myeloid Leukemia100
CLLNCT05536349P2recruitingLeukemia60
WMNCT07231952P2recruitingWaldenstrom Macroglobulinemia40
HO171NCT06014489P2recruitingAML, Adult142PMID 42007248
MBG453NCT05201066P2active not recruitingMyelodysplastic Syndromes33
CLLNCT05650723P2active not recruitingLeukemia, Lymphocytic, Chronic, B-Cell50
AVONCT03580928P2active not recruitingChronic Lymphocytic Leukemia (CLL)72PMID 39645236
VALUABLENCT04758975P2recruitingChronic Lymphocytic Leukemia (CLL)55
GONCT06917911P2recruitingCore Binding Factor Acute Myeloid Leukemia162
VCANCT05305859P2recruitingLeukemia, Myeloid, Acute30
MMNCT02899052P2active not recruitingMultiple Myeloma120PMID 34470049
SAVNCT05736965P2recruitingAML, Adult58
VenSwitchNCT06156579P2recruitingAML27
AVSNCT05736978P2recruitingAML58
ERASENCT05628623P2not yet recruitingLeukemia, Myeloid, Acute184PMID 24062400
CLLNCT03824483P2recruitingChronic Lymphocytic Leukemia (CLL)230PMID 34826411
AMLNCT06773208P2recruitingAcute Myeloid Leukemia (AML)30
BLAST MRD AML-2NCT04284787P2active not recruitingAcute Myeloid Leukemia60
LOXO-305NCT06466122P2recruitingChronic Lymphocytic Leukemia30
AMLNCT05603884P2recruitingLeukemia, Myeloid, Acute66
CLL2-BZAGNCT04515238P2active not recruitingChronic Lymphoid Leukemia42PMID 39883943
MOLTONCT04082897P2active not recruitingCLL Transformation28PMID 39270702
RIVER-81NCT06191263P2recruitingAcute Myeloid Leukemia98
VACNCT05566054P2recruitingAcute Monocytic Leukemia92
T-ALLNCT06210750P2withdrawnT Acute Lymphoblastic Leukemia0
CLLNCT04447768P2active not recruitingChronic Lymphocytic Leukemia (CLL)100
VenetoclaxNCT04501939P2active not recruitingChronic Lymphocytic Leukemia5PMID 34398557
CLLNCT03986034P2recruitingChronic Lymphocytic Leukemia75PMID 27178240
RR-CLLNCT03226301P2active not recruitingChronic Lymphocytic Leukemia in Relapse230PMID 40249856
ENABLENCT04763928P2active not recruitingAcute Myeloid Leukemia101
VARIANTNCT05701215P2active not recruitingChronic Myeloid Leukemia10
IVNCT05105841P2completedChronic Lymphocytic Leukemia (CLL)20
PEVENAZANCT04266795P2completedAcute Myeloid Leukemia (AML)164PMID 39606906
B-ALLNCT06078306P2unknownB Acute Lymphoblastic Leukemia20
IMPROVENCT04754035P2unknownChronic Lymphocytic Leukemia31PMID 35921541
G-CSFNCT05780879P2terminatedSecondary Acute Myeloid Leukemia10
V-FIRSTNCT03455504P2unknownAcute Myeloid Leukemia124PMID 40048742
ERADICNCT04010968P2completedIntermediate Risk Chronic Lymphocytic Leukemia120
STIMULUS-AML1NCT04150029P2terminatedAcute Myeloid Leukemia90
AMLNCT04905407P2terminatedAcute Myeloid Leukemia66
PrE0405NCT03834688P2completedMantle Cell Lymphoma33
CaptivateNCT02910583P2completedLeukemia323PMID 34618601
VenExNCT04267081P2completedAcute Myeloid Leukemia104PMID 39357056
CLL2-BAAGNCT03787264P2completedChronic Lymphoid Leukemia46PMID 35594173
VeRitAsNCT03455517P2completedChronic Myeloid Leukemia77PMID 36632738
STIMULUS-MDS3NCT04812548P2terminatedMyelodysplastic Syndrome (MDS)20
CORALNCT05209308P2withdrawnCLL0
PrE0403NCT03113422P2completedFollicular Lymphoma56PMID 40355425
CLLNCT04016805P2terminatedChronic Lymphocytic Leukemia41
CLL2-GiVeNCT02758665P2completedLeukemia, Lymphocytic, Chronic41
COSMOSNCT02639910P2completedLeukemia, Lymphocytic, Chronic, B-Cell24PMID 34414843
GDC-0199NCT02141282P2completedChronic Lymphocytic Leukemia127PMID 31023700
VeronicaNCT03584009P2terminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer103
GDC-0199NCT02187861P2completedFollicular Lymphoma163PMID 32785666

Terminated and withdrawn Venetoclax trials (106)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

All Venetoclax trials (686)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT05725200EVIDENTStudy to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerP2recruiting40Oslo University HospitalSep 2022
NCT02689440Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaP2active not recruiting155M.D. Anderson Cancer CenterFeb 2016
NCT05947851VRA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).P3recruiting735Merck Sharp & Dohme LLCAug 2023
NCT07320235IMAGINEImetelstat Combinations in Relapsed AMLP1recruiting36Douglas TremblayJan 2026
NCT05955261A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaP2suspended70St. Jude Children's Research HospitalJul 2023
NCT06390319ALLAdding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)P2recruiting100St. Jude Children's Research HospitalDec 2024
NCT07604233Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLP1/P2not yet recruiting30M.D. Anderson Cancer CenterNov 2026
NCT06967610PVOPhase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).P2recruiting40M.D. Anderson Cancer CenterJul 2025
NCT07520006Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesP1/P2not yet recruiting150Nurix Therapeutics, Inc.May 2026
NCT05099471VIWA-1Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaP2recruiting80Christian BuskeMar 2025
NCT05734495Pirtobrutinib and Venetoclax in Waldenström MacroglobulinemiaP2active not recruiting46Dana-Farber Cancer InstituteMay 2023
NCT06073821BGB-11417Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)P3active not recruiting652BeOne MedicinesNov 2023
NCT04523428REVEALREtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)P2recruiting60Stichting Hemato-Oncologie voor Volwassenen NederlandDec 2020
NCT05791409AETHERVenetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLLP1/P2recruiting112Stichting Hemato-Oncologie voor Volwassenen NederlandApr 2024
NCT07175415HEM-iSMART EHEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesP1/P2not yet recruiting42Princess Maxima Center for Pediatric OncologyOct 2026
NCT06644183IOA-244Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)P1/P2recruiting64Jennifer R. Brown, MD, PhDMar 2025
NCT07581002REVIVALA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)P2/P3not yet recruiting660AbbVieJul 2026
NCT07014917ESR-23-22182Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLP2recruiting62Zulfa OmerDec 2025
NCT06991920Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous LineageN/Anot yet recruiting50Institute of Hematology & Blood Diseases Hospital, ChinaJun 2026
NCT07294677CAVALRYCApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLP1/P2recruiting104University of ChicagoMar 2026
NCT06558604GLOASISPhase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell LymphomaP2recruiting100The Lymphoma Academic Research OrganisationFeb 2025
NCT04628026Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2P3recruiting650University of UlmSep 2022
NCT05091424A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaP1recruiting137Hoffmann-La RocheMar 2022
NCT05745714HEM-iSMART CHEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesP1/P2recruiting26Princess Maxima Center for Pediatric OncologyOct 2025
NCT07425808FIT-AMLFLT3-ITD Targeted Therapy in Fit AML PatientsP2/P3not yet recruiting230European Organisation for Research and Treatment of Cancer - EORTCDec 2026
NCT05751044HEM-iSMART BHEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesP1/P2recruiting26Princess Maxima Center for Pediatric OncologyOct 2025
NCT02416388BIG-1Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CRP2/P3recruiting3,100University Hospital, AngersJan 2015
NCT07513129Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic LymphomaP1not yet recruiting18M.D. Anderson Cancer CenterSep 2026
NCT06561074T-ALLA Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)P2recruiting22M.D. Anderson Cancer CenterSep 2025
NCT06943872CELESTIAL-RRCLLA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)P3recruiting630BeOne MedicinesJun 2025
NCT06466395A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated LeukemiasP1recruiting22M.D. Anderson Cancer CenterFeb 2025
NCT06247540Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaP2withdrawn0Northwestern UniversityMar 2024
NCT07277231BGB-11417A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaP3recruiting500BeOne MedicinesJan 2026
NCT07007312Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLP3recruiting1,300Kura Oncology, Inc.Sep 2025
NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaP2recruiting33Gottfried von Keudell, MD PhDFeb 2026
NCT07007052TAGVENPhase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm PatientsP2not yet recruiting33French Innovative Leukemia OrganisationDec 2025
NCT04802590Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell LymphomaP2active not recruiting210The Lymphoma Academic Research OrganisationJan 2022
NCT05431257LD-VenExAzacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML ProfilingP2recruiting117Rigshospitalet, DenmarkMay 2022
NCT07059975UPDATE AMLUPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLEarly P1recruiting36Joanna YiOct 2025
NCT04941716Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialP2recruiting20Fred Hutchinson Cancer CenterMay 2023
NCT05442216TAGALONGTagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating AgentsP2recruiting53Joshua ZeidnerMay 2024
NCT07238686Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDSP2recruiting40Beijing 302 HospitalJun 2025
NCT07078591Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AMLP2recruiting50Beijing 302 HospitalJun 2025
NCT06855810CCCG-TALL-2025Newly-diagnosed Pediatric T-cell ALL ProtocolP2/P3recruiting610Institute of Hematology & Blood Diseases Hospital, ChinaMar 2025
NCT06764238CCCG-I/HR-ALLNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolP2/P3recruiting1,800Institute of Hematology & Blood Diseases Hospital, ChinaJan 2025
NCT04739813Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaP1active not recruiting34National Cancer Institute (NCI)Jul 2021
NCT06810778PTCLDuvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)P1/P2recruiting12Jonsson Comprehensive Cancer CenterMay 2025
NCT03314181A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple MyelomaP2active not recruiting156AbbVieApr 2018
NCT05183035AMLVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)P3recruiting130PedAL BCU, LLCOct 2022
NCT07539818Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AMLP3not yet recruiting788Institute of Hematology & Blood Diseases Hospital, ChinaApr 2026
NCT07082452SEVENAZAA Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive InductionP3not yet recruiting262Gustave Roussy, Cancer Campus, Grand ParisSep 2025
NCT07311746Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaP1/P2not yet recruiting36M.D. Anderson Cancer CenterJun 2026
NCT07407140VAG-3+7-GVAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLP3not yet recruiting300Institute of Hematology & Blood Diseases Hospital, ChinaApr 2026
NCT07148180A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and VenetoclaxP1/P2recruiting31Jacqueline Garcia, MDFeb 2026
NCT06520098Benefit VAA Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)P2recruiting100VA Office of Research and DevelopmentOct 2025
NCT05766514HMATrial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive InductionP2withdrawn0University of FloridaApr 2025
NCT06448013A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaP1recruiting22M.D. Anderson Cancer CenterMar 2025
NCT06397027A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute LeukemiasP1recruiting22M.D. Anderson Cancer CenterDec 2024
NCT05910801V-MINDTafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaP2recruiting100Academic and Community Cancer Research UnitedJan 2024
NCT06841952Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid LeukemiaN/Anot yet recruiting158The First Affiliated Hospital of Soochow UniversityFeb 2025
NCT04062266AZA + Venetoclax as Maintenance Therapy in Patients With AML in RemissionP2active not recruiting50M.D. Anderson Cancer CenterSep 2019
NCT07374029Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AMLP1recruiting30David AviganFeb 2026
NCT06598384VA as Maintenance Therapy Post Allo-HSCT in MDS and AMLP2not yet recruiting40Navy General Hospital, BeijingSep 2024
NCT06419634ORM-6151Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeP1recruiting105Bristol-Myers SquibbMay 2024
NCT06454409Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid LeukemiaP1suspended20City of Hope Medical CenterMay 2025
NCT05677919Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic LeukemiaP2active not recruiting72Mayo ClinicJan 2023
NCT07159620Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsP2recruiting27The First Affiliated Hospital of Soochow UniversitySep 2025
NCT06471946VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDSP1/P2recruiting54Navy General Hospital, BeijingOct 2024
NCT07511062Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLP1not yet recruiting32Northside Hospital, Inc.Aug 2026
NCT03868722Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early TreatmentP2/P3recruiting212Rigshospitalet, DenmarkOct 2019
NCT05292664Venetoclax Basket Trial for High Risk Hematologic MalignanciesP1recruiting30Andrew E. Place, MDMar 2023
NCT07396480Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 TrialP3recruiting186First Affiliated Hospital of Zhejiang UniversityMar 2026
NCT05404906AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First RemissionP2/P3recruiting124The First Affiliated Hospital of Soochow UniversityJun 2022
NCT04843904SAVESafe Accelerated Venetoclax Escalation in CLLP1active not recruiting40Dana-Farber Cancer InstituteApr 2021
NCT02115295Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaP2recruiting508M.D. Anderson Cancer CenterMay 2014
NCT07478991VENP-A-QUIAzacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)P3not yet recruiting376PETHEMA FoundationMar 2026
NCT06696183SEQUENCEGilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentP2recruiting60Technische Universität DresdenApr 2025
NCT05735184A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLP1recruiting420Kura Oncology, Inc.Jul 2023
NCT07153497Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)P2not yet recruiting132National Cancer Institute (NCI)May 2026
NCT03766763Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage AP2active not recruiting82French Innovative Leukemia OrganisationMay 2019
NCT06972641Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationP2/P3recruiting126Ruijin HospitalJun 2025
NCT05986240Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AMLP1recruiting38Montefiore Medical CenterMay 2024
NCT07493161Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLN/Arecruiting110Institute of Hematology & Blood Diseases Hospital, ChinaApr 2026
NCT05530421SELVEDgeSelinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple MyelomaP2recruiting33University of MiamiMar 2023
NCT03613532Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNP1active not recruiting102Jacqueline Garcia, MDOct 2018
NCT07522801ALL-TARGETA Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALLP2not yet recruiting93Philippe ROUSSELOTSep 2026
NCT07454226ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALLN/Arecruiting92Institute of Hematology & Blood Diseases Hospital, ChinaMay 2026
NCT07495631Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaN/Arecruiting43Institute of Hematology & Blood Diseases Hospital, ChinaApr 2026
NCT07283094FHD-286FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid LeukemiaP1recruiting33Montefiore Medical CenterFeb 2026
NCT06846671CaDAnCe-302A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsP3recruiting250BeOne MedicinesApr 2025
NCT06456463TRILLIUMA Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyP2recruiting83Stemline Therapeutics, Inc.Jan 2025
NCT07407660Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus VenetoclaxP3not yet recruiting250Peking University People's HospitalFeb 2026
NCT07481175INITIATEInhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)P1recruiting38Thomas Aagaard RasmussenApr 2026
NCT07154264TAI-SHAN10A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)P2recruiting66Dizal (Jiangsu) Pharmaceutical Co., Ltd.Sep 2025
NCT06524375BRAVEA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment PeriodP2active not recruiting118Genentech, Inc.Aug 2024
NCT06084819Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaP2recruiting200Chinese PLA General HospitalAug 2023
NCT07358195Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney TransplantationEarly P1not yet recruiting3Massachusetts General HospitalJul 2026
NCT07060001Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease MarkerP2not yet recruiting112The Methodist Hospital Research InstituteApr 2026
NCT07177079HDAHigh-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)P1recruiting30Kittika PoonsombudlertMar 2026
NCT07052422VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCTP2/P3not yet recruiting160Nanfang Hospital, Southern Medical UniversityJul 2025
NCT06221683GMCAIIClinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLP2recruiting500Children's Hospital of Soochow UniversityJan 2024
NCT06548230MDSA Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)P1/P2recruiting40M.D. Anderson Cancer CenterMar 2025
NCT05740449HEM-iSMART AHEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesP1/P2withdrawn0Princess Maxima Center for Pediatric OncologyOct 2023
NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaP2recruiting102OHSU Knight Cancer InstituteDec 2025
NCT06852222cAMeLot-2A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)P3recruiting600Janssen Research & Development, LLCJun 2025
NCT07199855Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic LeukemiaP2active not recruiting24Zhejiang UniversityJun 2025
NCT07014462DLIT-AMLA Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AMLP1enrolling by invitation20University of VermontSep 2025
NCT07047183Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic SyndromesP2recruiting46Yehui TanJul 2025
NCT06445959Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibP1/P2recruiting78M.D. Anderson Cancer CenterAug 2024
NCT05401097IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)P2recruiting125Alice MimsSep 2022
NCT07218510Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity TrialP2recruiting33City of Hope Medical CenterJan 2026
NCT07032727Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsP2recruiting68M.D. Anderson Cancer CenterSep 2025
NCT05864742Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaP2active not recruiting40Peter MacCallum Cancer Centre, AustraliaSep 2023
NCT05211336VIPORVenetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemP1active not recruiting14National Cancer Institute (NCI)Apr 2022
NCT07437950Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)P2not yet recruiting126National Cancer Institute (NCI)Oct 2026
NCT07023588Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual DiseaseP2recruiting70Yehui TanJun 2025
NCT02966756A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaP2recruiting110AbbVieOct 2017
NCT07024706MAVRiCPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± ObinutuzumabP2not yet recruiting80AstraZenecaJan 2026
NCT06317649AMLVenetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)P2recruiting147National Cancer Institute (NCI)Sep 2024
NCT05564390MYELOMATCHMYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)P2recruiting2,000National Cancer Institute (NCI)Jun 2024
NCT07582159Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaP2not yet recruiting35City of Hope Medical CenterDec 2026
NCT05057494MAJICA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP3active not recruiting607AstraZenecaSep 2022
NCT03462719GLOWA Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)P3active not recruiting211Janssen Research & Development, LLCApr 2018
NCT06516978A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLP2not yet recruiting528The First Affiliated Hospital with Nanjing Medical UniversityOct 2024
NCT07469046VAH vs VA in Newly Diagnosed Elderly AMLP3not yet recruiting308Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineApr 2026
NCT06782542OLUVENAZAOlutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyP2recruiting16Justin Watts, MDMar 2026
NCT07507825VHAGExploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)P2not yet recruiting61First People's Hospital of HangzhouMar 2026
NCT07075016EVOLVE 1Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive ChemotherapyP3recruiting227Stichting Hemato-Oncologie voor Volwassenen NederlandAug 2025
NCT05287568CC-486 and Venetoclax for Acute Myeloid LeukemiaP1recruiting35University of Colorado, DenverDec 2022
NCT05963074TAILORA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic LeukemiaP2recruiting320Janssen Research & Development, LLCMay 2024
NCT07490288Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AMLN/Arecruiting27Institute of Hematology & Blood Diseases Hospital, ChinaMay 2026
NCT04560322Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLP2recruiting40Massachusetts General HospitalOct 2020
NCT06522386GATE1GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaP2active not recruiting50M.D. Anderson Cancer CenterJan 2025
NCT07439211GAVELAssessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid LeukemiaP1not yet recruiting48Jacqueline Garcia, MDJul 2026
NCT04968015LAMSA2020Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First RemissionP2active not recruiting134French Innovative Leukemia OrganisationMay 2022
NCT04895436ReVenGStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)P2recruiting75AbbVieMar 2022
NCT052632848-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid LeukemiaP1suspended30City of Hope Medical CenterDec 2022
NCT06863259Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALLP1recruiting28Children's Hospital Medical Center, CincinnatiMay 2025
NCT06802523Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid LeukemiaP1suspended53National Cancer Institute (NCI)Apr 2026
NCT07514832VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm TrialP2recruiting48Beijing 302 HospitalApr 2026
NCT06317662Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaP2recruiting153National Cancer Institute (NCI)Jun 2025
NCT06470841CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AMLP2not yet recruiting85Navy General Hospital, BeijingSep 2024
NCT06387121Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLP2recruiting53Institute of Hematology & Blood Diseases Hospital, ChinaApr 2024
NCT06191978ASTX727A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)P1recruiting40M.D. Anderson Cancer CenterMar 2024
NCT05486481ALTITUDEVenetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)P1/P2withdrawn0Alfred Chung, MDJan 2024
NCT05853965BELI(E)VECombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple MyelomaP1/P2recruiting45Universitätsklinikum Hamburg-EppendorfJun 2023
NCT05342584Venetoclax AMLVenetoclax Plus Intensive Chemotherapy in AML and Advanced MDSP1recruiting99Montefiore Medical CenterMay 2022
NCT04797767Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsP1/P2recruiting62University of WashingtonFeb 2022
NCT03504644Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic LeukemiaP1/P2active not recruiting40ECOG-ACRIN Cancer Research GroupAug 2018
NCT03013998Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaP1/P2recruiting3,000Beat AML, LLCNov 2016
NCT07264010Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical StudyP2/P3not yet recruiting87Nanfang Hospital, Southern Medical UniversityDec 2025
NCT06284486A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibP1/P2recruiting8M.D. Anderson Cancer CenterSep 2024
NCT06757855Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CMLP1/P2recruiting29Institute of Hematology & Blood Diseases Hospital, ChinaJan 2025
NCT06042725MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaP1recruiting100Mayo ClinicMar 2024
NCT04639362CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.P2active not recruiting85Stichting Hemato-Oncologie voor Volwassenen NederlandDec 2020
NCT05782127Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic SyndromesP1/P2active not recruiting36Groupe Francophone des MyelodysplasiesDec 2023
NCT06651229A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsP1recruiting155Janssen Research & Development, LLCMar 2025
NCT06557421STOP VENDe-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding PatientsP2recruiting50Institut Paoli-CalmettesFeb 2026
NCT04256317A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)P2/P3recruiting316Taiho Oncology, Inc.May 2020
NCT07486726Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid LeukemiaP1/P2not yet recruiting112Shanghai Jiao Tong University School of MedicineMar 2026
NCT07163793Pilot Study of Reduced Venetoclax ExposureP2recruiting41Northwell HealthOct 2024
NCT05951959TrAVeRseA Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaP2active not recruiting108AstraZenecaDec 2023
NCT05768711AVENHIRAzacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)P2active not recruiting44Groupe Francophone des MyelodysplasiesOct 2023
NCT06686108Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse PreventionP2recruiting59Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOct 2024
NCT05168930ZANU-VENZanubrutinib and Venetoclax in CLL (ZANU-VEN)P2recruiting45Dana-Farber Cancer InstituteFeb 2022
NCT06611839IDH1-AML-2024Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AMLP1/P2recruiting23Institute of Hematology & Blood Diseases Hospital, ChinaOct 2025
NCT06635681DAV-AML-2024Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AMLP2recruiting380Institute of Hematology & Blood Diseases Hospital, ChinaSep 2024
NCT04269902CLLTesting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyP3recruiting247National Cancer Institute (NCI)Mar 2021
NCT05904106VINCENTVenetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AMLP2recruiting146Technische Universität DresdenApr 2024
NCT04140487Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmP1/P2recruiting97M.D. Anderson Cancer CenterDec 2019
NCT06712121Venetoclax and Decitabine in R/R T-ALLP2recruiting28Seoul National University HospitalJan 2025
NCT06511882Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRDP2recruiting37H. Lee Moffitt Cancer Center and Research InstituteNov 2024
NCT03422393Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent IbrutinibP1active not recruiting24Michael ChoiMay 2018
NCT07132684Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia PatientsP3recruiting240Institute of Hematology & Blood Diseases Hospital, ChinaAug 2025
NCT07183878Ven-BUCYVenetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)N/Arecruiting138First Affiliated Hospital of Zhejiang UniversityAug 2025
NCT06544109Ven APLVenetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsP2/P3enrolling by invitation98The First Affiliated Hospital of Soochow UniversityAug 2023
NCT07605949RAVENRevumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AMLP2not yet recruiting88UNC Lineberger Comprehensive Cancer CenterJul 2026
NCT07387471WMStudy to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)P2recruiting14AbbVieMar 2026
NCT06668558VERDIVenetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaP2recruiting29Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y MielodisplasiasDec 2024
NCT05520567A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaP1/P2active not recruiting70Astellas Pharma Global Development, Inc.Jan 2023
NCT06536010Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AMLN/Arecruiting50Yang XiaotianNov 2021
NCT03768063IMbrella BA Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyP3active not recruiting1,000Hoffmann-La RocheFeb 2019
NCT04227847A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesP1recruiting178Seagen, a wholly owned subsidiary of PfizerAug 2020
NCT06445907Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid LeukemiaP1active not recruiting17M.D. Anderson Cancer CenterFeb 2025
NCT06483906Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.P2recruiting56Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineJul 2024
NCT06537843VenCMSafety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid LeukemiaP2recruiting100Hospital Municipal São JoséDec 2023
NCT06742463VHAG in Treating R/R T-ALL/LBLP2recruiting50First Affiliated Hospital of Zhejiang UniversityDec 2024
NCT06481241Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLN/Arecruiting77Institute of Hematology & Blood Diseases Hospital, ChinaJun 2024
NCT05834244ADVENT-AMLA Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)P1recruiting32M.D. Anderson Cancer CenterOct 2023
NCT04847453Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisP1active not recruiting24National Cancer Institute (NCI)Aug 2022
NCT04543916Venetoclax and Irinotecan in Relapsed/Refractory SCLCP1/P2withdrawn0Virginia Commonwealth UniversityJun 2021
NCT07133997Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaP1recruiting26City of Hope Medical CenterJun 2026
NCT06744556HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AMLP2active not recruiting41Institute of Hematology & Blood Diseases Hospital, ChinaJan 2025
NCT06481228Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLN/Arecruiting82Institute of Hematology & Blood Diseases Hospital, ChinaJun 2024
NCT05197192A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLP3recruiting202German CLL Study GroupApr 2022
NCT03319901Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALLP1/P2active not recruiting82Dana-Farber Cancer InstituteOct 2017
NCT06954987Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)P2not yet recruiting244National Cancer Institute (NCI)Jul 2026
NCT03701282Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic LeukemiaP3active not recruiting720National Cancer Institute (NCI)Feb 2019
NCT07012447Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid MutationsP2recruiting32yuejun LiuApr 2025
NCT06504459Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLP2recruiting40OHSU Knight Cancer InstituteJan 2025
NCT07131059MRD-positive AML Clinical StudyN/Arecruiting120Institute of Hematology & Blood Diseases Hospital, ChinaMay 2024
NCT05536349CLLTime-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)P2recruiting60M.D. Anderson Cancer CenterDec 2022
NCT07231952WMA Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)P2recruiting40Memorial Sloan Kettering Cancer CenterNov 2025
NCT03984448Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasP2/P3active not recruiting363National Cancer Institute (NCI)Oct 2019
NCT06634394APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AMLP1recruiting39Aptevo TherapeuticsOct 2024
NCT06428019TLSA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)P3recruiting170AbbVieAug 2024
NCT06014489HO171A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AMLP2recruiting142Stichting Hemato-Oncologie voor Volwassenen NederlandJan 2024
NCT04840602Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaP2recruiting92National Cancer Institute (NCI)Jan 2022
NCT05805098VHAVenetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLP2/P3recruiting60The First Affiliated Hospital of Soochow UniversityMar 2023
NCT04623541EPCORE™ CLL-1Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeP1/P2active not recruiting194GenmabNov 2020
NCT06571825RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CRP4recruiting118He HuangJul 2024
NCT05201066MBG453Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.P2active not recruiting33Novartis PharmaceuticalsFeb 2023
NCT05391750Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple MyelomaP1active not recruiting7Emory UniversityOct 2022
NCT03946878Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaP2active not recruiting32M.D. Anderson Cancer CenterAug 2019
NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyP2recruiting79The First Affiliated Hospital with Nanjing Medical UniversityDec 2025
NCT04273139Ibrutinib + Venetoclax in Untreated WMP2active not recruiting45Dana-Farber Cancer InstituteJul 2020
NCT07392242A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaP2recruiting45Memorial Sloan Kettering Cancer CenterJan 2026
NCT03826992CPX-351Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute LeukemiaP1recruiting21Children's Hospital Medical Center, CincinnatiDec 2018
NCT05807932FLAMSAVenetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLP1/P2recruiting38Heinrich-Heine University, DuesseldorfJun 2023
NCT05010122ASTX727ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeP1/P2recruiting42M.D. Anderson Cancer CenterJul 2021
NCT06765928Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCTP2not yet recruiting73Ruijin HospitalJan 2025
NCT04801797Venetoclax + Azacitidine vs. Induction Chemotherapy in AMLP2active not recruiting172Massachusetts General HospitalMay 2021
NCT03661307Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeP1/P2recruiting73M.D. Anderson Cancer CenterOct 2018
NCT07557056Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2not yet recruiting25Jennifer WoyachMay 2026
NCT07255872A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaP2/P3not yet recruiting216Sichuan Baili Pharmaceutical Co., Ltd.Mar 2026
NCT07486479Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLP3not yet recruiting204The First Affiliated Hospital of Soochow UniversityMar 2026
NCT07451912Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AMLP1/P2recruiting29The First Affiliated Hospital of Soochow UniversitySep 2025
NCT06783790Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTP2recruiting20Institute of Hematology & Blood Diseases Hospital, ChinaJan 2025
NCT06158100DLIVenetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)P1suspended25Antonio M Jimenez JimenezDec 2024
NCT07514936Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaP2recruiting120Chinese PLA General HospitalNov 2024
NCT05554393Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)P2recruiting153National Cancer Institute (NCI)Sep 2024
NCT06621199Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AMLP2recruiting42First Affiliated Hospital of Zhejiang UniversityJul 2024
NCT06621212Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AMLP2recruiting72First Affiliated Hospital of Zhejiang UniversityJul 2024
NCT06115135A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple MyelomaP2recruiting39OncotherapeuticsJun 2024
NCT06429098Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AMLP2recruiting40The First Affiliated Hospital of Soochow UniversityJan 2024
NCT05650723CLLZanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based ObinutuzumabP2active not recruiting50Weill Medical College of Cornell UniversityMay 2023
NCT05365035A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsP2recruiting60M.D. Anderson Cancer CenterSep 2022
NCT04988555DSP-5336A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)P1/P2recruiting606Sumitomo Pharma America, Inc.Feb 2022
NCT04708054Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSP2/P3recruiting324M.D. Anderson Cancer CenterOct 2021
NCT04855695Avo In R/R And Previously Untreated MCLP1/P2recruiting72Austin I KimJul 2021
NCT04588922Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLP1/P2recruiting160Sellas Life Sciences GroupMay 2021
NCT03874052Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaP1recruiting51Jennifer SaultzAug 2019
NCT03580928AVOAcalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLP2active not recruiting72Dana-Farber Cancer InstituteAug 2018
NCT06754267Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLP2recruiting36First Affiliated Hospital of Zhejiang UniversityDec 2024
NCT06386302Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaN/Arecruiting184Institute of Hematology & Blood Diseases Hospital, ChinaAug 2024
NCT06232694Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AMLN/Arecruiting54The First Affiliated Hospital with Nanjing Medical UniversityJan 2024
NCT04758975VALUABLEVenetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)P2recruiting55Paolo GhiaSep 2022
NCT05660473Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaP2recruiting100Institute of Hematology & Blood Diseases Hospital, ChinaAug 2022
NCT06328179Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.N/Arecruiting34Huai'an First People's HospitalMay 2022
NCT03844815Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid LeukemiaP1active not recruiting26University of ChicagoNov 2019
NCT04872790Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute LeukemiaP1active not recruiting20OHSU Knight Cancer InstituteSep 2022
NCT06390306The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBPrecruiting30Peking University People's HospitalJul 2024
NCT03223610Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaP1/P2recruiting155National Cancer Institute (NCI)Feb 2018
NCT03054896A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's SyndromeP2active not recruiting69Dana-Farber Cancer InstituteMar 2017
NCT07044687SCStudy to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in IndiaP4recruiting100AbbVieJul 2025
NCT06660368BCL2i CLAG-M in R/R Acute Myeloid LeukemiaP2recruiting52H. Lee Moffitt Cancer Center and Research InstituteNov 2024
NCT06429449Mitoxantrone for Venetoclax Resistant Acute Myeloid LeukemiaP1recruiting30University of Colorado, DenverJul 2024
NCT06152809CIML NK Cells With Venetoclax for AMLP1recruiting10Dana-Farber Cancer InstituteFeb 2024
NCT03539744A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.P3active not recruiting265AbbVieOct 2018
NCT04774393Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaP1/P2recruiting84M.D. Anderson Cancer CenterMay 2021
NCT03331198CLLStudy Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)P1/P2recruiting320Juno Therapeutics, a Subsidiary of CelgeneNov 2017
NCT06917911GOTesting the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)P2recruiting162National Cancer Institute (NCI)Feb 2027
NCT06643962Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction TherapyN/Arecruiting83Affiliated Hospital of Nantong UniversityOct 2024
NCT06232655Cladribine Venetoclax in Monocytic AMLP2recruiting20University of Colorado, DenverFeb 2024
NCT04965493BRUIN CLL-322A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)P3active not recruiting600Loxo Oncology, Inc.Sep 2021
NCT03336333SEQUOIAA Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLP3active not recruiting590BeiGeneOct 2017
NCT02250937Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeP2active not recruiting116M.D. Anderson Cancer CenterOct 2014
NCT05356169Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid LeukemiaP2/P3active not recruiting312Institute of Hematology & Blood Diseases Hospital, ChinaMay 2022
NCT06399640Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaP1recruiting60Vanderbilt-Ingram Cancer CenterAug 2024
NCT05939180VA vs DA for Newly Diagnosed Hig-risk AMLP2/P3recruiting116The First Affiliated Hospital of Soochow UniversityApr 2024
NCT04898894Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaP1active not recruiting37St. Jude Children's Research HospitalNov 2021
NCT04608318CLL17Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)P3active not recruiting897German CLL Study GroupMar 2021
NCT03471260Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesP1/P2recruiting96M.D. Anderson Cancer CenterMar 2018
NCT03214562Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaP1/P2recruiting116M.D. Anderson Cancer CenterSep 2017
NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaP2recruiting120National Cancer Institute (NCI)Oct 2025
NCT07244367Maintenance Venetoclax in AML Fit PatientsN/Arecruiting80Sohag UniversitySep 2025
NCT06237192MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult PatientsN/Arecruiting200National Research Center for Hematology, RussiaApr 2023
NCT05226455Venetoclax in Patients With MDS or AML in Relapse After AHSCTP1/P2active not recruiting55Groupe Francophone des MyelodysplasiesNov 2022
NCT06561880FLT3AML-2024The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 MutationP1/P2recruiting66Institute of Hematology & Blood Diseases Hospital, ChinaOct 2024
NCT06337331Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell TransplantP2withdrawn0Northside Hospital, Inc.Aug 2024
NCT03844048An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialP3active not recruiting165AbbVieSep 2019
NCT06554626Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLP2recruiting20First Affiliated Hospital of Zhejiang UniversityAug 2024
NCT06129734Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantP1/P2recruiting20Benjamin TomlinsonJul 2025
NCT06536959VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSP2recruiting67Beijing 302 HospitalJul 2024
NCT04401748VeronaStudy Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic SyndromeP3active not recruiting531AbbVieSep 2020
NCT06496308Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentP3recruiting78Ruijin HospitalJul 2024
NCT03969446Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractoryP1recruiting54City of Hope Medical CenterMay 2020
NCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaN/Aactive not recruiting28Anhui Medical UniversityJul 2025
NCT02756897Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic LeukemiaP2active not recruiting234M.D. Anderson Cancer CenterJul 2016
NCT06903702A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid LeukemiaP2recruiting100Memorial Sloan Kettering Cancer CenterJun 2025
NCT06746519BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid LeukemiaP1/P2recruiting135Chen SuningDec 2024
NCT06652685Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid LeukemiaP2not yet recruiting218Ruijin HospitalOct 2024
NCT06451861Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AMLP2recruiting240Guangdong Provincial People's HospitalAug 2024
NCT06384261A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive TherapyP2active not recruiting140OncoVerity, Inc.Jul 2024
NCT06501196A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic SyndromeP1recruiting170BlossomHill TherapeuticsJun 2024
NCT05305859VCAVenetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AMLP2recruiting30The First Affiliated Hospital of Xiamen UniversityJan 2022
NCT03041688AMG-232Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid LeukemiaP1active not recruiting58National Cancer Institute (NCI)Feb 2018
NCT02899052MMStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)P2active not recruiting120AbbVieJan 2017
NCT03523975Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaP1/P2recruiting28City of Hope Medical CenterDec 2018
NCT06770257Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive ChemotherapyP2withdrawn0Institute of Hematology & Blood Diseases Hospital, ChinaDec 2025
NCT06471738Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaP2recruiting30Chinese PLA General HospitalJul 2024
NCT05673057Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic SyndromeP1/P2active not recruiting249Molecular Partners AGDec 2022
NCT04975919Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaP2active not recruiting20M.D. Anderson Cancer CenterSep 2021
NCT04419519Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With VenetoclaxP2active not recruiting81Memorial Sloan Kettering Cancer CenterMay 2020
NCT03113643AMLSL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)P1recruiting72Dana-Farber Cancer InstituteJun 2017
NCT03128879Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLP2recruiting90M.D. Anderson Cancer CenterJun 2017
NCT06311227Venetoclax for the Treatment of Patients With Relapsed Hairy Cell LeukemiaP2recruiting20National Cancer Institute (NCI)Dec 2024
NCT04150887ELEVATECusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid LeukemiaP1active not recruiting61OncoVerity, Inc.Dec 2019
NCT06372717A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDSP1recruiting100Apollo Therapeutics LtdJun 2024
NCT06007911Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaP1withdrawn0Medical College of WisconsinAug 2024
NCT06387420A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid LeukemiaP1/P2not yet recruiting180AkesoApr 2024
NCT06177067Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaP1recruiting24St. Jude Children's Research HospitalApr 2024
NCT05736965SAVA Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid LeukemiaP2recruiting58Shanghai Tong Ren HospitalFeb 2023
NCT04450173Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular LymphomaP2active not recruiting40University of California, DavisFeb 2021
NCT04447716An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentP1active not recruiting4Thomas Jefferson UniversityOct 2020
NCT03850574TUSCANYClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaP1/P2recruiting240Aptose Biosciences Inc.Mar 2019
NCT03586609Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaP2recruiting145M.D. Anderson Cancer CenterOct 2018
NCT05529069Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsP2recruiting30M.D. Anderson Cancer CenterJan 2023
NCT06393985Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALLP2recruiting30The First Affiliated Hospital of Soochow UniversityApr 2024
NCT05157971Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic LeukemiaP1active not recruiting24City of Hope Medical CenterMar 2022
NCT06672146Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)P2recruiting93National Cancer Institute (NCI)May 2025
NCT05554406Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)P2recruiting335National Cancer Institute (NCI)Sep 2024
NCT06361329Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALLP3recruiting81First Affiliated Hospital of Zhejiang UniversityApr 2024
NCT06192979Optimize First-line Treatment for AL Amyloidosis With t (11; 14)N/Arecruiting41Jin Lu, MDJan 2024
NCT06156579VenSwitchCombination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AMLP2recruiting27University Hospital TuebingenNov 2023
NCT05428969BEXMABA Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological MalignanciesP1/P2active not recruiting181Faron Pharmaceuticals LtdJun 2022
NCT05184842Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLP2recruiting91Montefiore Medical CenterMar 2022
NCT04068597Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesP1/P2recruiting250CellCentric Ltd.Aug 2019
NCT07318662Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMMLactive not recruiting224Guangdong Provincial People's HospitalJan 2020
NCT03710772Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaP2active not recruiting51M.D. Anderson Cancer CenterMay 2019
NCT05736978AVSAdaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD ResultsP2recruiting58Shanghai Tong Ren HospitalMar 2023
NCT05453903AMLA Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed TherapiesP1active not recruiting196Janssen Research & Development, LLCOct 2022
NCT05222984Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxP1active not recruiting17City of Hope Medical CenterJul 2022
NCT05628623ERASETesting the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial TreatmentP2not yet recruiting184Eastern Cooperative Oncology GroupOct 2024
NCT05192889Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxP1/P2active not recruiting35St. Jude Children's Research HospitalAug 2022
NCT04086264IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaP1/P2active not recruiting218AbbVieNov 2019
NCT03824483CLLStudy of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)P2recruiting230Memorial Sloan Kettering Cancer CenterFeb 2019
NCT02846623Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeP2active not recruiting50M.D. Anderson Cancer CenterJan 2017
NCT05388006Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2recruiting27Mayo ClinicJan 2023
NCT04939272Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaP1/P2active not recruiting8City of Hope Medical CenterJun 2022
NCT05861050Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaP1/P2recruiting50City of Hope Medical CenterAug 2023
NCT07044544Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid MalignanciesP1recruiting20University of Alabama at BirminghamJul 2025
NCT06773208AMLA Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)P2recruiting30Memorial Sloan Kettering Cancer CenterJan 2025
NCT05317403Venetoclax to Augment Epigenetic Modification and ChemotherapyP1recruiting40Medical College of WisconsinMar 2023
NCT03862157Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaP1/P2active not recruiting40M.D. Anderson Cancer CenterFeb 2019
NCT03836261AMPLIFYStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLP3active not recruiting984Acerta Pharma BVFeb 2019
NCT02942290MDSA Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)P1active not recruiting129AbbVieJan 2017
NCT04284787BLAST MRD AML-2BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid LeukemiaP2active not recruiting60National Cancer Institute (NCI)Feb 2021
NCT06763341A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaP1recruiting12City of Hope Medical CenterJul 2025
NCT06990321Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid LeukemiaP3recruiting68Yehui TanJun 2025
NCT07007949a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid LeukemiaP2recruiting42The First Affiliated Hospital of Soochow UniversityJun 2025
NCT06466122LOXO-305Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKiP2recruiting30Kerry RogersNov 2024
NCT05074355Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative NeoplasmsP2recruiting40University Health Network, TorontoNov 2023
NCT04790045LymBIOLymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based RegimensP4not yet recruiting30Paolo GhiaNov 2023
NCT05603884AMLVCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)P2recruiting66The First Affiliated Hospital of Xiamen UniversityDec 2022
NCT05455294Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsP1active not recruiting16Jacqueline Garcia, MDJul 2022
NCT05506332Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid LeukemiaP1recruiting10University Hospital, AntwerpJul 2022
NCT05211570AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaP1/P2recruiting78AB ScienceJun 2022
NCT05010772Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionP1recruiting125M.D. Anderson Cancer CenterOct 2021
NCT04657081AMLPharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)P1/P2active not recruiting101Taiho Oncology, Inc.Feb 2021
NCT04229979REGALGalinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2P3active not recruiting127Sellas Life Sciences GroupFeb 2021
NCT04581512Study to Evaluate the Safety and Tolerability of EP0042P1/P2recruiting70Ellipses PharmaNov 2020
NCT04515238CLL2-BZAGSequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLLP2active not recruiting42German CLL Study GroupOct 2020
NCT04161248Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaEarly P1active not recruiting40Canadian Cancer Trials GroupSep 2020
NCT04216524Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmP2recruiting40M.D. Anderson Cancer CenterMay 2020
NCT04128501Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant SettingP2active not recruiting100M.D. Anderson Cancer CenterMay 2020
NCT04082897MOLTOObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmationP2active not recruiting28Niguarda HospitalOct 2019
NCT03513562Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance MutationsP2active not recruiting28Ohio State University Comprehensive Cancer CenterMar 2019
NCT03629171Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaP2recruiting52M.D. Anderson Cancer CenterOct 2018
NCT03467867A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLLP2active not recruiting25Georgetown UniversityApr 2018
NCT06394011Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML PatientsP2recruiting60The First Affiliated Hospital of Soochow UniversityFeb 2024
NCT03737981Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic LeukemiaP3active not recruiting465National Cancer Institute (NCI)Jan 2019
NCT05016947Venetoclax Plus Inotuzumab for B-ALLP1active not recruiting23Dana-Farber Cancer InstituteSep 2021
NCT05379166Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic SyndromeP2active not recruiting33Uma BorateJun 2022
NCT06324994Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.P2not yet recruiting10Dalian Medical UniversityMay 2024
NCT05668026AMBERAdministration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ARTP1/P2recruiting18University of AarhusApr 2024
NCT06220162VAC Regimen for AML Patients Who Failed to Response to VA RegimenP2recruiting32The First Affiliated Hospital of Soochow UniversityFeb 2024
NCT05360160ASTX727A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)P1/P2recruiting43M.D. Anderson Cancer CenterOct 2022
NCT05376111Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL PatientsP2recruiting28The First Affiliated Hospital of Soochow UniversityApr 2022
NCT05053659Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin LymphomaP1active not recruiting23Paolo Caimi, MDJun 2022
NCT03980171LEVERAGEStudy of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular LymphomaP1/P2active not recruiting50Peter MacCallum Cancer Centre, AustraliaAug 2019
NCT02392572ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic SyndromeP1/P2recruiting120M.D. Anderson Cancer CenterNov 2015
NCT05597306VenBomVenetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaP1recruiting18Terrence J Bradley, MDNov 2022
NCT04817241ASTX727Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia PatientsP1/P2active not recruiting5National Cancer Institute (NCI)Feb 2022
NCT06082934Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic LeukemiaP1/P2recruiting30Xijing HospitalNov 2023
NCT05657652CAV Regimen for R/R Ph- B-ALLN/Arecruiting36The First Affiliated Hospital of Soochow UniversityOct 2022
NCT05336812Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic LeukemiaP2recruiting52Ohio State University Comprehensive Cancer CenterSep 2022
NCT04746235Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid LeukemiaP2active not recruiting85M.D. Anderson Cancer CenterFeb 2021
NCT04282811Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italyactive not recruiting321Gruppo Italiano Malattie EMatologiche dell'AdultoJul 2020
NCT00501826Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaP2recruiting160M.D. Anderson Cancer CenterJul 2007
NCT06629818Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)P2recruiting36Peking Union Medical College HospitalOct 2024
NCT06191263RIVER-81Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AMLP2recruiting98Ryvu Therapeutics SAJan 2024
NCT05451771Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisP1/P2recruiting53Rajshekhar Chakraborty, MDOct 2022
NCT05566054VACVenetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic LeukemiaP2recruiting92The First Affiliated Hospital of Soochow UniversityMar 2022
NCT06210750T-ALLAdding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)P2withdrawn0National Cancer Institute (NCI)Aug 2024
NCT06514261Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AMLP1suspended45National Cancer Institute (NCI)Dec 2024
NCT06928376A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML PatientsP2recruiting160Chinese PLA General HospitalApr 2024
NCT05554419Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)P2not yet recruiting184National Cancer Institute (NCI)Jul 2026
NCT05600894Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmP2active not recruiting132National Cancer Institute (NCI)Jun 2023
NCT02992522Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaP1active not recruiting22Beth ChristianFeb 2017
NCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLN/Aenrolling by invitation94Anhui Medical UniversityFeb 2025
NCT05054465ITALLI001A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALLP1/P2not yet recruiting48Israeli Medical AssociationOct 2021
NCT04447768CLLThe Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)P2active not recruiting100Memorial Sloan Kettering Cancer CenterDec 2020
NCT04572763Copanlisib Plus Venetoclax in R/R DLBCLP1/P2active not recruiting48Dana-Farber Cancer InstituteSep 2021
NCT04981912Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL PatientsP1active not recruiting4University of California, San DiegoSep 2021
NCT04501939VenetoclaxCirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on VenetoclaxP2active not recruiting5University of California, San DiegoAug 2020
NCT04655755Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaP1/P2active not recruiting52M.D. Anderson Cancer CenterJan 2021
NCT04169737Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2recruiting168M.D. Anderson Cancer CenterJul 2020
NCT03986034CLLEarly Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)P2recruiting75National Heart, Lung, and Blood Institute (NHLBI)Jun 2019
NCT03534323Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSP1/P2active not recruiting55Dana-Farber Cancer InstituteJul 2018
NCT06382168DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaP1/P2recruiting39Delta-Fly Pharma, Inc.Jun 2024
NCT06434662Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AMLP2recruiting34First Affiliated Hospital of Zhejiang UniversityFeb 2024
NCT06265545Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaN/Arecruiting120Institute of Hematology & Blood Diseases Hospital, ChinaFeb 2024
NCT04416451A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone LymphomaP2active not recruiting6Memorial Sloan Kettering Cancer CenterMay 2021
NCT03226301RR-CLLA Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 AberrationsP2active not recruiting230Stichting Hemato-Oncologie voor Volwassenen NederlandJun 2017
NCT02993523Viale-aA Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction TherapyP3active not recruiting443AbbVieFeb 2017
NCT04188405Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaP2completed20M.D. Anderson Cancer CenterMay 2020
NCT03709758Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AMLP1active not recruiting50Dana-Farber Cancer InstituteOct 2018
NCT05522192Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaP1/P2unknown70Hui ZengJul 2022
NCT05386576ALLA Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)Early P1active not recruiting12Memorial Sloan Kettering Cancer CenterJun 2022
NCT04603001Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsP1active not recruiting260Eli Lilly and CompanyNov 2020
NCT06357182Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid LeukemiaP1recruiting24OHSU Knight Cancer InstituteAug 2024
NCT04550442Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaP1/P2terminated34M.D. Anderson Cancer CenterSep 2020
NCT05564650Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeP1completed6Thomas Jefferson UniversityJan 2023
NCT03808610Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic LeukemiaP1/P2terminated53M.D. Anderson Cancer CenterApr 2019
NCT07039877Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL PatientsP2recruiting12Hospital Universitario Dr. Jose E. GonzalezJan 2025
NCT05182385BCP-ALLVenetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)P1/P2active not recruiting30Goethe UniversityDec 2021
NCT04763928ENABLETrial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and VenetoclaxP2active not recruiting101Gruppo Italiano Malattie EMatologiche dell'AdultoDec 2021
NCT03872180Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell LymphomaP2active not recruiting23Emory UniversityApr 2019
NCT05268003A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaP2terminated4M.D. Anderson Cancer CenterJun 2022
NCT04278768AMLDose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)P1/P2suspended366Curis, Inc.Jul 2020
NCT05005299VICTORYVenetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell TransplantationP1unknown18Melbourne HealthJun 2022
NCT05144243SCStudy to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in ChinaP4active not recruiting44AbbVieJan 2022
NCT03557619A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological MalignanciesP1recruiting12AbbVieJul 2019
NCT04809181Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS PatientsP2unknown95First Affiliated Hospital of Zhejiang UniversityMar 2021
NCT03404193Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic SyndromeP2terminated235M.D. Anderson Cancer CenterJan 2018
NCT05901974Venetoclax Combined With Azactidine in the Treatment of ALALP2recruiting23Sheng-Li Xue, MDJul 2023
NCT05618366Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin LymphomaP1terminated3Weill Medical College of Cornell UniversityJun 2023
NCT04102020VIALE-MA Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional ChemotherapyP3completed112AbbVieMar 2020
NCT03573024Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid LeukemiaP2completed36University of Colorado, DenverNov 2018
NCT04160052Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic SyndromeP1/P2terminated51M.D. Anderson Cancer CenterOct 2019
NCT06578546Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALLP2unknown30The First Affiliated Hospital of Soochow UniversityFeb 2024
NCT06105658Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AMLP2unknown20Anhui Provincial HospitalOct 2023
NCT06109064Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDSP2unknown14Anhui Provincial HospitalOct 2023
NCT05807347Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid LeukemiaP2unknown42Hematology department of the 920th hospitalFeb 2023
NCT06045819PREDICLAXRelation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)recruiting100University Hospital, CaenApr 2024
NCT05701215VARIANTVenetoclax After TKI to Target Persisting Stem Cells in CMLP2active not recruiting10Thomas Ernst, PD Dr. med.Aug 2023
NCT03609593Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaP2completed42Nicole LamannaNov 2018
NCT05665530A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesP1completed86Prelude TherapeuticsSep 2023
NCT03926624Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageP3terminated167Delta-Fly Pharma, Inc.Nov 2019
NCT05881265Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic LeukemiaP2recruiting30Shanghai Jiao Tong University School of MedicineMay 2023
NCT06763666CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AMLP4not yet recruiting172Nanfang Hospital, Southern Medical UniversityFeb 2025
NCT05841771Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.P2recruiting78Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineJan 2023
NCT05829226AMLA Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)P1completed101PureTechDec 2022
NCT04607772RRStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2withdrawn0Karyopharm Therapeutics IncNov 2020
NCT04613622Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemiaunknown500National Taiwan University HospitalAug 2020
NCT04616274Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemiaunknown500National Taiwan University HospitalJul 2020
NCT03900884PALVENPalbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast CancerP1active not recruiting17Peter MacCallum Cancer Centre, AustraliaSep 2019
NCT03713580Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin LymphomaP1active not recruiting25Case Comprehensive Cancer CenterMar 2019
NCT06087419A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma PatientsP1/P2unknown42Institute of Hematology & Blood Diseases Hospital, ChinaOct 2023
NCT03740529A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLP1/P2completed803Loxo Oncology, Inc.Mar 2019
NCT05371054VVIPStudy of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid MalignanciesP1/P2completed8National Cancer Institute (NCI)Apr 2023
NCT03466294Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AMLP2completed42University of Colorado, DenverMay 2018
NCT06200220Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemiaunknown45Poitiers University HospitalDec 2023
NCT05503355A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AMLP1/P2unknown80BioSight Ltd.Aug 2022
NCT04905810Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent FailureP2recruiting20Brian JonasFeb 2022
NCT05863845Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCLN/Aunknown52Ruijin HospitalJun 2023
NCT03708003Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLLP2terminated30Swiss Cancer InstituteMar 2019
NCT03662724VENregVenetoclax Registryunknown100Hannover Medical SchoolNov 2017
NCT04937166DSP107A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological MalignanciesP1terminated25Kahr MedicalJan 2022
NCT02296918Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLP1completed69Acerta Pharma BVDec 2014
NCT03567876Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCLP2completed141Fondazione Italiana Linfomi - ETSSep 2018
NCT06563804A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMMLP1/P2terminated13Servier Bio-Innovation LLCFeb 2025
NCT05105841IVStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)P2completed20AbbVieNov 2021
NCT06742086A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female ParticipantsP1completed72AbbVieDec 2024
NCT04964505Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid LeukemiaP1terminated16Brian JonasJul 2021
NCT05317936LOXO-305Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With VenetoclaxP1/P2terminated3M.D. Anderson Cancer CenterNov 2022
NCT04266795PEVENAZAA Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive ChemotherapyP2completed164TakedaOct 2020
NCT05546060Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLHP1unknown20Beijing Friendship HospitalJul 2022
NCT05996406Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)P2active not recruiting36Peking Union Medical College HospitalSep 2023
NCT05513131Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAMLP2unknown30The First Affiliated Hospital with Nanjing Medical UniversitySep 2021
NCT04161885VIALE-TA Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)P3terminated465AbbVieFeb 2020
NCT06078306B-ALLCD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).P2unknown20The First Affiliated Hospital of Soochow UniversityApr 2024
NCT04754035IMPROVEClinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaP2unknown31Paolo GhiaNov 2017
NCT06068621Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid LeukemiaP2completed200Chinese PLA General HospitalMar 2023
NCT04330820RELAXTrial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)P1/P2unknown55Technische Universität DresdenApr 2020
NCT02242942Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic LeukemiaP3completed445Hoffmann-La RocheDec 2014
NCT03069352A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyP3completed211AbbVieMay 2017
NCT05780879G-CSFA Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid LeukemiaP2terminated10University of Michigan Rogel Cancer CenterJun 2024
NCT06508489SAR443579A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological MalignanciesP1/P2terminated7SanofiAug 2024
NCT06070948A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female ParticipantsP1withdrawn0AbbVieOct 2023
NCT05262465Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAMLN/Aunknown300guomeiJul 2020
NCT04476199Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCTP2active not recruiting100Gruppo Italiano Trapianto di Midollo OsseoDec 2019
NCT04687761Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years OldP1/P2completed113PETHEMA FoundationNov 2020
NCT04477486Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell LymphomaP2completed13AbbVieSep 2020
NCT04666649Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)P1completed27University of Maryland, BaltimoreMar 2021
NCT05025423Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell LymphomaP2terminated7Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJun 2022
NCT06993883AMLUse of Venetoclax , AML , Sohag , Egyptcompleted43Sohag UniversityMar 2023
NCT05662956A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML PatientsP2completed114Hematology department of the 920th hospitalDec 2022
NCT03485547BPDCNStudy of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)P1completed5Dana-Farber Cancer InstituteAug 2018
NCT05654194Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AMLP3unknown30The First Affiliated Hospital of Soochow UniversityOct 2022
NCT06449482Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense ChemotherapyP1/P2terminated6Institute of Hematology & Blood Diseases Hospital, ChinaMay 2023
NCT05594784Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLP2completed79Institute of Hematology & Blood Diseases Hospital, ChinaOct 2022
NCT04435691Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid LeukemiaP1/P2terminated110M.D. Anderson Cancer CenterJul 2020
NCT04285567CRISTALLOA Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 MutationP3completed166Hoffmann-La RocheMay 2020
NCT06030089VENETACIBLEPlasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + VenN/Acompleted20Centre Hospitalier Universitaire de NiceFeb 2024
NCT05264883Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AMLP3unknown170The First Affiliated Hospital with Nanjing Medical UniversityMar 2021
NCT06150040AML-NETAcute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]P1/P2terminated1Centre Leon BerardSep 2024
NCT04926285VEN-OMSafety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)P1completed6University of Illinois at ChicagoJun 2022
NCT05275439SLPhase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AMLP1terminated106Shattuck Labs, Inc.Mar 2022
NCT04512105Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid LeukemiaP1completed6University of California, IrvineDec 2020
NCT04867928Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid LeukemiaP2unknown35Gruppo Italiano Malattie EMatologiche dell'AdultoMar 2022
NCT04372433IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMMLP1completed67Immune-Onc TherapeuticsSep 2020
NCT03455504V-FIRSTVenetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid LeukemiaP2unknown124Gruppo Italiano Malattie EMatologiche dell'AdultoOct 2018
NCT04010968ERADICEvaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic LeukemiaP2completed120French Innovative Leukemia OrganisationSep 2019
NCT04553692IGM-8444Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersP1terminated272IGM Biosciences, Inc.Sep 2020
NCT05941585Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid LeukemiaN/Acompleted60Institute of Hematology & Blood Diseases Hospital, ChinaAug 2023
NCT05177731Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AMLP3active not recruiting188Chen SuningMar 2022
NCT05149378Venetoclax Based Regimen for R/R T-ALLP2completed25The First Affiliated Hospital of Soochow UniversityNov 2021
NCT03732703MyDRUGMyeloma-Developing Regimens Using Genomics (MyDRUG)P1/P2completed103Multiple Myeloma Research ConsortiumApr 2019
NCT04939363A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;P2completed12Bnai Zion Medical CenterAug 2021
NCT05583175Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid MalignanciesP2unknown50Xianmin Song, MDNov 2022
NCT04150029STIMULUS-AML1A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for ChemotherapyP2terminated90Novartis PharmaceuticalsSep 2020
NCT03226418Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaP2completed75University of NebraskaJul 2017
NCT03932318Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML PatientsP1/P2withdrawn0Actinium PharmaceuticalsMar 2023
NCT05084027Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCTP2unknown50First Affiliated Hospital of Zhejiang UniversityOct 2021
NCT04285268Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaP2withdrawn0Rutgers, The State University of New JerseyMay 2020
NCT05799079Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell TransplantP2terminated1Sanjay MohanApr 2023
NCT04874194Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1P1/P2terminated24M.D. Anderson Cancer CenterDec 2021
NCT04589728Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96completed202Gruppo Italiano Malattie EMatologiche dell'AdultoFeb 2021
NCT03955783Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic MalignanciesP1completed78Sanjay MohanJun 2019
NCT03940352AMLHDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)P1terminated52Novartis PharmaceuticalsJun 2019
NCT05659992Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid LeukemiaP2completed30Chinese PLA General HospitalDec 2022
NCT05464836Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBLP2terminated2M.D. Anderson Cancer CenterApr 2023
NCT04905407AMLTamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)P2terminated66Syros PharmaceuticalsAug 2021
NCT05168202A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromesP1terminated56Bristol-Myers SquibbJan 2022
NCT03834688PrE0405Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of AgeP2completed33PrECOG, LLC.Jan 2020
NCT03547115A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLP1terminated84MEI Pharma, Inc.May 2018
NCT03530683PF-07901801A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaP1terminated189PfizerMay 2018
NCT03867682Venetoclax and Lintuzumab-Ac225 in AML PatientsP1/P2unknown38Actinium PharmaceuticalsJan 2020
NCT03112174SYMPATICOStudy of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)P3completed366Pharmacyclics LLC.Jun 2017
NCT04599634VENOMVenetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesP1completed11National Cancer Institute (NCI)Dec 2021
NCT03576547Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaP1/P2terminated9M.D. Anderson Cancer CenterJun 2018
NCT04790903RA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)P1terminated50Hoffmann-La RocheJul 2021
NCT04029688A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid TumorsP1/P2terminated38Hoffmann-La RocheJan 2020
NCT05362942Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid LeukemiaP2unknown52Beijing 302 HospitalMay 2022
NCT05155709AMLA Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.P1completed14Novartis PharmaceuticalsMay 2022
NCT05433532Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsP2completed20The First Affiliated Hospital of Soochow UniversityMay 2022
NCT05079230ENHANCE-3Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid LeukemiaP3terminated378Gilead SciencesJul 2022
NCT04336982A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid LeukemiaP1terminated22CelgeneAug 2020
NCT05893472A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.P1/P2unknown45ZePing ZhouApr 2023
NCT04824924A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive ChemotherapyP2unknown100Shanghai Jiao Tong University School of MedicineMar 2021
NCT04659044Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaP2terminated3Academic and Community Cancer Research UnitedApr 2021
NCT02910583CaptivateIbrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)P2completed323Pharmacyclics LLC.Sep 2016
NCT04778397ENHANCE-2Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedP3terminated258Gilead SciencesJul 2021
NCT05976217Safety and Efficacy of Venetoclax in Idiopathic Pulmonary FibrosisEarly P1completed3University of Alabama at BirminghamOct 2023
NCT02956382Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaP1/P2completed24Georgetown UniversityMar 2017
NCT04778410Study of Magrolimab Combinations in Participants With Myeloid MalignanciesP2terminated54Gilead SciencesJun 2021
NCT03063944STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive ChemotherapyP1completed37Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityMar 2017
NCT02950051GAIAStandard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationP3completed926German CLL Study GroupDec 2016
NCT04267081VenExStudy of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity ScreeningP2completed104Helsinki University Central HospitalFeb 2020
NCT03399539Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple MyelomaP1completed8Mayo ClinicMay 2018
NCT04070768GOStudy of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113P1completed18John QuigleySep 2019
NCT04487106Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeP2completed21M.D. Anderson Cancer CenterJul 2020
NCT05361057Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML PatientsP2terminated20Institute of Hematology & Blood Diseases Hospital, ChinaJun 2022
NCT03295240The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell LymphomaEarly P1completed10Memorial Sloan Kettering Cancer CenterSep 2017
NCT05107856PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesP1terminated21Prelude TherapeuticsMar 2022
NCT04887857OMNIVERSEA Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)P1completed6CelgeneDec 2021
NCT04655391Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationP1withdrawn0City of Hope Medical CenterJun 2022
NCT03492125A Study Of The Selective PKC-β Inhibitor MS- 553P1/P2terminated60MingSight Pharmaceuticals, IncMay 2018
NCT04752163DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaP1/P2terminated17M.D. Anderson Cancer CenterMar 2021
NCT04092179Study of Enasidenib and Venetoclax in IDH2-Mutated Blood CancersP1/P2terminated27University Health Network, TorontoNov 2020
NCT06085638Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic LeukemiaP1/P2withdrawn0M.D. Anderson Cancer CenterSep 2023
NCT02397720Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaP2completed150M.D. Anderson Cancer CenterApr 2015
NCT05312112Real World Outcomes Using Novel Agents for AML in the UKunknown1,000Guy's and St Thomas' NHS Foundation TrustMay 2022
NCT03787264CLL2-BAAGSequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLLP2completed46German CLL Study GroupJan 2019
NCT05909553Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult VolunteersP1completed15AbbVieJun 2023
NCT04075747V-FASTA Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaP1completed57Jazz PharmaceuticalsDec 2019
NCT04755244ALX148A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)P1terminated14ALX Oncology Inc.May 2021
NCT03064867Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell LymphomaP1/P2active not recruiting65Molly GalloglyJun 2017
NCT03751436Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate CancerP1completed10Roswell Park Cancer InstituteAug 2019
NCT03735875Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid LeukemiaP1/P2terminated8M.D. Anderson Cancer CenterJan 2019
NCT03534180Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell LymphomaP2completed12City of Hope Medical CenterAug 2018
NCT03406156CLLA Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination TherapyP3completed120AbbVieAug 2018
NCT03672695Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.P1completed37Institut de Recherches Internationales ServierNov 2018
NCT03455517VeRitAsActivity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaP2completed77Gruppo Italiano Malattie EMatologiche dell'AdultoOct 2018
NCT04912063IVStudy to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic SyndromeP1terminated40AbbVieJun 2021
NCT04812548STIMULUS-MDS3A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS ParticipantsP2terminated20Novartis PharmaceuticalsMay 2021
NCT03739554CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLLP1completed5Cyclacel Pharmaceuticals, Inc.Jan 2019
NCT03236857A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory MalignanciesP1completed143AbbVieNov 2017
NCT04017546CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDSP1completed14Cyclacel Pharmaceuticals, Inc.Aug 2019
NCT02966782MDSA Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)P1completed70AbbVieMar 2017
NCT05471700Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia PatientsN/Acompleted40Zhujiang HospitalSep 2022
NCT04722601A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular LymphomaP1/P2terminated2University of ChicagoSep 2021
NCT04990778Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell LymphomaP2withdrawn0M.D. Anderson Cancer CenterNov 2021
NCT05053425Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AMLN/Aunknown30LanZhou UniversityOct 2021
NCT05209308CORALRituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLLP2withdrawn0MEI Pharma, Inc.Nov 2022
NCT05282719Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in AdultsP2unknown33The First Affiliated Hospital of Soochow UniversityApr 2022
NCT03552692Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell LymphomaP2terminated22Fondazione Italiana Linfomi - ETSSep 2018
NCT05048615Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AMLP2completed15Hospital Universitario Dr. Jose E. GonzalezJul 2021
NCT03176277A Study of ONO-7475 in Patients With Acute LeukemiasP1/P2terminated42Ono Pharmaceutical Co., Ltd.Jun 2017
NCT03113422PrE0403Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line TherapyP2completed56PrECOG, LLC.Dec 2017
NCT04752527Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk FeaturesP2unknown42The First Affiliated Hospital of Soochow UniversityFeb 2021
NCT03801525ULTRA-VStudy to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)P2/P3terminated277TG Therapeutics, Inc.May 2019
NCT03484520MK7965A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaP1terminated48AbbVieJul 2018
NCT03505944VALERIAVenetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell LymphomaP1/P2unknown59Nordic Lymphoma GroupJul 2018
NCT04146038Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseP2completed5Rutgers, The State University of New JerseyOct 2020
NCT04038437LITA Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AMLP1completed35Jazz PharmaceuticalsOct 2019
NCT03873857FORTEA Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federationcompleted71AbbVieFeb 2019
NCT04277442Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaP1completed1National Cancer Institute (NCI)Mar 2020
NCT03276468Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory LymphomasP2completed136The Lymphoma Academic Research OrganisationFeb 2018
NCT04810598Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal FunctionP1completed12AbbVieJul 2021
NCT02755597BelliniA Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyP3completed291AbbVieJul 2016
NCT02611323FLA Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2completed133Hoffmann-La RocheMar 2016
NCT02005471MURANOA Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)P3completed389Hoffmann-La RocheMar 2014
NCT03194932Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous LineageP1completed62St. Jude Children's Research HospitalJul 2017
NCT03379051Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLP1/P2terminated78TG Therapeutics, Inc.Mar 2018
NCT04016805CLLStudy to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxP2terminated41TG Therapeutics, Inc.Aug 2019
NCT02877550Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma PatientsP1completed25Swiss Cancer InstituteFeb 2017
NCT03634228Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid LeukemiaP1/P2terminated16M.D. Anderson Cancer CenterDec 2018
NCT02758665CLL2-GiVeTrial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLLP2completed41University of UlmSep 2016
NCT03000257ABBV-181A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid TumorsP1completed182AbbVieDec 2016
NCT03941964AMLA Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive ChemotherapyP3completed60AbbVieAug 2019
NCT02756611VENICE IA Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)P3completed258AbbVieJun 2016
NCT04748848A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive TherapyP1terminated1CelgeneOct 2021
NCT03886649Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.P1terminated7Swiss Cancer InstituteNov 2019
NCT04172844PAVEPevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaP1terminated16Medical College of WisconsinJan 2020
NCT03390296OX40OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaP1/P2completed50M.D. Anderson Cancer CenterDec 2017
NCT05215405Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LLno longer available0Kathleen Ludwig
NCT03082209A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic MalignanciesP1completed153AbbVieMar 2017
NCT04214860APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid MalignanciesP1completed51Aprea TherapeuticsDec 2019
NCT03856112Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple MyelomaP1/P2withdrawn0National Cancer Institute (NCI)Jun 2019
NCT02639910COSMOSStudy to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKiP2completed24MorphoSys AGNov 2016
NCT02980731VENICE IIA Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).P3completed210AbbVieDec 2016
NCT02141282GDC-0199A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor TherapyP2completed127AbbVieSep 2014
NCT01794520Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple MyelomaP1/P2completed117AbbVieOct 2012
NCT04073147VENOBI-CNSVenetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS LymphomaP1terminated4Klinikum StuttgartMay 2020
NCT03036904V+DA-EPOCH-RStudy of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell LymphomasP1completed31Weill Medical College of Cornell UniversityFeb 2017
NCT03873493A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic LeukemiaP2completed14AbbVieJan 2020
NCT02987400Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCLP2completed22Arbeitsgemeinschaft medikamentoese TumortherapieJan 2017
NCT03218683Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.P1terminated70AstraZenecaAug 2017
NCT03583424Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin LymphomaP1/P2completed19Ohio State University Comprehensive Cancer CenterSep 2018
NCT03625505A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid LeukemiaP1completed61AbbVieOct 2018
NCT04419389R/RAPR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)P1/P2terminated1Aprea TherapeuticsMar 2021
NCT02287233A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous LeukemiaP1/P2completed94AbbVieDec 2014
NCT03045328Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLLP2completed22Steven E. CoutreSep 2017
NCT03357627A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaP1completed43Calithera Biosciences, IncFeb 2018
NCT03943342Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib ResistanceP2withdrawn0Kerry RogersMar 2020
NCT04171791CTCLA Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)P1completed4Yale UniversityJan 2020
NCT03312530A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaP1/P2completed49Hoffmann-La RocheNov 2017
NCT03584009VeronicaA Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor TherapyP2terminated103Hoffmann-La RocheSep 2018
NCT02951117A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer TreatmentP1withdrawn0AbbVieAug 2017
NCT04509622LDACA Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)P3completed14AbbVieOct 2020
NCT04230564Acute Myeloid Leukemia Real World Treatment Patternswithdrawn0PfizerOct 2020
NCT03217838Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.P1terminated50AstraZenecaJul 2017
NCT02265731Study Evaluating Venetoclax in Subjects With Hematological MalignanciesP1/P2completed38AbbVieSep 2014
NCT02640833A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K InhibitorP1withdrawn0AbbVieJul 2016
NCT04298918A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast CancerP1/P2terminated1Hoffmann-La RocheSep 2020
NCT04274907NSCLCA Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) ExpressionP1terminated2AbbVieJun 2020
NCT03755947Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic LeukemiaP2completed3Grupo Cooperativo de Hemopatías MalignasDec 2018
NCT03441555A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid LeukemiaP1completed36AbbVieMay 2018
NCT01211457AMLStudy of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)P1/P2unknown65Cyclacel Pharmaceuticals, Inc.Jun 2010
NCT03878524SMMARTSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialP1terminated2OHSU Knight Cancer InstituteApr 2020
NCT02670044A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic TherapyP1completed88Hoffmann-La RocheMar 2016
NCT03343678This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxP1withdrawn0Boehringer IngelheimJan 2018
NCT03181126A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic LymphomaP1completed69AbbVieNov 2017
NCT04422210ES-SCLCA Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).P1terminated2Hoffmann-La RocheSep 2020
NCT04493099Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLP1/P2withdrawn0M.D. Anderson Cancer CenterOct 2020
NCT01742988CUDC-907Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With LymphomaP1completed106Curis, Inc.Dec 2012
NCT04274933A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor TherapyP1terminated4AbbVieMay 2020
NCT04454580Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapyunknown15Ospedale Maggiore Di TriesteAug 2020
NCT01671904CLLA Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)P1completed84Genentech, Inc.Jan 2014
NCT03567616A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaP2terminated8AbbVieOct 2018
NCT03701321Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple MyelomaP1/P2withdrawn0National Cancer Institute (NCI)Jan 2019
NCT03135262FLA Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)P1/P2terminated29Hoffmann-La RocheJun 2017
NCT03884972Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK InhibitorP1withdrawn0M.D. Anderson Cancer CenterJun 2019
NCT03797261A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesP1terminated9AbbVieMar 2019
NCT03000660ABT-199Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL AmyloidosisP1terminated3Tufts Medical CenterJan 2017
NCT01685892A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic LeukemiaP1completed82Genentech, Inc.Nov 2012
NCT03785184A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyP2withdrawn0AbbVieApr 2019
NCT02391480A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerP1completed128AbbVieApr 2015
NCT03255096A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6P1completed39Hoffmann-La RocheAug 2017
NCT02055820NHLA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCLP1/P2completed267Hoffmann-La RocheNov 2013
NCT03592576Expanded Access to Navitoclaxno longer available0AbbVie
NCT02187861GDC-0199A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)P2completed163Hoffmann-La RocheDec 2014
NCT03123029Expanded Access to Venetoclaxavailable0AbbVie

Venetoclax clinical trials: frequently asked questions

How many Venetoclax clinical trials are there?
686 Venetoclax clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 257 are actively recruiting participants. 116 are marked completed.
Are Venetoclax clinical trials recruiting in 2026?
Yes — 257 Venetoclax trials are actively recruiting in 2026, with 2387 U.S. sites across 50 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Venetoclax being studied for?
Venetoclax is being studied for Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML) and 574 more. The trials are grouped by indication on this page.
What phase is Venetoclax in?
Venetoclax clinical trials span 5 Phase 4, 59 Phase 3, 269 Phase 2, 158 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Venetoclax clinical trials?
The lead sponsor across the most Venetoclax trials is M.D. Anderson Cancer Center, with 253 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Venetoclaxas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai:

Venetoclax Clinical Trials (2026): 686 Studies | Hipa.ai